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SUMMARY 
One percent of the world population suffers from the neurodevelopmental disorder 
schizophrenia. During the last years, above hundreds of risk genes and functional changes in 
glutamatergic, GABAergic and dopaminergic signalling have been identified. Furthermore, 
prenatal complications increase the risk to develop schizophrenia. First symptoms occur 
between puberty and early adolescence and are divided into positive, negative and cognitive 
symptoms. Until today no suitable cellular test system has been developed to study the disease 
background and treatment opportunities. The development of iPSC technology enables the 
investigation of schizophrenia related changes based on patient-derived cells.  
 
In this thesis, fibroblast derived from healthy and disease individuals were reprogrammed into 
iPSC and further differentiated into cortical neurons. Each developmental step starting as iPSC 
and resulting as neurons showed the same morphological properties independent from the 
donor. Despite these similarities changes in early neurodevelopmental processes were 
observed in iPSC-derived neurons from patients with schizophrenia. The neurite outgrowth, 
the PSD95 cluster density and the calcium flux were reduced in case of schizophrenia. 
Transcriptome analysis revealed changes in gene expression related to gene of neuronal 
development, synapse, calcium signalling and immune response. In increased expression of 
MHCII related genes was measured via transcriptome analysis and immunocytochemical 
staining in cells from patients witch schizophrenia. Additionally, the effect of the antipsychotics 
clozapine, haloperidol and olanzapine as well as the mimetic peptides narpin, neurexide and 
FN4-NF3 on neurite outgrowth were investigated. A significantly reduced neurite outgrowth 
was observed in iPSC-derived neurons from CTR 1 after treatment with haloperidol or 
olanzapine. Above mentioned characteristics of cortical neurons cells exhibited similarities to 
previously described primary cells from patients with schizophrenia. Based on these findings 
iPSC-derived neurons could be used as test system for basic research and for the 
development of new therapeutical approaches for neurodevelopmental diseases like 
schizophrenia.  
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ZUSAMMENFASSUNG 
Ca. 1% der Weltbevölkerung ist an der neuronalen Entwicklungsstörung Schizophrenie 
erkrankt. In den letzten Jahrzehnten wurden über hundert potentielle Risikogene und 
zahlreiche Veränderungen in glutamatergen, GABAergen und dopaminergen Signalwegen 
identifiziert. Auch pränatale Vorkommnisse wie Infektionen der Mutter oder Komplikationen bei 
der Geburt erhöhen das Risiko an Schizophrenie zu erkranken. Erste Symptome treten 
zwischen der Pubertät und dem frühen Erwachsensein auf. Die Patienten leiden an positiven, 
negativen und kognitiven Symptomen sowie an Anomalien ihrer Gehirnmorphologie. Bis heute 
gibt es kein geeignetes zelluläres Modellsystem, um die Ursachen der Krankheit sowie 
mögliche Behandlungsansätze zu erforschen. Die Entwicklung der iPSC Technologie 
ermöglicht die Erforschung des Krankheitsbildes Schizophrenie an Patienten-abgeleiteten 
Zellen.  
 
In dieser Arbeit wurden Fibroblasten aus gesunden und erkrankten Individuen zu induzierten 
pluripotenten Stammzellen (iPSC) reprogrammiert und in neuronale, kortikale Zellen 
differenziert. Die iPSC, die neuronalen Vorläuferzellen und die Neurone zeigten gleiche 
morphologische Merkmale unabhängig vom Spender. Unterschied in frühen neuronalen 
Entwicklungsschritten wurden in Neuronen von Patienten mit Schizophrenie im Vergleich zu 
iPSC-abgeleitet Neuronen von gesunden Individuen nachgewiesen. Das 
Neuritenauswachsen, die Anzahl an PSD95 Clustern und die Calciummobilisierung waren 
reduziert in Neuronen von Patienten. Transkriptomanalysen zeigten eine veränderte 
Genexpression von Genen wichtig für die Ausbildung von synaptischen Strukturen, neuronaler 
Entwicklung, den Calciumtransport und die Immunantwort. Eine erhöhte Expression von 
MHCII Genen wurde in Transkriptomanalysen und in neuronalen Vorläuferzellen mittels 
immunocytochemischer Färbung nachgewiesen. Zusätzlich wurde der Einfluss von den 
bekannten Antipsychotika Clozapin, Haloperidol und Olanzapin sowie den mimetischen 
Peptiden Narpin, Neurexide und FN4-NF3 auf das Neuritenauswachsen untersucht.  Eine 
signifikante Reduktion des Neuritenauswachsens wurde nach Applikation von Haloperidol und 
Olanzapin in iPSC-abgeleiteten Neuronen von CTR 1 nachgewiesen. Die hier beschriebenen 
Eigenschaften der kortikalen neuronalen Zellen zeigen Übereinstimmungen mit bisherigen 
Forschungsergebnissen von humanen Zellen aus Schizophreniepatienten. Daraus resultiert 
eine mögliche Anwendung als neuronales Testsystem mit patienten-abgeleiteten Zellen für die 
Erforschung des Krankheitsbildes Schizophrenie und die Entwicklung neuer 
Therapiekonzepte.   
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1. INTRODUCTION 
1.1 Mental disorder schizophrenia  
Approximately one percent of the world’s population is affected by some form of schizophrenia 
[1]. This complex and symptomatically heterogeneous disorder is characterised by a strong 
genetic predisposition and a variety of morphological changes in the brain. Additionally, 
environmental factors have an impact on the occurrence and the course of the disease [2]. In 
case of schizophrenia, quality of life for the patients and their families is diminished and 
personal as well as societal costs are immensely increased [3, 4]. The suicide rate of patients 
with schizophrenia is increased as well [5]. First symptoms are diagnosed between the age of 
15-35 years. The occurrence of schizophrenia is equal between men and women [6], but the 
onset is delayed in women [7].  
 
For classification and detection of psychiatric disorders, the ‘Diagnostic and Statistical Manual 
of Mental Disorders’ (DSM) was developed to help clinicians. Treatment of the disease mostly 
starts after presenting first symptoms, even if a treatment would be more efficient in an early 
disease stage. More effective early stage treatments are still needed. 
1.1.1 Symptoms of schizophrenia 
Three different categories of symptoms are common in the course of schizophrenia: positive, 
negative and cognitive symptoms [8], which continuously reappear in episodes. This chronic 
and relapsing aetiopathology differs among patients. Positive symptoms comprise 
hallucinations and delusions, psychomotor anomalies, bizarre and disorganized thoughts, 
speech and behaviour. They are diagnosed in the first episode of psychosis, and are mostly 
treated with antipsychotics. Patients with negative symptoms are characterized by an affective 
and social dysfunction. They show a decreased expression of speech and diminished social 
interactions. Diagnosis and treatment of negative symptoms are difficult. Finally, cognitive 
symptoms include limited attention to the environment and deficits in working memory and 
language. Additionally, executive functions like planning and decision making are impaired [9]. 
The prefrontal cortex represents the most affected brain region in patients with schizophrenia 
exhibiting cognitive symptoms [10].  
1.1.2 Hypotheses of schizophrenia 
In the early twentieth century, Paul Eugen Bleuler introduced the term schizophrenia, which 
described a fundamental disorder of thoughts and feelings. At that time, the disease was 
characterised by the four ‘A’s: disturbances of associations, affect, ambivalence and autistic 
isolation [11]. The American psychiatrist Silvano Arieti was convinced that schizophrenia has 
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a psychological etiology. He suggested the main cause was a wrong family situation and an 
ambivalent mother which inhibited the building of a stable ego [12]. 
 
In the second half of the twentieth century researchers focused on biochemical mechanisms 
to explain the pathology. The pathophysiology is characterised by aberrations in multiple 
neurotransmitter systems, like dopamine, glutamate or ᵞ-aminobutyric acid (GABA). The 
effective treatment with dopamine receptor antagonists such as chlorpromazine and 
haloperidol helped to develop the first hypothesis of schizophrenia: the dopamine hypothesis 
[13]. The neurotransmitter dopamine is important for neuronal signaling in many brain regions, 
like the prefrontal cortex [14]. In case of schizophrenia a hyperactive dopamine transmission 
is suggested to trigger the disease. Positive, negative and cognitive symptoms may result from 
aberrant dopamine transmission [15] or an imbalance of dopamine receptors [16, 17]. In 2006, 
Coyle et al. developed an alternative hypothesis of schizophrenia based upon changes of 
glutamatergic signaling [18]. Phencyclidine (PCP) and other compounds blocking the N-
methyl-D-aspartic acid (NMDA)-type glutamatergic receptors induced typical behavior effects 
such as psychotic symptoms [19, 20]. These findings led to the concept that a dysfunction or 
dysregulation of NMDA receptor-mediated neurotransmission may evoke symptoms of 
schizophrenia. Another explanation was put forth by diminished GABAergic inhibition. GABA 
is the primary inhibitory neurotransmitter, important for the inhibitory-excitatory balance in the 
human brain [21]. A reduced neuronal GABA concentration and neurotransmission [22] or 
disruption of GABAergic interneurons [23] may underlie many symptoms of schizophrenia. 
 
Neurodevelopmental hypothesis 
These theories try to explain symptoms which occur in late adolescence or in early adulthood. 
The neurodevelopmental hypothesis describes schizophrenia as a neurodevelopmental 
disorder with psychosis as final stage of the disease [24].  Here, suitable environmental risk 
factors which affect in utero development, birth, childhood and early adolescence are 
encompassed (Fig. 1). The risk increased during periods of maternal malnutrition [25, 26], 
infections during pregnancy [27] and obstetric complications [28]. The risk for later 
development of schizophrenia was highest, when stress factors impinged during the second 
trimester of pregnancy. Adverse maternal life events like death or illness of a close relative 
increased the risk during this vulnerable time [29]. Prenatal infections of the mother like 
influenza, Toxoplasma gondii or Herpes Simplex Virus Type 2 enhance the risk for the child 
[27]. The incidence of schizophrenia was highest during an influenza epidemic [30]. Cytokines 
which are released in case of an infection may influence the disease risk. They are important 
mediators of an immune response. Excessive amounts of Interleukin-8 or tumor necrosis 
factor- are linked with the occurrence of schizophrenia [27, 31]. Fetal brain and early neural 
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development are disturbed by an immense cytokine release as well [32, 33]. Other 
complications during validity like hypoxia increase the risk, too [34]. During childhood and early 
adolescence severe trauma, infections [27] and consumption of cannabis [35, 36] increase the 
chance of developing schizophrenia. Patients exhibit an impaired early brain development and 
a delayed maturation [37]. Abnormalities in social and intellectual properties during childhood 
are observed as well [38]. Developmental milestones were reached slower and the frequency 
of speech and educational problems was higher [38]. The place and season of birth are the 
most significant risk factor compared to genetics [39]. People living in an urban environment 
[40] or in a minority status had a higher risk for developing schizophrenia [41].  
 
Fig. 1: Overview of environmental factors and neural development influencing the course 
of schizophrenia. Major developmental processes are indicated by horizontal lines. First prenatal 
development (in months), followed by postnatal development (in years). Shaded boxes indicate time 
frames of the first trimester of gestation and adolescence. In the upper part environmental factors that 
may impact neural development. Blue lines show the course of schizophrenia, starting with an 
asymptomatic state in childhood followed by full expression of the disease in late adolescence. (adapted 
from [42]) 
1.2 Neuropathology of schizophrenia 
The neuropathology of schizophrenia is complex and multifaceted. It changes over time and 
depends on age and length of the illness. Post-mortem tissue and induced pluripotent stem 
cells (iPSC) from patients can be used to study the neuropathology. 
 
As early as 1976, Johnstone et al. observed enlarged ventricles in patients with schizophrenia 
using computerized axial tomography techniques [43]. Later, meta-analyses confirmed this 
finding [44, 45] and investigated decreased gray matter, brain volume and brain weight [46]. 
Further morphological changes were observed in the prefrontal cortex, temporal loops and the 
hippocampus.  Supporting the neurodevelopmental hypothesis, the prefrontal cortex exhibited 
excessive loss of gray matter and cortical thinning during childhood of patients with 
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schizophrenia [47]. In later periods of the disease a reduced size of the hippocampus [48], 
decreased asymmetry of the brain hemispheres [49] and an altered gyrification [50] were 
observed. Disruptions of cortical cytoarchitecture may be related to abnormal neuronal 
migration, embryonal neuronal development and neuronal connectivity [51]. Dislocated 
neurons are found in cortical layer 2 and 3 [52] as well as in the subcortical white matter [53]. 
During early gestation cell proliferation is essential for normal cortical development. Diminished 
cell proliferation led to smaller cortical surface area and aberrant cortical organization [54].  
 
Neural progenitor cells from patients with schizophrenia exhibited a reduced migration relative 
to control cells in a neurosphere migration assay [55] and changes in the apical polarity of 
neural rosettes [56]. Maternal infections or stress cause stimulated cytokine pathways which 
negatively impact mechanisms of symmetric neural progenitor cells division in the developing 
embryo. Further aberrations in early neuronal development were obvious during the 
differentiation process. The loss of pluripotency markers was found to be delayed in iPSC-
derived neurons from patients with schizophrenia [57]. Efficiency to differentiate into 
glutamatergic or dopaminergic neurons was impaired in case of schizophrenia [58].  
 
In adolescent, the size of neurons is reduced leading to diminished dendritic and axonal 
arborizations [59-61]. Selemon and Goldman-Rakic supposed a reduced neuropil hypothesis 
for schizophrenia [62]. The neuropil is defined as space between cells in the brain including 
axons, dendrites and synapses. Over time the neuropil decreased because of aberrations in 
dendrites and axons. Studies investigating the dendritic arbors in cortical areas found a 14-
29 % reduction of dendritic length or dendritic number in the prefrontal cortex [63-66]. In cortical 
layer V Black et al. measured a 40 % reduced basilar dendritic field size [63]. Loss of dendrites 
and axons resulting in an increase of neuronal density, which can provoke a selective reduction 
of large pyramidal neurons [67]. A reduction in the number and length of neurites was observed 
in iPSC-derived neurons from patients with schizophrenia as well [58, 68]. A possible cause of  
neuropil shrinkage can be an excessive synaptic pruning during brain development and 
maturation [69]. Synapses are essential for functionality and connectivity in the brain. 
Schizophrenia is known as a disease with synaptic dysfunction [70]. The main finding in the 
synaptic morphology was a reduction of dendritic spines in post-mortem studies [63, 66] and 
iPSC-derived neurons [71]. The postsynaptic density (PSD) is a multiprotein complex and 
plays a central role in the dendritic spines architecture and the regulation of synaptic plasticity. 
Post synaptic density protein 95 (PSD95) is a major structural component of the PSD and 
interacts with many membrane-spanning molecules. PSD95 was reduced in iPSC-derived 
neurons from patients with schizophrenia [55]. Beside a reduction of important synaptic 
proteins, the number of glutamatergic synapses were reduced, too [59, 60]. As a result, 
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imbalance of the excitatory-inhibitory neuronal signaling may impact neuronal synaptic 
transmission and connectivity [72]. Decreased neuronal connectivity in iPSC-derived neurons 
from patients with schizophrenia was observed by Brennand et al. [55].  
 
Furthermore, an increased microglial cell density is present in the prefrontal cortex and other 
parts of the brain from patients with schizophrenia [73, 74]. Microglia are important for the 
immune response in the brain and are the base for the pro-inflammatory cytokines. An increase 
in pro-inflammatory cytokines has been also found [75]. Activated microglia and enriched pro-
inflammatory cytokines impact fundamentally neurogenesis and may impact the course of 
schizophrenia. 
1.3 Genetics of schizophrenia 
Schizophrenia is known as a polygenetic disease characterised by a variety of genetic 
aberrations. Human brain material and iPSC-derived neurons are used for genetical analysis. 
Patient-derived material contain the whole genetic repertoire of the donor, allowing a most 
relevant study of genetic aberrations. Family and twin studies demonstrated a high heritability 
[76, 77] but the concordance in monozygotic twins was only 50% [78]. The risk increases in 
case of a family history of psychosis indicating the importance of the genetic origin.  
 
Genome-wide association studies (GWAS), next-generation sequencing and transcriptome 
analysis identified risk genes and genetic changes in coding and non-coding regions of 
patients with schizophrenia [79]. The genetics of schizophrenia is highly divergent. Today, the 
cause is unclear because of the complicated interaction of genetic, epigenetic, developmental 
and environmental factors which collectively impact normal brain development and maturation 
[24]. A variety of genes related to dopaminergic, glutamatergic, neurodevelopmental 
processes, synapse, calcium channels and immune system activation are important parts of 
the genetic mechanism of schizophrenia.  
 
In 2014, a large collaboration of researchers from the Psychiatric Genomics Consortium 
identified 108 conservatively defined loci that meet genome-wide significance in schizophrenia. 
75% percent of the loci include protein-coding genes for dopaminergic signaling (DRD2) and 
glutamatergic neurotransmission [80, 81]. Combining environmental factors and genetic 
predisposition the ‘two hit hypothesis’ of schizophrenia has developed. The first hit is the 
genetic background which is influenced by the second hit of all environmental factors [82]. 
Deregulated genes belong to gene families involved in cell migration, proliferation, axonal 
outgrowth, myelination and synaptogenesis supporting the neurodevelopmental theory [83]. 
The expression of an important synaptic protein PSD95 is changed and depends on the age 
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of disease onset. Young patients exhibited a reduced PSD95 thalamic level [84] and elderly 
patients an increased PSD95 protein expression [85]. Kristiansen et al. reported a decreased 
PSD95 protein expression in sub regions of the prefrontal cortex of post-mortem brains [86].  
 
Changes in gene expression responsible for synaptic plasticity [80] are important for synapse 
formation and stabilization [87, 88] and can lead to a disturbed synaptic phenotype observed 
in patients with schizophrenia. Aberrations in genes related to voltage-gated calcium channels 
are found in genetical analyses [89]. Voltage-gated calcium channels are regulators of 
neuronal excitability, activity and synaptic plasticity. Changes in neurobiological and functional 
key processes may explain disease mechanisms of aberrant brain development and disturbed 
pathophysiology [90]. 
 
The major histocompatibility complex (MHC) is the most powerful region of association for 
schizophrenia [91]. Patients with schizophrenia exhibited a reduced expression of MHC related 
genes [92, 93] which could be a link between the immune system and schizophrenia [80]. 
Eaton et al. showed an increased prevalence to autoimmune disorders [94]. In the genetic 
analysis of schizophrenia one gene has been most associated with the disease and is handled 
as one potential risk gene. This gene is named Disrupted in schizophrenia 1 (DISC1). DISC1 
is an important regulator of embryonic and adult neurogenesis [95], brain development [96] 
and signalling pathways [97]. These findings suggest that mutation in DISC1 impair 
morphology and functionality of the human brain and is one of the key players. Wen et al. 
generated iPSC from four members of the family with known DISC1 mutation. In their analysis 
DISC1 mutation causes dysregulation of genes related to nervous system development, 
dendritic spine formation and synaptic transmission [98]. 
1.4 Development of drugs for schizophrenia  
The development of first generation antipsychotics (FGA) for schizophrenia started in the 
1950s. The length of hospitalization and the risk of a relapse could be reduced by these drugs 
[99]. All FGA are characterised by a high affinity for dopamine D2 receptors (see Tab. 1). FGA, 
such as haloperidol have an effective binding to the dopamine D2 receptor and dissociate 
slowly [100]. Positive symptoms are treated well with this type of antipsychotic. Almost 30 % 
of drugs are ineffective and produce intolerable side effects [101, 102]. These drugs are no 
treatment option and their benefit is low compared to the side effects. Second generation 
antipsychotics (SGA) were developed to improve the treatment options for schizophrenia.  
SGA are characterized by a higher affinity to serotonin 5-HT receptors than to dopamine D2 
receptors. No effective antipsychotic is known without some degree of D2 receptor binding 
[103].  
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The SGA clozapine and olanzapine are characterized by a binding affinity for serotonin, 
adrenergic, dopamine, histamine and muscarinic receptors (see Tab. 1). Clozapine is known 
to reduce negative and cognitive symptoms and is used for patients who are non-responder to 
FGAs or show neurological side effects. Its binding affinity to dopamine D2 receptors is 
reduced in comparison to classical FGA. 
 
Tab. 1: Relative neurotransmitter receptor affinities for first and second generation 
antipsychotics at therapeutic doses. (adapted from [104] and modified) 
 
Beside dopamine, NMDA receptor signaling has been targeted to find a treatment for negative 
symptoms in schizophrenia [105]. Potential effects of SGAs may be associated with the 
inhibition of the hypofunction of NMDA receptor [106]. Drugs targeting the glutamatergic 
system and rescue the hypofunction of NMDA receptor, give an opportunity for patients with 
schizophrenia who failed to respond to dopaminergic agents [107].  
 
Zhao et al. established a large-scale high-throughput screening assay using human iPSC-
derived neural progenitor cells [108]. They used an integrated stable, luciferase-based 
receptor system to screen known bioactive compounds as well as (Food and Drug 
Administration) FDA-approved drugs according to their effect on an important signaling 
pathway for schizophrenia. Cultivation in 384-well plates allows parallel approaches and 
individual changes of culture conditions. iPSC-derived neural cell types are a promising 
Receptor Clozapine Olanzapine Haloperidol 
D1 + ++ + 
D2 + ++ ++++ 
D3 + + +++ 
D4 ++ ++ +++ 
5-HT1A - - - 
5-HT1D - - - 
5-HT2A +++ +++ + 
5-HT2C ++ ++ - 
5-HT6 ++ ++ - 
5-HT7 ++ - +++ 
DA transporter ++ ++  
Na transporter + ++  
Legend:  -  minimal to none;    +  low;    ++ moderate;    +++ high;    ++++  very high 
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approach to identify new disease mechanisms and unprecedented drug targets and allow the 
development of new drugs and therapy options for schizophrenia. 
1.5 Autism 
Schizophrenia and autism are both neuronal disorders with a complex genetic etiology and 
overlapping behavioral phenotypes. Comparable to schizophrenia 1 % of the world population 
[109] is affected by autism. In the past, autism was mentioned as “schizophrenia syndrome of 
childhood” [110, 111]. Symptoms of autism occur early between the 6th and the 12th months 
of life. Autism is mostly diagnosed up to the 4th year of life [112]. Deficits in social interaction, 
cognitive and executive functions and problems in emotional processing are commonly 
observed in both disorders [113]. A subset of patients with autism have auditory and visual 
hallucinations in acute phases like patients with schizophrenia [114].  
 
Beside psychotic problems, a variety of morphological changes of the brain and the synapses 
are described for patients with autism. During the childhood, patients show aberrations in early 
brain morphology [115] and functionality [116]. Postmortem studies of brains derived from 
patients with autism found aberrations in synapse number, spine morphology [117, 118] and 
an impaired synapse maturation [117]. Synaptic dysfunction during early brain development 
belongs to the autism phenotype too [119]. 
 
Comparable to schizophrenia, autism has a strong genetic background with a heritability at 
50 % [120]. Genetical analyses described changes in gene expression encoding proteins for 
the formation of the PSD as well as synaptic development and functionality [121]. Interestingly 
17 out of 107 genes were mentioned before in sequencing studies for schizophrenia including 
genes related to glutamatergic synaptic transmission [122]. Overlapping symptoms, 
morphological and genetical changes in autism and schizophrenia may base on shared 
disease relevant molecular, cellular and signaling processes.  
1.6 Induced pluripotent stem cells as a model for neuropsychiatric 
disorders 
In 2007, Yamanaka et al. described the successful reprogramming of human fibroblasts into 
iPSC [123]. Reprogramming was enabled by the introduction of four specific transcription 
factors Oct3/4, Sox2, c-Myc, Klf4 via retroviral transduction. Currently different somatic cell 
types can be used for the generation of iPSCs: fibroblasts [123, 124], keratinocytes [125], hair 
follicles [126], dental pulp cells [127] as well as blood cells [128, 129]. After reprogramming, 
iPSC can be differentiated into cell types of all three germ layers, in vitro. A differentiation into 
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neuronal cells was preferred to study disease’s neuropathology of autism [130, 131] and 
schizophrenia [68]. Schizophrenia was one of the first neurodevelopmental diseases, modeled 
using patient specific iPSC-derived neurons [68, 132]. iPSC-derived neuronal cells carry 
patient’s genetic repertoire and can be used to investigate morphological, developmental and 
functional changes in disease relevant cell types as described above. iPSC represent an 
unlimited source for patient-derived neurons, which are otherwise difficultly accessible from 
patient brains. The generation of iPSC-derived neurons is well described and does not raise 
ethical concerns. Until today iPSC technology is the only method to study mechanisms of 
human neurodevelopment. During the differentiation of iPSC into neuronal cells like cortical 
neurons, each step of the early neuronal development and relevant signaling processes can 
be followed and analysed. 
1.7 Aims and objectives of the thesis 
Aim of the thesis is to investigate the early cortical neuronal development of patients with 
schizophrenia and to identify disease relevant mechanisms for new therapeutic approaches. 
Human fibroblasts from three patients with schizophrenia, three patients with autism and three 
healthy individuals will serve as cellular starting material. After reprogramming, iPSC will be 
differentiated into cortical neuronal cells in vitro and characterised. Neuronal and disease 
relevant morphological and functional characteristics will be proofed via immunocytochemical 
staining and live cell imaging. Early neurodevelopmental processes like brain layer marker 
expression, neurite outgrowth, synapse formation and calcium influx and efflux will be 
focussed, to identify potential disease relevant changes based on the schizophrenic genetic 
background. Disease relevant changes in gene expression will be investigated by 
transcriptome analysis of iPSC-derived neurons. The effects of first and second-generation 
antipsychotics on early neuronal development will be analysed using the neurite outgrowth 
experiment. Findings will evaluate the explanatory power and the potential application of 
patient-specific iPSC-derived neurons as cellular model system for schizophrenia. 
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2. MATERIAL AND METHODS 
2.1 Material 
2.1.1 General material, chemicals and equipment 
 
Tab. 2: General material 
general material manufacture, city 
24, 12 and 6 well-plate                                      Constar®, Corning Incorporated, New York, USA 
24 well µ-plate  ibidi GmbH, Martinsried, Germany 
37 µm Reversible Strainers Stemcell Technologies, Vancouver, Canada 
AggreWell 800 Stemcell Technologies, Vancouver, Canada 
Cell culture flasks (75, 25 cm²)  
 
Corning Incorporated, New York, USA 
Cell scraper Constar®, Corning Incorporated, New York, USA 
Cryo tubes™ Greiner Bio-One, Frickenhausen, Germany 
Eppendorf Tubes® (1,5 and 2 ml) Eppendorf AG, Hamburg, Germany 
Falcon Tubes (15 and 50 ml)  Corning Incorporated, New York, USA 
Parafilm Pechiney Plastic Packaging, Chicago, USA 
Pauster Pipette  Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Petridish (10 cm²) Constar®, Corning Incorporated, New York, USA 
Plastic pipets Greiner Bio-One, Frickenhausen, Germany 
Syringes (5 ml and 20 ml) Corning Incorporated, New York, USA 
Syringes filter (0.45 µm) Corning Incorporated, New York, USA 
 
Tab. 3: Chemicals and reagents 
chemical and reagent manufacture, city 
1 kb DNA marker 
New England Biolabs, Frankfurt am Main, 
Germany 
Acetic acid Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Agarose Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
AggreWellTM Rinsing Solution Stemcell Technologies, Vancouver, Canada 
Ascorbic acid Sigma-Aldrich Inc., Munich, Germany 
B27 supplement Thermo Fisher Scientific, Waltham, USA 
-mercaptoethanol Sigma-Aldrich Inc., Munich, Germany 
Bacto™ Agar BD, Biosciences, Heidelberg Germany 
BDNF (brain derived neuronal factor) 
New England Biolabs, Frankfurt am Main, 
Germany 
BrainPhysTM Neuronal Medium Stemcell Technologies, Vancouver, Canada 
Cal520® AM AAT Bioquest®, CA, USA 
Clozapine Sigma-Aldrich Inc., Munich, Germany 
Dibutyryl-cAMP Enzo Life Sciences GmbH, Lörrach, Germany 
Dimethylsulfoxid (DMSO) Sigma-Aldrich Inc., Munich, Germany 
Dorsomorphin dihydrochloride Tocris, Bristol, UK 
Dulbecco´s modified eagle´s medium 
(DMEM/F-12), glucose  
Life Technologies™ Gibco®, Darmstadt, 
Germany 
Dulbecco´s Phospate Buffered Saline 
(DPBS) 
Life Technologies™ Gibco®, Darmstadt, 
Germany 
Effectene Transfection Reagent Qiagen GmbH, Hilden, Germany 
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Ethanol (96%) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) 
Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
UltraPure™ Ethidium Bromide Thermo Fisher Scientific, Waltham, USA 
Fetal Bovine Serum (FBS) 
Life Technologies™ Gibco®, Darmstadt, 
Germany 
Fibroblast growth factor-Basic (bFGF) Sigma-Aldrich Inc., Munich, Germany 
Fibroblast Growth Medium 2 PromoCell, Heidelberg, Germany 
Fungizone Thermo Fisher Scientific, Waltham, USA 
GDNF (glia derived neuronal factor) Tocris, Bristol, United Kingdom 
Gelantin Sigma-Aldrich Inc., Munich, Germany 
Gentamicin Sigma-Aldrich Inc., Munich, Germany 
Haloperidol Sigma-Aldrich Inc., Munich, Germany 
Insulin Sigma-Aldrich Inc., Munich, Germany 
Isopropanol Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
KnockOutTM serum  Thermo Fisher Scientific, Waltham, USA 
Laminin Sigma-Aldrich Inc., Munich, Germany 
L-glutamine PAA Laboratories GmbH, Pasching, Austria 
Matrigel Corning Incorporated, New York, USA 
M-MulV Reverse Transcriptase 
New England Biolabs, Frankfurt am Main, 
Germany 
mTeSRTM1 medium Stemcell Technologies, Vancouver, Canada 
N2 Supplement Thermo Fisher Scientific, Waltham, USA 
Natriumacetat Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Natriumchlorid (NaCl) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Neurobasal™ Medium Thermo Fisher Scientific, Waltham, USA 
NeuroCult SM1 Neuronal Supplement Stemcell Technologies, Vancouver, Canada 
Non-essential amino acids PAA Laboratories GmbH, Pasching, Austria 
Normal Goat Serum (NGS) 
Jackson ImmunoResearch Laboratories Inc., 
West Grove, PA, USA  
Olanzapine Sigma-Aldrich Inc., Munich, Germany 
Paraformaldehyd (PFA) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Penicillin/Streptomycin (100x) 
Life Technologies™ Gibco®, Darmstadt, 
Germany 
Phusion® High-Fidelity DNA 
Polymerase 
New England Biolabs, Frankfurt am Main, 
Germany 
PluriSTEM™ human ES/iPS medium  Merck KGaA, Darmstadt, Germany 
Poly-l-ornithine (PLO) Sigma-Aldrich Inc., Munich, Germany 
Puromycin PAA Laboratories GmbH, Pasching, Austria 
Recombinant Human Noggin Fc 
Chimera Protein 
Bio-Techne GmbH, Wiesbaden-Nordenstadt, 
Germany 
RLT Buffer Qiagen GmbH, Hilden, Germany 
RQ1 Rnase-Free Dnase Promega, Fitchburg, USA 
SB 431542 Tocris, Bristol, UK 
Sodium Azid Sigma-Aldrich Inc., Munich, Germany 
Sodium bicarbonate Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Sodium pyruvate Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
STEMdiffTM Neural Induction Medium Stemcell Technologies, Vancouver, Canada 
STEMdiffTM Neural Progenitor Freezing 
Medium 
Stemcell Technologies, Vancouver, Canada 
STEMdiffTM Neural Progenitor Medium Stemcell Technologies, Vancouver, Canada 
STEMdiffTM Neural Rosette Selection 
Reagent 
Stemcell Technologies, Vancouver, Canada 
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StemPro™ Accutase Cell Dissociation 
Reagent 
Life Technologies™ Gibco®, Darmstadt, 
Germany 
Tris-base Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Triton-X-100 Sigma-Aldrich Inc., Munich, Germany 
Trypsin 
Life Technologies™ Gibco®, Darmstadt, 
Germany 
Y-27632 dihydrochloride (ROCK 
inhibitor) 
Tocris, Bristol, UK 
 
Tab. 4: Instruments and equipment 
instrument manufacture, city 
Amaxa 4D Nucleofector® system Lonza, Cologne, Germany 
C25 Incubator shaker  New Bunswick Scientific, New Jersey, USA 
Cell Observer SD  Zeiss, Oberkochen, Germany 
Centrifuge (5424 and 5810 R) Eppendorf AG, Hamburg, Germany 
Centrifuge 
Andreas Hettich GmbH & Co KG, Tuttlingen, 
Germany 
Centrifuge 5424 & 5415R & MiniSpin Eppendorf AG, Hamburg, Germany 
CO2 incubator CB 150 WTC Binder, Tuttlingen, Germany 
DNA-agarose-gel fluorescence-system 
IntasScience Imaging Instruments GmbH, 
Göttingen, Germany 
Gelelektrophorese-Kammer HU13 Thermo Fisher Scientific, Waltham, USA 
ImageXpress micro XL Molecular Devices, CA, USA 
Mr. Frosty™ Freezing Container Thermo Fisher Scientific, Waltham, USA 
Nanodrop, Specthrophotometer ND-
100 
Thermo Fisher Scientific, Waltham, USA 
Neubauer Counting chamber 
Marienfeld GmbH & Co. KG, Lauda- 
Königshofen, Germany 
PCR-Gerät Primus 96 plus MWG   Biotech AG, Ebersberg, Germany 
PH-Meter (Seven easy) Mettler Toledo, Gießen, Germany 
Pipetboy  
INTEGRA Biosciences GmbH, Femwald, 
Germany 
Pipette (0.5-10 µl; 10-100 µl; 100-1000 
µl) 
Eppendorf AG, Hamburg, Germany 
Scale BP 3100S Sartorius AG, Göttingen, Germany 
Scale XS205 & AE160 Mettler-Toledo GmbH, Giessen, Germany 
T3000 Thermocycler Biometra GmbH, Göttingen, Germany 
Thermomixer (comfort) Eppendorf AG, Hamburg, Germany 
Vortex Genie 2 Scientific Industries Inc., Biochemia, USA 
Water bath GFL®, Burgwedel, Germany 
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2.1.2 Antibodies 
 
Tab. 5: Primary Antibodies 





SSEA 4 mouse 1:500 
Cell Signaling Technology, Frankfurt am 
Main, Germany 
Tra 1-81 mouse 1:500 
Cell Signaling Technology, Frankfurt am 
Main, Germany 
Hoechst 33258  1:1000 Sigma-Aldrich Inc., Munich, Germany 
CTNT mouse 1:200 Thermo Fisher Scientific, Waltham, USA 
SOX17 goat 1:250 
R&D Systems GmbH, Wiesbaden- 
Nordenstadt, Germany 
ZO 1 mouse 1:150 Thermo Fisher Scientific, Waltham, USA 
PAX 6 rabbit 1:300 BioLegend, CA, USA 
Nestin mouse 1:1000 
Synaptic Systems GmbH, Göttingen, 
Germany 
SOX 1 rabbit 1:500 Abcam, Cambridge, UK 










Synaptic Systems GmbH, Göttingen, 
Germany 
NeuN mouse 1:500 Merck KGaA, Darmstadt, Germany 
PSD95  mouse 1:200 
New England Biolabs, Frankfurt am 
Main, Germany 
VGluT mouse 1:300 
Synaptic Systems GmbH, Göttingen, 
Germany 
Gephyrin  mouse 1:100 
Synaptic Systems GmbH, Göttingen, 
Germany 
VGaT rabbit 1:1000 
Synaptic Systems GmbH, Göttingen, 
Germany 
MAP2 mouse 1:1000 Sigma-Aldrich Inc., Munich, Germany 
GFAP rabbit 1:500 NeuroMab, Davis CA, USA 
cTIP2 rat 1:600 Abcam, Cambridge, UK 
Tü39 mouse 1:200 BioLegend, CA, USA 
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goat 1:800 Invitrogen GmbH, Darmstadt, Germany 
AlexaFluor 488-
anti-mouse IgG2 
goat 1:800 Invitrogen GmbH, Darmstadt, Germany 
Alexa Fluor 488-
pure anti-mouse 
goat 1:600 Dianova GmbH, Hamburg, Germany 
Cy3-pure anti-
rabbit 
goat 1:600 Dianova GmbH, Hamburg, Germany  
Cy3-anti-rabbit goat 1:600 Dianova GmbH, Hamburg, Germany 
Cy5-anti-rabbit goat 1:600 Dianova GmbH, Hamburg, Germany 
Alexa Fluor 488-
anti-mouse 
goat 1:600 Dianova GmbH, Hamburg, Germany 
Cy3-anti-mouse goat 1:600 Dianova GmbH, Hamburg, Germany 
Cy5-anti-mouse goat 1:600 Dianova GmbH, Hamburg, Germany 
Cy5-anti-goat donkey 1:600 Dianova GmbH, Hamburg, Germany 
2.1.3 Buffer and Solutions 
 
Tab. 7: Buffer and Solutions 
buffer and solution ingredients 
4 % (w/v) PFA/PBS 40 g PFA +1 l PBS; pH 7.4 
20 % (v/v) Triton X-100 20 ml Triton X-100 + 1 l water 
0,02 % EDTA/PBS 500 µl 0.5 M EDTA, 0.9 g NaCl in 500 ml DPBS 
Blocking solution 0.5 % NGS + PBS 
Permeabilisation solution 0.2 % Triton X-100 + 0.5 % NGS in PBS 
Poly-L-ornithine coating 20 % PLO + PBS 
Laminin coating 10 % laminin + DMEM/F-12 
Matrigel coating 10 % matrigel + DMEM/F-12 
TAE-Puffer (50x) 
2 M Tris + 250 mM Natriumacetat + 50 mM EDTA, pH 
7.8 with 96 % (v/v) acetic acid 
2.1.4 Cell lines 
 
Tab. 8: Cell lines 
cell line manufacture, city 
EmbryoMax - Primary Mouse 
Embryo Fibroblasts (MEF) 
Merck KGaA, Darmstadt, Germany 
Phoenix-AMPHO (ATCC® CRL-
3213™) 
ATCC, Teddington, UK 
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2.1.5 Media 
 
Tab. 9: List of cell culture media 
F12-10 Carrier Medium 
10 % FKS + 50 µg/ml gentamicin, 50 units/ml fungizone in 
DMEM/F12 
Dissociation medium 0.2 % Trypsin in DMEM/F12 
3N medium 
1:1 Mix of N2- and B27-medium 
N2-medium: 
1x N2 supplement, 5 µg/ml insulin, 1 mM L-glutamine, 
100 µM non-essential amino acids, 100 µM 2-
mercaptoethanol, 50 U/ml penicillin, 50 mg/ml streptomycin 
in DMEM/F12 
B27-medium: 
1x B27 supplement, 2 mM L-glutamine, 50 U/ml penicillin, 
50 mg/ml streptomycin in Neurobasal Media 
STEMdiffTM Neural 
Induction Medium + 
supplements 
STEMdiffTM Neural Induction Medium plus Dorsomorphin 
dihydrochloride (1 µM), SB 431542 (10 µM) and 
recombinant Human Noggin Fc Chimera Protein (500 ng/ml) 
BrainPhysTM Neuronal 
medium + supplements 
For 10 ml BrainPhysTM Neuronal Medium: 
200 µl NeuroCultTM SM1 Neuronal Supplement, 100 µl N2 
supplement, 2 µl of 100 µ/ml BDNF, 2 µl of 100 µg/ml 
GDNF, 50 µl of 100 mg/ml dibutyryl cAMP, 7 µl of 50 mg/ml 
ascorbic acid 
iPSC-Freeze medium 
1:1 Mix of Medium A and B 
Medium A: 50 % DMEM/F-12 + 50 % Knockout serum 
Medium B: 80 % DMEM/F-12 + 20 % DMSO 
Fibroblast Freeze medium 80 % FBS + 20 % DMSO 
MEF medium 
10 % FKS, 1 % Penicillin/Streptomycin, 1 % L-glutamine 
(200 mM) in DMEM/F12 
hES medium 
10 % Knockout serum, 2 mM L-glutamine, 1 % 
Penicillin/Streptomycin, 0.1 mM non-essential amino acids, 
0.1 mM 2-Mercaptoethanol, 10 ng/ml bFGF in DMEM/F12 
Phoenix medium 
2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 0.1 mM non-
essential amino acids, 1 mM sodium pyruvate, 10 % FBS in 
DMEM/F12 
2.1.6 Human material 
Skin Biopsies from three healthy individuals, three patients with schizophrenia and three 
patients with autism were obtained by the psychiatry in Tübingen.  
Tab. 10: Signature for samples 
explanation signature 
healthy individual number 1 CTR 1 
healthy individual number 2 CTR 2 
healthy individual number 3 CTR 3 
patient with schizophrenia number 1 SZ 1 
patient with schizophrenia number 2 SZ 2 
patient with schizophrenia number 3 SZ 3 
patient with autism number 1 ASD 1 
patient with autism number 2 ASD 2 
patient with autism number 3 ASD 3 
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2.1.7 Commercially available Kits 
 
Tab. 11: Kits 
2.1.8 Mimetic peptides, plasmids and vectors 
 
Tab. 12: Mimetic peptides 





Narpin 51  6467.5 3, 9, 12 
scrambled Narpin 51  6467.5 3, 9, 12 
Neurexide 56  4801.4 9, 27, 50 
scrambled Neurexide 58  4801.4 9, 27, 50 
FN4-NF3 64  5454.1 3, 9, 18 
scrambled FN4-NF3 70  5454.1 3, 9, 18 
 
Tab. 13: Plasmids for reprogramming 
plasmid source concentration (µg/ml) 
gRNA_Cloning-Vector Addgene #41824 1 
pCAS9_GFP Addgene #44719 1 
pMXs-Oct3/4 Addgene #13366 1000 
pMXs-Sox2 Addgene #13367 1100 
pMXs-c-Myc Addgene #13375 1200 
pMXs-Klf4 Addgene #13370 1280 
pRev CMV-EGFP NMI, control GFP plasmid 115 
VSV-G NMI, empty cloning vector 1736 
 
  
Kit manufacture, city 
MinElute PCR Purification Kit (50) Qiagen GmbH, Hilden, Germany 
NEBuilder® HiFi DNA Assembly Master 
Mix 
New England Biolabs, Frankfurt am Main, 
Germany 
P3 Primary Cell 
4D-Nucleofector® X Kit S (32 RCT) 
Lonza Ltd, Basel, Switzerland 
PSC Cardiomyocyte Differentiation Kit Thermo Fisher Scientific, Waltham, USA 
PureLink® Quick Plasmid Miniprep Kit Life Technologies GmbH, Darmstadt, Germany 
QIAamp DNA Mini Kit (50) Qiagen GmbH, Hilden, Germany 
QIAGEN Plasmid Plus Midi Kit (100) Qiagen GmbH, Hilden, Germany 
Qiagen QuiaQuick® Gel Extraction Kit Qiagen GmbH, Hilden, Germany 
RNAeasy Mini Kit Qiagen GmbH, Hilden, Germany 
STEMdiff™ Definitive Endoderm Kit Stemcell Technologies, Vancouver, Canada 
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2.1.9 Software 
Fiji, version 2017 – open source, https://fiji.sc/ 
Imaris8 x64, version 8.1.2 - Bitplane AG, Zurich, Switzerland 
MetaXpress, 64 bit, version 5.1.0.41 - Molecular Devices, CA, USA 
Origin 2015 - OriginLab Corporation, MA, USA 
StatView, version 5.0 - SAS Institute Inc., NC, USA 
GraphPad Instat, version 3.10 – GraphPad Software, Inc., CA, USA 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Skin Biopsy and Fibroblast cultivation 
Skin biopsies were collected at the University Department of Psychiatry and Psychotherapy of 
Tübingen and transported in 50 ml falcons containing F12-10 Carrier Medium.  After 
mechanical dissection with a sterile scalpel, skin pieces were incubated in a 50 ml tube 
containing dissociation medium for two to four days. Samples were washed three times with 
F12-10 Carrier medium and transferred to 10 cm petridishes. After an incubation time of 15 
minutes for cell adhesion, dishes were filled with 10 ml of Fibroblast Growth Medium 2. 
Samples were incubated at 37 °C, 5 % CO2 and medium was changed every two to three days. 
Outgrowth of fibroblasts was observed with a phase-contrast microscope, using a 10x 
objective. Skin pieces exhibited an outgrowth of approximately 20 mm were transferred to a 
new 10 cm petri dish and further cultivated. When 100 % confluence of fibroblasts was 
reached, cells were separated using trypsin for five minutes and transferred to 75 cm2 dish. 
Fibroblasts were passaged until passage 5. For each passage cells were cryopreserved using 
Fibroblast Cryo Medium. 
2.2.1.2 Transfection of Phoenix-AMPHO cells and retroviral transduction of fibroblasts 
7-8x105 Phoenix-AMPHO (ATCC, Teddington, UK) cells per well were cultivated in a 6-well 
plate. For each well 4 ml of Phoenix medium were used. In total 8 wells were covered with 
Phoenix-AMPHO cells. For the transfection of two wells 1.1 µg DNA+VSV-G, 270 µl EC-Puffer 
and 17.1 µl Enhancer were mixed and incubated for 5 minutes at room temperature. 100 µl 
plasmid and 20 µl effectene were added and incubated for 10 minutes at room temperature. 
In total, 5 different plasmids were used: pMXs-Oct4 (Addgene #13366), pMXs-c-Myc (Addgene 
#13375), pMXs-Sox2 (Addgene #13367), pMXs-KLF4 (Addgene #13370) and pRev CMV-
EGFP. 120 µl of the transfection mix were seeped on Phoenix-AMPHO cells and incubated for 
6 hours at 37 C, 10 % CO2, with additional full medium change. Next day, patient-derived 
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fibroblasts were seeded in 6-well plates at a density of 2x105 cells per well using Fibroblast 
Growth Medium 2 (PromoCell, Heidelberg, Germany). The following three days fibroblasts 
were retroviral infected with the supernatant of Phoenix-AMPHO cells in the morning and 
evening. For transduction, wells with fibroblasts were filled with 2 ml Fibroblast Growth Medium 
2 without antibiotics. The Supernatant of all GFP-producing Phoenix-AMPHO cells was 
collected in a 50 ml tube and sterilised with a 0.45 µm filter. 2 ml per well of this supernatant 
was pipetted on fibroblasts as transduction control. A minimum of one well was infected per 
donor. During the night cells were incubated in a 34 C incubator. During the day cells were 
cultured in a 37 °C incubator. To check the transduction efficiency, GFP expression on day 
three was analysed via fluorescence microscopy. Transduction medium of infected fibroblasts 
was changed every second day. Six days after transduction, fibroblasts were detached and 
seeded on mouse embryonic fibroblasts (MEF)-coated plates and fed with hES medium. For 
MEF cultivation, 6-well plates were coated with gelantin (0.1% in H2O) for four hours at 4 °C 
and washed twice with H2O. 2x104 MEFs per cm were seeded on top of the gelantin and fed 
with MEF medium. After one day, MEF coated plates were used for cultivation of infected 
fibroblasts. Fibroblasts were grown on MEF-coated plates until a clonal morphology occured. 
Medium was changed every second day and iPSC clones were manually passaged weekly. 
2.2.1.3 Cultivation of iPSCs on MEFs 
For cultivation of iPSCs on MEFs well plates were coated with MEFs. Therefore, 1x106 MEFs 
were plated in 6-well plates and cultured at 37 °C with hES medium. After two days of 
cultivation, iPSCs were plated on top of the MEFs. iPSCs were cultivated until the typical clone 
shape was visible and manually passaged. For young passages (1-3) iPSC clones were 
cultivated again on MEFs. Afterwards cultivation was carried out on Matrigel-coated plates. 
2.2.1.4 Cultivation of iPSC on Matrigel 
For storing single cells or clone pieces, cells were resuspended in iPSC freezing medium and 
frozen at -80 °C for 48 h with “Mr. Frosty”. For long-term storage cells were placed in liquid 
oxygen. For long-term cultivation iPSCs were cultured on Matrigel (Corning Incorporated, New 
York, USA). A Matrigel stock solution was stored at -80 C and diluted according to the 
manufacturers recommendation (ca. 1:100) in cold DMEM/F-12, tips and medium were cooled 
to 4 C, for covering with Matrigel well plates. Wells were filled with a minimum amount of diluted 
Matrigel solution in order to cover the plate bottom. Plates were incubated for at least 2 hours 
at room temperature. Plates were stored at 4°C for up to two weeks. For cultivation of iPSCs, 
clone fragments or single cells were thawed, suspended in warm DMEM/F-12 and centrifuged 
at 300 g for 5 min. Subsequently, DMEM was discarded and cells resuspended in cultivation 
medium.  iPSC clones were cultivated in mTeSR1 (Stemcell Technologies, Vancouver, 
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Canada) or Pluristem medium (Merck KGaA, Darmstadt, Germany). mTeSR1 medium was 
changed daily, Pluristem medium three times a week. iPSC clones were passaged when 
clones showed a dense fragmentation or clones started to overgrow, normally once a week. 
Clones were passaged using EDTA/PBS or mechanical scratching with pipette tips. In case of 
detachment by EDTA/PBS treatment, cells were washed twice with PBS and further incubated 
for maximum 7 minutes. In the presence of larger amounts of differentiated cells, clones were 
treated only for 2 minutes with EDTA/PBS. Afterwards cells were washed with cultivation 
medium and transferred to a new Matrigel-coated well plate. For mechanical passaging clones 
were scraped with a 100 µl pipette and transferred to a new Matrigel-coated well. Up and down 
pipetting was omitted to keep the clone fragments stable. For both passaging methods, cells 
were equally distributed by shaking the well plate horizontal and vertical in the incubator. To 
enable efficient cell adhesion, medium was changed only after 48h.  
2.2.1.5 Endodermal differentiation 
For endodermal differentiation, cells were incubated with mTeSR1 medium and 10 µM Y-
27632 dihydrochloride (ROCK inhibitor) for two hours. StemPro™ Accutase Cell Dissociation 
Reagent (Life Technologies™ Gibco®, Darmstadt, Germany) was used for dissociation of 
iPSC cells. 3x105 cells were seeded in a 24-well plate, covered with glass cover slips and filled 
with mTeSR1/ 10 µM ROCK inhibitor. Next day, medium was changed according to the 
instuctions given by the STEMdiffTM Definitive Endoderm Kit protocol (Stemcell Technologies, 
Vancouver, Canada). After 5 days of differentiation cells were fixed with 4 % PFA and stained 
with human anti-SOX17 antibody. 
2.2.1.6 Mesodermal differentiation 
PSC Cardiomyocyte Differentiation Kit supplied by Thermo Fisher Scientific was used for 
mesodermal differentiation. According to the manufacturers protocol, cells were dissociated 
into single cells. 0,8x105 cells were plated in a 12 well plate covered with glass cover slips and 
filled with mTeSR1 medium (Stemcell Technologies, Vancouver, Canada). For the next three 
days, mTeSR1 medium was changed daily. On day four, medium was changed to 
differentiation medium A. On day six, medium was changed to differentiation medium B. Media 
were changed every second day. After 8 days, cells were further incubated in cardiomyocyte 
maintenance medium with a change every second day. When rhythmic contraction of cells 
occurred, cells were fixed using 4 % PFA and stained against cardiomyocyte marker genes 
like cardiac troponin T (mouse anti-CTNT, Thermo Fisher Scientific).  
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2.2.1.7 Neural Progenitor Cell (NPC) generation and cultivation 
The success of NPC generation depends on the quality and purity of the iPSC culture. If 
necessary, differentiated cells were mechanically removed one day before further processing. 
For detachment, iPSC were washed twice with PBS and incubated for 7 minutes in StemPro™ 
Accutase Cell Dissociation Reagent (Life Technologies™ Gibco®, Darmstadt, Germany) at 
37 °C, 5 % CO2. The cells were detached via slowly up and down pipetting with a 1 ml pipette, 
collected in 5 ml DMEM/F-12, centrifuged, resuspended in STEMdiffTM Neural Induction 
Medium (Stemcell Technologies, Vancouver, Canada) plus ROCK inhibitor and counted. 2 to 
3x106 iPSCs were plated in one well of an AggreWellTM plate (Stemcell Technologies, 
Vancouver, Canada). AggreWellTM plates were coated with AggreWellTM Rinsing Solution for 
5 minutes. Subsequently, plates were centrifuged at 2000 x g for 5 minutes to discard all air 
bubbles in the plate. After washing with PBS and DMEM, each well was filled with 500 µl 
STEMdiffTM Neural Induction Medium plus ROCK inhibitor (final concentration 10 µM). 
Calculated volume of iPSC suspension was transferred into the AggreWellTM plate and slowly 
and evenly distributed via up and down pipetting.  Afterwards the AggreWellTM plate was 
centrifuged at 100 x g for 3 minutes. The plate was incubated at 37 °C, 5 % CO2 for 5 days 
with daily medium change. After 5 days, the 37 µm Reversible Strainers (Stemcell 
Technologies, Vancouver, Canada) cells was used to harvest cells. All cells of one 
AggreWellTM well were plated into one well of a poly-L-ornithine/ laminin-coated 6-well plate 
and cultivated for 7 days in STEMdiffTM Neural Induction Medium. For poly-L-ornithine/ laminin 
coating, plates were first coated with 20 % poly-L-ornithine in PBS for minimum two hours at 
room temperature, followed by two times washing with PBS and once with DMEM/F-12. 
Afterwards 10 % laminin in cold DMEM/F-12 were filled in the wells for further incubation of a 
minimum of two hours at 37 °C. 
 
After cultivation with daily medium change for 7 days, neural rosettes were selected using the 
STEMdiffTM Neural Rosette Selection Reagent (Stemcell Technologies, Vancouver, Canada). 
To this end, medium was discarded and cells were incubated with 1 ml STEMdiffTM Neural 
Rosette Selection Reagent for one hour at 37 °C. Afterwards medium was discarded and each 
well was washed with warm DMEM/F-12 for several times. Total medium was collected in a 
15 ml tube and centrifuged at 300 x g for 5 minutes. The cell pellet was resuspended in 
STEMdiffTM Neural Induction Medium and plated on a poly-L-ornithine/ laminin-coated 6-well 
plate. Cells were cultivated using STEMdiffTM Neural Induction Medium plus Dorsomorphin 
dihydrochloride (1 µM), SB 431542 (10 µM) and recombinant Human Noggin Fc Chimera 
Protein (500 ng/ml) up to 80-90% confluence. After the first passage, cultivation medium was 
changed to STEMdiffTM Neural Progenitor Medium (Stemcell Technologies, Vancouver, 
Canada). Cells were passaged a maximum of 10 passages. 
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2.2.1.8 Freezing and thawing of NPC 
3x106 dissociated NPCs were frozen in 1 ml STEMdiffTM Neural Progenitor Freezing Medium 
(Stemcell Technologies, Vancouver, Canada). For the first two days, cells were cooled down 
with “Mr. Frosty”. Subsequently, tubes were stored in liquid oxygen. For thawing, tubes were 
thawed using a 37 °C water bath and immediately resuspended in 15 ml prewarmed DMEM/F-
12. Tubes were centrifugated at 300 x g for 10 minutes, medium was discarded and cells were 
resuspended in 2 ml STEMdiffTM Neural Progenitor Medium.   
2.2.1.9 Neuronal differentiation and cultivation 
For neuronal differentiation, NPCs were detached from plates using StemPro™ Accutase Cell 
Dissociation Reagent, dissociated and 1x106 cells were transferred to 6-well plates and 
incubated in 3N medium plus 10 % bFGF. After two days of predifferentiation cells were 
dissociated again using StemPro™ Accutase Cell Dissociation Reagent and counted with the 
help of the Neubauer counting chamber. Glass coverslips with a diameter of 12 mm or 15 mm 
were coated first with 20 % poly-L-ornithine in PBS for minimum two hours at room 
temperature, followed by minimum of two 2 hours coating with 10 % laminin in DMEM/F-12. 
Each well of a 24-well plate or a 12-well plate were filled with one glass coverslips placed on 
the bottom. 1x105 cells were plated in a well of a 24-well or 12-well plate with glass coverslips. 
3N medium and BrainPhysTM Neuronal Medium (Stemcell Technologies, Vancouver, Canada) 
were used for cultivation and changed twice a week.  
2.2.1.10 High-content analysis of neurite outgrowth  
For neurite outgrowth experiments neurons were differentiated in poly-l-ornithine/ laminin-
coated 24-well µ-plates (ibidi, Munich, Germany) using 3N medium. Per well, 1x105 cells were 
seeded and cultured for four days. After differentiation, cells were fixed with 4 % PFA solution 
and stained with surface marker -III-tubulin and nuclei marker Hoechst 33258. For the 
detection of -III-tubulin primary antibodies, anti-mouse Alexa-488 conjugated secondary 
antibody was used. Because of similar fluorescence excitation and emission spectra, FITC and 
DAPI channel of the microscope were used for recording the antibody staining. Images were 
automatically retrieved via ImageXpress micro XL and analysed using the “MetaXpress High-
content Image Acquisition and Analysis” software (64 bit, 5.1.0.41). Automated segmentation 
of nuclei and neurite outgrowth was carried out with an adjusted “Neurite Outgrowth” tool. FITC 
and DAPI channels were imaged for each image. As an example, a screenshot of the software 
surface is shown in Fig.2. DAPI channel was used for the staining and detection of nuclei. To 
this end, a nucleus was defined as a segment with a minimal width of 8 µm and a maximal 
width of 16 µm. A threshold of 3000 gray levels above local background was set for defined 
segments. For the detection of cell bodies, segments were processed by applying a pixel 
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fluorescence intensity above local background of 2000 gray levels in the -III-tubulin staining 
(FITC channel). Subsequently, identified objects with a maximal width of 25 µm and minimal 
area of 150 µm2 were defines as cell bodies. For the detection of neurites, segments were 
processed by applying a pixel fluorescence intensity above local background of 2500 gray 
levels in the -III-tubulin staining (FITC channel). An outgrowth was defined as a segment with 
a maximal width of 8 µm and minimal cell growth of 20 µm. This length was calculated from 
the center of the nuclei. Normally, a nuclei had a radius of 10 µm. Outgrowth shorter than 
10 µm from the border of the nucleus were excluded from the final readout. The number of 
total cells was determined automatically based on the Hoechst signal (DAPI channel). Number 
of cells with neurites longer than 10 µm were counted manually during analysis. To calculate 
the percentage of neurons with neurites, number of cells with neurites >10 µm was divided by 
total number of cells. In each experiment, the  percentage of neurons with neurites was 
calculated for a single donor. Relative neurite induction was calculated with the control CTR 1 
set 100 %. Likewise, mean neurite length was calculated for each experiment and each donor. 
To this end, the sum of the total neurite outgrowth was divided by the number of cells with 
neurites >10 µm in length or by the number of total cells. In each experiment, more than 150 
cells were analysed. Six independent experiments were performed applying the same 
parameters. Kruskal-Wallis test and Dunn’s post hoc test were used for statistical evaluation. 
Statistics were performed on groups: healthy, SZ and ASD. Parameters set were kept constant 
for all images.    
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Fig. 2: Parameters set for neurite outgrowth. Screenshot of parameters for the neurite outgrowth 
experiment using the MetaXpress software.  
2.2.1.11 Treatment of neurons with drugs and peptides 
To test the effects of drug or peptide treatment, 1x105 cells were seeded in one well of a 24-
well µ-plate (ibidi GmbH, Martinsried, Germany) and treated once after 24 hours as depicted 
in Tab. 14 and 15. Subsequently, cells were cultivated for 48 hours, fixed with 4 % PFA 
solution, stained using -III-tubulin antibody and Hoechst and automatically analysed as 
described above.  
 
For antipsychotic treatment, drugs clozapine, haloperidol and olanzapine were diluted in 
DMSO. Percentage of neurons with neurites and mean neurite length were calculated for each 
treatment condition. Data were normalised to value of solvent control in each experiment. 
Kruskal-Wallis test and Dunn’s post hoc test were used for statistic. 
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Tab. 14: Range of drug concentrations 
drug solvent concentrations in µM 
clozapine DMSO 0.15, 0.62, 1, 1.5, 2, 4 
haloperidol DMSO 0.005, 0.027, 0.067, 0.133, 1.3, 4 
olanzapine DMSO 0.15, 0.25, 0.5, 1, 2, 4 
  
Three different types of mimetic peptides (Tab. 14) were applied in neurite outgrowth 
experiment. As control a scrambled version of the peptides was added at identical 
concentrations. H2O served as solvent control. Percentage of neurons with neurites and mean 
neurite length were calculated for each treatment condition as described above. Data were 
normalised to value of solvent control in each experiment. Kruskal-Wallis test and Dunn’s post 
hoc test were used for statistic. 
 
Tab. 15: Range of peptide concentrations 
mimetic peptide solvent concentrations in µM 
Narpin H2O 3, 9, 12 
Neurexide H2O 9, 27, 50 
FN4-NF3 H2O 3, 9, 18 
2.2.1.12 Analysis of PSD95 cluster density 
For the analysis of PSD95 cluster density, iPSC-derived neurons were differentiated for eight 
weeks according to differentiation protocol described above (see section: Neuronal 
differentiation and cultivation). Cells were fixed with 4 % PFA solution and stained for synaptic 
markers PSD95 and VGluT as well as for the surface marker -III-tubulin. Nuclei were stained 
with Hoechst. Confocal fluorescence z-stacks of neuronal cultures were acquired with Cell 
Observer SD equipped with a 63 x Plan-Apochromat oil immersion objective. Within each 
experiment, all settings for exposure times, contrast, brightness, resolution and threshold 
values were kept constant. For each donor 40 neurons were imaged per experiment. Acquired 
z-stacks were further processed and analysed with Imaris8 software without knowing the group 
classification. A surface mask was built for the -III-tubulin channel (parameters: surface area 
detail level: 0.3 µm, Background subtraction: 1.00 µm). Along neurites, a region of interest of 
20 µm in length was selected to build a mask. This mask was used to generate a new channel 
for the PSD95 and VGluT staining. According to the size (parameter: XY diameter 0.5 µm, Z 
diameter 1.00 µm), synaptic puncta of PSD95 and VGluT staining were marked as spots. For 
colocalization, a new channel mask was generated for PSD95 spots. Again, synaptic spots 
were analysed with VGluT channel. As requirement for colocalization, the intensity for the new 
masked channel of PSD95 spots had to be more than 1. Imaris8 software was applied to 
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calculate the number of synaptic spots in the areas of interest. The percentage of synaptic 
spots in each neuritic segment was normalised to CTR1 in each experiment. Density of PSD95 
spots was defined as the percentage of synaptic PSD95 spots in a 20 µm neuritic segment. 
For calculating of the density of PSD95/ VGluT colocalization, only double positive spots for 
PSD95 and VGluT were included. Three independent experiments were performed. Statistics 
was performed in groups: healthy, SZ and ASD. Kruskal-Wallis test and Dunn’s post hoc test 
were used for statistics. 
2.2.1.13 Functional assay for calcium mobilization  
For calcium imaging, iPSC-derived neurons were cultivated for eight weeks in 24-well plates 
covered with glass cover slips. In the first six weeks neurons were fed with 3N medium followed 
by a two weeks feeding with BrainPhysTM Neuronal Medium (Stemcell Technologies, 
Vancouver, Canada) plus supplements. For calcium imaging, neurons were stained with 1 µM 
Cal520® AM (AAT Bioquest) dissolved in BrainPhysTM Neuronal Medium for 30 minutes. 
Cal520® AM medium was discarded and cells were incubated in BrainPhysTM Neuronal 
Medium for further 10 minutes. The cover slips were inserted in the Patch Clamp rack. 
BrainPhysTM Neuronal Medium covered cells. Calcium waves were measured for 120 seconds 
with the Cell Observer SD microscope. 20 images were retrieved per second. Images were 
analysed with open source software Fiji. To this end, the nuclei of a spontaneously active 
neuronal cell was selected as region of interest (ROI). Fluorescence intensity of each ROI and 
each image was determined. Fluorescence intensity of one ROI over 120 seconds was 
visualised using the diagram tool of the Origin software. The number of peaks per 120 seconds 
was determined manually. As a measure for peak dynamics, the time from the inflection point 
until the peak maximum was calculated in seconds. This time is named peak length for the 
following analysis. Each peak was analysed manually and normalised to values of CTR 1 in 
each experiment. Three independent experiments were performed for one donor per group. 
Kruskal-Wallis test and Dunn’s post hoc test were used for statistic.   
2.2.2 Molecular Biology 
2.2.2.1 Immunocytochemistry 
For immunocytochemistry, cells were fixed using 4 % PFA solution for 10 minutes. Fixed cells 
were stored in well plates with DPBS. For staining, cells were permeabilised and blocked using 
the permeabilization and blocking solution including 0.2 % Triton-X-100 and NGS for 30 
minutes. Afterwards the indicated concentration of primary antibody (see Tab. 5) were 
incubated over night at 4 °C or for minimum of two hours at room temperature. Primary and 
secondary antibodies were diluted in blocking solution. During the incubation time cells were 
slowly moved on a swinging compensator. After incubation, cells were washed three times for 
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5 minutes using DPBS. Afterwards secondary antibody was incubated for two hours at room 
temperature in the dark. Cells were washed again three times using DPBS. Nuclear staining 
was performed using Hoechst for 30 minutes at room temperature in the dark. Again cells were 
washed three times using DPBS and once using H2O. For long-term storage cover slips were 
fixed with Mounting medium overnight and stored at 4°C. For live cell staining, cells were 
exposed to primary antibodies for 10 min. After a further washing step, cells were fixed for 10 
min in 4 % PFA solution, and finally stained  
2.2.2.2 RNA isolation 
Cells were harvested, and centrifuged at 2000 g for five minutes. Having discarded the 
supernatants, the pellets were resuspended in 350 µl of RLT buffer. For long-term storage 
pellets were frozen at -20 °C. RNAeasy Mini Kit (Qiagen GmbH, Hilden, Germany) was used 
for RNA isolation. According to manufacturer’s protocol, RNA dissolvent in 350 µl of RLT buffer 
was thawed and mixed with 350 µl of 70 % ethanol. Total suspension was added to the silica-
membrane RNeasy spin columns and centrifuged for 30 seconds at 10000 rpm. After 
discarding the flow-through, spin column was washed with 700 µl of RW1 buffer and 
centrifuged for 30 seconds at 10000 rpm. Again, flow-through was discarded and 500 µl of 
RPE buffer were added to the spin column and centrifuged for 30 seconds at 10000 rpm. This 
step was repeated once. RNA eluates were collected and diluted with RNase free water (50 µl) 
and centrifuged for 1 minute at 10000 rpm. RNA can be stored at -20 C. 
2.2.2.3 DNase digestion 
RQ1 RNase-Free DNase was used for DNase digestion. For each sample 8 µl of RNA were 
mixed with 1 µl 10x buffer and 1 µl RQ1 RNase-Free DNase and incubated for 30 minutes at 
37°C. 1 µl of stop solution was added and incubated for 10 minutes at 65 C. The RNA was 
used as a substrate for cDNA preparation after DNase digestion. 
2.2.2.4 cDNA synthesis  
Primers were diluted 1:50 in water. To a sample of 6 µl of RNA, 2 µl Oligo DT Primer, 0.4 µl 
dNTP and 7,6 µl H2O were added in one PCR tube. After incubation for 5 minutes at 70 °C, 
2 µl RT Buffer, 1 µl Murine RNAse Inhibitor and 1 µl M-MuLV were added and incubated for 
one further hour at 42 °C followed by five minutes incubation at 80 °C. cDNA was stored at 
- 20°C. 
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2.2.2.5 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used for the mRNA detection of embryonic stem cell 
marker genes in iPSCs. cDNA prepared from iPSC clones served as starting material. 
Components for a standard PCR approach are listed in Tab. 16. The respective PCR program 
is shown in Tab. 17. A PCR amplification of genomic DNA was performed to validate the 
mutation in the DISC1 locus in iPSC and NPCs of CTR 1. QIAamp DNA Mini Kit (Qiagen 
GmbH, Hilden, Germany) was used for extraction of genomic DNA. Substances for one 
experiment (Tab. 18) and PCR program (Tab. 19) are mentioned below. 
Tab. 16: Components for standard PCR 
component volumen for 20 µL approach (µl) 
10x buffer 2.5 




Primer forward und reverse (10 µM) 0.5 
 
Tab. 17: Standard PCR program 
step PCR program time/temperature 
1 initialization 2 min/94 °C 
2 denaturation 1 min/94 °C 
3 annealing 45 s/58 °C 
4 elongation 45 s/72 °C 
5 final elongation 10 min/72 °C 
6 final hold ∞ /4 °C 
The steps 2-4 were repeated for 32 cycles. 
 
Tab. 18: Components for genomic PCR  
component volumes for a 20 µL sample (µl) 
5x Phusion GC buffer 4 
10 mM dNTP 0.4 
DMSO 1 
Phusion DNA Polymerase 0.2 
H2O 10 
genomic DNA (200 ng/µL) 0.4 
Primer forward und reverse (10 µM) 1 
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Tab. 19: Genomic PCR program  
step PCR program time/temperature 
1 initialization 1 min 30 s/98 °C 
2 denaturation 10 s/98 °C 
3 annealing 60 s/63 °C 
4 elongation 15 s/72 °C 
5 final elongation 10 min/72 °C 
6 final hold ∞ /4 °C 
The steps 2-4 were repeated for 35 cycles. 
2.2.2.6 Agarose gel electrophoresis 
DNA fragments were separated with agarose gel electrophoresis according to their size. Here 
DNA samples were mixed with 6x DNA loading buffer and loaded on a 1-2 % agarose gel in 
TAE buffer. To visualise all separated DNA bands with UV light, 10 µl ethidium bromide 
(10 mg/ml) was added to the gel. Gel electrophoresis was run at a voltage of 120 Volt for 45 
minutes. The fragment size was identified using a DNA ladder.  
2.2.2.7 Design of sgRNA 
The online tool “ChopChop“ (http://chopchop.cbu.uib.no/) was used for designing of suitable 
sgRNA sequences. Human DISC1 gene (Ensembl-ID ENSG00000162946) was selected as a 
target sequence. Two sgRNAs in the beginning and in the end of exon 2 were selected as 
useful targets. Suitable PCR primers were chosen as recommended by the online tool. 851 
base pairs of exon 2 were deleted to achieve a complete inactivation of the gene and a 
disturbed protein production. Homology sequences had to be added to insert both gRNA 
sequences into the gRNA cloning vector using the HiFi DNA Assembly Master Mix. Below, 
additional bases attached to the gRNAs are shown. Plasmid sequencing was performed for 
sequence control. Production of gRNA plasmids was done by Kathrina Haag in her master 
thesis. 
 
forward strand 5’ to 3’: 
-TCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGNNNNNNNNNNNNNNNNNNN- 
reverse strand 5’ to 3’:  
-ACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACNNNNNNNNNNNNNNNNNNNC- 




Fig. 3: Sequencing of gRNA plasmids. Part of the gRNA sequencing of gRNA1 and gRNA2 which 































Fig. 4: Part of the sequence of DISC1 gene. For visualisation, part of the DISC1 gene is shown. 
Binding position of primers for genomic DNA PCR are highlighted in yellow, binding positions of gRNAs 
are marked in red. After successful CRISPR event 851 base pairs had been deleted. 
2.2.2.8 Electroporation 
gRNA plasmids were introduced into iPSCs of donor CTR 1 via nucleofection. Stem cells were 
cultivated in mTeSR1 without antibiotics for minimum of one passage. Medium mTeSR1 with 
4 ng/µl bFGF and 10 µM ROCK inhibitor was changed two hours before nucleofection. Cells 
were washed with DPBS and detached with StemPro™ Accutase Dissocation Reagent. The 
number of cells was calculated with the Neubauer Counting Chamber. Amaxa 4D-
Nucleofector™ system was used for transfection of stem cells in 16-well nucleocuvettes stripes 
of the P3 primary cell 4D-Nuclofector® X Kit S produced by Lonza. 200.000 cells were 
resuspended in 10 µl of P3 solution per well for transfection. Plasmids were diluted in P3 
solution. Thereby, different amounts of DNA (0.5, 0.75 and 1 µg) and Cas9:gRNA ratios (1:1, 
1:3 and 1:2) were tested. 10 µl of cell suspension and 10 µl of plasmid solution were combined 
in one well and electroporated with the program CB-150. Prewarmed medium was added to 
the cells immediately. Cells were cultivated on Matrigel coated 6-well plates in mTeSR1 
medium supplemented with 10 µl/ml bFGF and 10 µg/ml ROCK inhibitor. Medium was 
changed one day after electroporation. Successfully transfected cells were selected by G418 
selection for 72 hours. G418 resistance is encoded by the Cas9 plasmid, which is part of the 
transfection cocktail. Medium supplemented with bFGF was changed daily until clones of 
typical clonal iPSC morphology occurred. First developed clones were dissociated into single 
cells using StemPro™ Accutase Dissociation Reagent and further cultivated at low density 
until discriminable clones of iPSC morphology occurred. Larger clones were cultivated 
separately in a 6-well plate for several passages. Cell pellets of iPSC clones were used for 
PCR analysis to proof the CRISPR event.     
2.2.2.9 Transcriptome analysis 
Transcriptome analysis was performed by CeGaT located in Tübingen. For transcriptome 
analysis iPSC-derived neurons were differentiated for four weeks using 3N medium as 
described above. After four weeks of neuronal differentiation on cover slips in 12-well plates, 
4x104 neuronal cells were harvested.  Therefore, cells were washed twice with PBS, scrapped, 
diluted in 350 µl RLT buffer and collected in 1.5 ml tubes. Tubes were frozen, stored and 
transported at -80°C. RNA extraction and transcriptome analysis were performed by CeGaT 
GmbH Tübingen. Lists of deregulated genes and significant deregulated genes (p=<0.05) from 
iPSC-derived neurons from patient with schizophrenia (SZ 1-3) or autism (ASD 1-3) in 
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comparison to healthy individuals (CTR 1-3) were provided. Lists of deregulated genes were 
used to analyse changes in gene expression with the PANTHER classification tool 
(http://pantherdb.org/). Statistical overrepresentation test was used to identify significant 
overrepresented gene groups of deregulated genes. Changes in gene expression have been 
classified according to their gene ontology group, molecular function, biological process and 
signaling pathway. 
2.2.3 Statistics 
All graphics were designed using Excel 2007, Origin2015 or Statview 5.0 (SAS Institute Inc., 
NC, USA). Statistical analyses were performed using Statview 5.0 or GraphPad InStat (Version 
3.10, GraphPad Software, CA, USA). No data were distributed normally. Mann-Whitney U-test 
was performed for pairwise comparisons. Kruskal-Wallis test and Dunn’s post hoc test were 
performed for comparisons in groups. P-values were assigned as follows: *: p<0.05; **: p<0.01; 
***: p<0.001. Error bars represent s.e.m. 
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3. RESULTS 
Aims of the thesis is to investigate the early cortical neuronal development of patients with 
schizophrenia and to identify disease relevant mechanisms for new therapeutic approaches. 
Therefore, iPSC from three patients with schizophrenia, three patients with autism and three 
healthy individuals were generated. Fibroblasts of each donor were used as cellular starting 
material and reprogrammed into iPSC. Generated iPSC were characterized concerning the 
expression of stem cell specific markers.  
3.1 Generation and characterization of human iPSCs  
The Psychiatry of Tübingen selected three patients with schizophrenia (SZ 1, SZ 2, SZ 3), 
three patients with autism (ASD 1, ASD 2, ASD 3), and three healthy individuals (CTR 1, 
CTR 2, CTR 3).  Only patients with a family history, for example father, mother or a sibling is 
affected, were selected. Gender and age of patients with schizophrenia and autism were not 
matched to healthy individuals. In total five men (SZ 1, SZ 3, ASD 1, ASD 2, CTR 3) and four 
women (SZ 2, ASD 3, CTR 1, CTR 2) were selected as donors. All patients were in medical 
treatment at the Department of Psychiatry and Psychotherapy, University hospital, Tübingen. 
Diagnose for patients with schizophrenia differs between donors. SZ 1 and SZ 3 were 
diagnosed with a schizoaffective disorder (DSM IV: 295.70). This kind of schizophrenia is 
characterized by a major depressive or manic episode. During this time patients have also 
delusions or hallucinations [133]. Patient SZ 2 was diagnosed with a schizoaffective residuum 
(DSM IV: 295.60). This type of schizophrenia is characterized by an absent of delusions and 
hallucination and prominent negative symptoms [133]. All patients with autism were diagnosed 
for Asperger syndrome (DSM IV: F84.5). Patients exhibit missing interaction with other 
individuals and the environment [133]. Focus of the work was to characterize patients with 
schizophrenia. Patients with autism served as disease control group because of shared 
symptoms and healthy individuals as healthy control group.  
 
For the generation of iPSC, skin biopsies were obtained from each donor as cellular starting 
material. Under sterile conditions, skin biopsies were mechanically sheared, enzymatically 
digested and cultivated. Outgrowing fibroblasts were cultivated until a confluent monolayer. 
Donor specific fibroblasts were used for the reprogramming process into iPSC. As 
reprogramming plasmids, the four Yamanaka factors (OCT3/4, SOX 2, KLF4, c-Myc) were 
transduced via retrovirus as described before [123]. Reprogrammed fibroblasts changed 
morphology and gene expression into stem cell specific characteristics. Growing abilities 
changed from a monolayer into a clonal growing. Fig. 5 shows typical stem cell morphology of 
newly generated iPSC colonies. Cells exhibit large nuclei and scant cytoplasm, comparable to 
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embryonic stem cell morphology Generated iPSC expressed stem cell specific marker genes, 
like the cell membrane markers stages-specific embryonic antigen (SSEA) 4 and tumor related 
antigen (Tra)1-81.  
 
  
Fig. 5: Phase-contrast images of fibroblasts and an iPSC clone. Exemplarily part of a fibroblast 
culture derived from a healthy individual is shown on the left side. Right side iPSC clone with typical 
stem cell morphology from the same donor is shown. Scale bars: 10 µm. 
 
After 10 passages, iPSC clones of all donors were tested for human embryonic stem cell 
marker expression [134] by immunocytochemical staining. Exemplary images of 
representative iPSC clones derived from each group are shown in Fig. 6. Based on the 
morphological analysis new generated iPSC showed clonal growing. All iPSC clones exhibited 
stem cell specific marker expression of stem cell markers SSEA 4 and Tra 1-81 (Supplement 
Fig. 1). 
 
In addition to immunocytochemical stainings, the expression of induced exogenous genes and 
typical endogenous embryonic stem cell marker genes were analysed in all iPSC clones by 
PCR (Fig. 7). An overexpression of induced exogenous genes (OCT3/4, SOX2, KLF4 and c-
Myc) is only necessary during the reprogramming process. A silent expression of induced 
exogenous genes after 10 passages is essential for a further usage of the iPSC clone. Specific 
primers for retroviral transcripts were used to differ between exogenous and endogenous 
expressed genes. The pluripotent human embryonal carcinoma cell line (NTERA) served as 
positive control for all stem cell markers. DNA of human derived fibroblast (HDF) served as a 
negative control for all stem cell markers. The expression of GAPDH was analysed as a loading 
control. 
 
The silencing of the four exogenous induced genes after passage 10 was shown for all iPSC 
clones. 21 typical stem cell markers including OCT3/4, NANOG and FGF4 were mostly 
expressed in all iPSCs. On basis of PCR analysis all new reprogrammed iPSCs from patient 
with schizophrenia and autism as well as the healthy control group showed a silenced 
expression of exogenous induced genes and exhibited stem cell specific gene expression. 
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Fig. 6: Immunocytochemical staining of iPSCs against stem cell marker genes SSEA 4 and Tra 
1-81. Exemplarily iPSC clones of one donor per group are shown. Via immunocytochemical staining the 
expression of stem cell marker genes SSEA 4 (A) and Tra 1-81 (B) is validated. Scale bars: 100 µm.  
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Fig. 7: RT-PCR analysis of embryonic stem cell marker genes in iPSCs. All iPSCs (CTR 1-3, SZ 1-
3, ASD 1-3) were analysed with regard to the expression of 21 typical stem cell markers (endogenous 
genes). The silenced expression of exogenous genes was confirmed (exogenous genes). NTERA 
served as positive, HDF as negative control for stem cell markers. Housekeeping gene GAPDH was 
used as loading control. NTERA=human embryonal carcinoma cell line, HDF=human derived fibroblast 
 
One test for pluripotency of iPSC is the differentiation into all three germ layers. Newly 
generated iPSCs were differentiated into ectoderm, early endoderm and cardiomyocytes as 
proof of pluripotency. Differentiation into endoderm and cardiomyocytes as cell type of the 
mesoderm, was done by Kathrina Haag during her master thesis.  
 
Exemplarily differentiation of iPSC from the healthy donor CTR 1 into cardiomyocytes and 
early endoderm is shown in Fig. 8. Germ layer specific markers were stained using 
immunocytochemistry. Cardiac troponin T (CTNT) served as cardiomyocytes marker, SOX 17 
as early endoderm marker. 
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Fig. 8: Immunocytochemical staining of differentiated iPSCs against mesodermal marker CTNT 
and endodermal marker gene SOX 17. (A) Staining of CTR 1-derived cells against a cardiomyocyte 
marker cTNT (cardiac Troponin T) after mesodermal differentiation. (B) Early endodermal transcription 
factor SOX17 was stained in CTR 1-derived cells as marker for endoderm germ layer. (A, B) Scale bars: 
100 µm. 
 
During cardiomyocyte differentiation cells changed morphology and structure. Shown in 
Fig. 8A cells got clustered and built three-dimensional strands. After 14 days of differentiation, 
single cell cluster started rhythmical contraction like a heart muscle. After differentiation cells 
were fixed and stained against cardiac Troponin T (CTNT) a typical marker for cardiomyocytes 
[135]. Successful differentiation into cardiomyocytes was also shown for CTR 2, CTR 3, ASD 1 
and ASD 2. 
 
For endodermal differentiation cells were differentiated into early endodermal cells. Single cell 
iPSCs were cultivated in differentiation medium for five days, fixed and stained. One typical 
marker for endodermal germ layer is the transcription factor SOX 17 [136]. Fig. 8B shows a 
positive immunocytochemical staining for SOX17 of CTR 1-derived cells. In contrast to 
cardiomyocytes, early endoderm cells grew in a monolayer. Differentiation into early endoderm 
was shown for CTR 2, CTR 3, ASD 1, ASD 2 and SZ 2. Missing differentiations are still in 
progress.  
 
As proof of pluripotency iPSC clones from donor CTR 1, CTR 2, CTR 3, ASD 1 and ASD 2 
were successfully differentiated into cardiomyocytes and early endoderm cells. The 
differentiation into the third germ layer, the ectoderm will be shown in the next chapter.  
In addition to stem cell specific gene expression and pluripotency, iPSC clones should not 
exhibit major genomic aberrations after the reprogramming and differentiation process. A 
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comparative genomic hybridization array was performed by the industrial partner CeGaT 
GmbH, located in Tübingen, to analyse genomic aberrations. For CTR 1, CTR 2, CTR 3, 
ASD 1, ASD 2, ASD 3, SZ 1 and SZ 2 big chromosomal changes could be excluded.  
3.2 Neuronal differentiation of iPSC-derived cells 
3.2.1 Generation of Neuronal Progenitor Cells  
For investigation of diseases relevant molecular and cellular mechanisms, the generation of 
neuronal cell types is essential. iPSC from each donor were differentiated first into neural 
progenitor cells (NPC) and afterwards into cortical neurons. Subtype of cortical neurons were 
chosen to focus prefrontal mechanisms more in detail.  
 
First part of the differentiation focussed on the generation of NPC. NPC can divide a limited 
number of times and have the capacity to differentiate into a subset of neuronal and glial cell 
types. Only a high-quality iPSC culture with dense and compact colonies and less 
undifferentiated cells, was used for generating NPC. iPSC were submitted to embryoid body 
formation, plated for neural rosette formation and selected for NPC. NPC were characterized 
according to their morphology and NPC marker gene expression (Supplement Fig. 2 and 3) 
As example NPC from one donor of each group are shown in Fig. 9.  
 
Growing characteristics differed between individual donors. NPCs derived from donor CTR 
grew like a rosette like structure in comparison to the wide spread single cells of the other 
donors. In comparison to iPSCs, NPCs of all donors grew as monolayer and had a bigger 
proportion of cytoplasm. Immunocytochemical staining against ZO 1, PAX 6, Nestin and SOX 1 
were used to show expression of NPC specific marker genes [137-139] (Fig. 9). NPC of all 
donors showed a concentrated expression of ZO 1 at the border of the cells. PAX 6 and Nestin 
were spread all over the cell with the highest concentration in the cell nucleus in all donors. 
The expression of the transcription factor SOX 1 was concentrated in the cell nucleus for all 
NPC lines.  
 
iPSC of each donor were differentiated into NPC. The rosette formation during the 
differentiation process differed between single donors. Changes in differentiation did not 
influence characteristics of final NPC. NPC of all donors grew in a monolayer and exhibited 
NPC specific gene expression. All generated NPC lines were used as cellular starting material 
for each differentiation into cortical neurons.  
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Fig. 9: Immunocytochemical staining of NPCs against marker genes ZO 1, PAX 6, Nestin and 
SOX 1. Expression of NPC marker genes like cell surface marker ZO 1 and transcription factor PAX 6 
(A) as well as Nestin and transcription factor SOX 1 (B) was validated via immunocytochemical staining 
in NPCs derived from one donor per group. ZO 1=Zona Occludens 1, PAX 6=Paired box gene 6, 
SOX 1=SRY box 1, Scale bars: 100 µm. 
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3.2.2 Differentiation into cortical neurons 
According to Shi et al. [140] NPCs were differentiated for eight weeks into a mixture of cortical 
neuronal cells and stained against typical neuronal markers. This protocol allows a defined 
and controlled differentiation and the investigation of early neurodevelopmental events of 
human cortical development. First of all, NPCs were detached and pre-differentiated using 3N 
medium plus fibroblast growth factor (FGF) which stimulates proliferation. After two days cells 
were detached again and disseminated on poly-l-ornithine/laminin-coated plates in 3N medium 
without FGF for the induction of cortical neurogenesis.  
 
Already during the first week, cells changed morphology and showed a typical neuronal 
morphology forming a dense neuronal network. Marker expression of iPSC-derived neurons 
from donor CTR 1 is shown in Fig. 10. Fig. 10A shows the expression of the major synaptic 
vesicle protein synaptophysin and the neuron-specific -III-tubulin, which served as whole cell 
surface marker in most of the images. The expression of the neuronal nuclear antigen NeuN 
analysed the maturation of the neuronal culture (Fig. 10B). The expression of synapse-specific 
markers is shown in Fig. 10C and 10D. Postsynaptic marker PSD95, enriched at the 
postsynaptic density of excitatory, glutamatergic neurons is co-stained with the vesicular 
glutamate transporter 1 (VGluT), important for uptake and storage of glutamate into synaptic 
vesicles at the presynaptic part (Fig. 10C).  Colocalization of postsynaptic PSD95 and 
presynaptic VGluT was taken as an indication for a potential synapse. In analogy, 
colocalization of gephyrin and VGAT was examined (Fig. 10D). Gephyrin is localised at 
postsynaptic parts of inhibitory, GABAergic neurons while the vesicular GABA transporter 
(VGAT) transports GABA into synaptic vesicles. The differentiation protocol produced a 
mixture of neural cells including astrocytes expressing the marker gene GFAP (Fig. 10E).  
 
In conclusion, a mixture of neural cells was successfully derived using this differentiation 
protocol. Exemplarily the positive expression of neuronal, synaptic and astrocytic markers is 
shown for donor CTR 1. A generation of neural cells enable to study disease relevant 
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Fig. 10: Immunocytochemical staining of iPSC-derived neurons against neuronal marker genes. 
iPSC-derived neurons from CTR 1 were stained against neuronal markers: (A) Synaptophysin, (B) 
NeuN, (C) PSD95 and VGluT and (D) gephyrin and VGAT. (E) Astrocytes were stained using GFAP 
marker gene. -III-tubulin and MAP2 were used as neuronal surface marker genes. 
SHP=Synaptophysin, PSD95=Post synaptic density protein 95, VGluT=vesicular glutamate transporter 
1, VGAT=vesicular GABA transporter, GFAP=glial fibrillary acidic protein, -III-tub=-III-tubulin, 
MAP2=microtubule associated protein 2, (A, B, E) Scale bars: 100 µm, (C, D) Scale bars: 10 µm. 
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3.3 Significant less Ctip2 expressing neurons in patients with 
schizophrenia  
Starting with NPCs and differentiate into neuronal cells mimic a very early embryonic neuronal 
development. Deep brain layer neurons are produced first followed by upper layer neurons. 
Ctip2 is a marker for subcortical projection neurons [141], neurons of brain layer V. To follow 
the dynamic development of human layer V neurons in culture, NPC were differentiated into 
cortical neurons and Ctip2 expression was analysed at different time points in culture. To 
analyse potential differences of Ctip2 expression related to a disease background, iPSC-
derived neurons of one donor per group were selected.  
 
Fig. 11A shows CTIP2 expression by immunocytochemistry in iPSC-derived neuronal cultures 
after 28 days of differentiation. As expected Ctip2 expression was confined to the nuclei [142]. 
Fig. 11B and 11C quantify the percentage of Ctip2 expressing cells for different time points 
and different donors. iPSC-derived neurons were differentiated, fixed and stained against Ctip2 
and Hoechst. Minimal six images were taken for each time point and each donor.  According 
to fluorescence intensity number of Ctip2 and Hoechst positive cells were obtained and 
percentage of Ctip2 positive cells was calculated. In Fig. 11C values of SZ 2 and ASD 1 were 
normalized to CTR 1 for each experiment. iPSC-derived neurons were cultivated for 56 days 
in four independent experiments and Ctip2 expression was analysed in a minimum of 10 
images afterwards. The percentage of Ctip2 expressing cells from patient with schizophrenia 
SZ 2 (55 %) and autism ASD 1 (21 %) was much lower than in CTR 1 (100 %) derived cells. 
Differences in Ctip2 expression were observed in the analysis of different time points, too. In 
Fig. 11B all values were minimized by the six day data of each donor as starting value. The 
Graph shows the percentages of Ctip2 expression from donor CTR 1, SZ 2 and ASD 1 of one 
neuronal differentiation. After 40 days, the percentage of Ctip2 positive neurons differs 
significantly among CTR 1, SZ 2 and ASD 1. SZ 2 (10 %) and ASD 1 (23 %) expressed 
significantly less Ctip2 positive cells in comparison to CTR 1. In contrast to the result of 56 
days differentiation of four independent experiments, iPSC-derived neurons from SZ 2 
exhibited less Ctip2 expressing cells than ASD 1. Until day 20, SZ 2 exhibited the most limited 
percentage of Ctip2 expressing cells. At time points 27 and 31 days, the percentage of Ctip2 
expressing cells is nearly similar to ASD 1. At 37 days, level of Ctip2 cells is in between CTR 1 
and ASD 1. 
 
Percentage of iPSC-derived Ctip2 positive neurons was highest for ASD 1 (29 %) after 15 days 
neuronal differentiation and kept that level until day 27. At day 31, percentage is nearly similar 
to SZ 2 and still higher than CTR 1. Order changed at day 37 and level of Ctip2 expressing 
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cells was lower than in CTR 1. Until day 20, iPSC-derived neurons from CTR 1 expressed less 
Ctip2 than ASD1 and more than SZ 2. For time point 27 and 31 days CTR 1 exhibited less 
Ctip2 positive neurons than the two other donors. After day 37 order changed and percentages 
of Ctip2 expressing iPSC-derived neurons was the highest in donor CTR 1. Differences in 
Ctip2 expressing cells did not belong to cell death or a reduced number of cells (Fig. 11D). In 
case of schizophrenia (166 %) significant more cells were analysed per images than in CTR 1. 
Differences in layer specific marker expression of one of the first developed brain layer gave 
hints for differences in the early neuronal development in iPSC-derived neurons from patients 
with schizophrenia.  
3.4 Significant reduction of neurite outgrowth in iPSC-derived 
neurons from patients with schizophrenia 
The changed expression of Ctip2 in iPSC-derived neurons from patients with schizophrenia 
suggest defects in early neuronal development. Neurite outgrowth is a characteristic of early 
neuronal development, too. Potential differences in neurite outgrowth during early neuronal 
development of iPSC-derived neurons from patients with schizophrenia was investigated.      
 
iPSC-derived neurons were differentiated for four days on 24-well µ-plates, fixed and stained 
against cell surface marker -III-tubulin. Images of Hoechst and -III-tubulin stained neuronal 
cultures were retrieved using the ImageXpress micro XL microscope. The neurite outgrowth 
of iPSC-derived neurons was analysed using the MetaXpress software. The procedure of 
calculating neurite outgrowth is shown in Fig. 12A. For each image, Hoechst staining was used 
for staining and counting of cell nuclei. -III-tubulin staining was used for the analysis of neurite 
outgrowth and neurite length. Data of CTR 1 served as normalization control in each 
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Fig. 11: Ctip2 expression analysis of iPSC-derived neurons. (A) Immunocytochemical staining 
against Ctip2 in CTR 1, SZ 2 and ASD 1. (B) Percentage of Ctip2 expressing cells during the first 40 
days of differentiation in iPSC-derived neurons from CTR 1, SZ 2 and ASD 1. n>6, for clarity reasons 
only significant points are marked, non-marked dots are not significant, day 6 H(2)=7.6, day 13 
H(2)=11.6, day 15 H(2)=15.3, day 20 H(2)=13.1, day 27 H(2)=6.8, day 31 H(2)=1, day 37 H(2)=0.3, day 
40 H(2)=21.9, (C) Percentage of Ctip2 positive cells of iPSC-derived neurons from CTR 1, SZ 2 and 
ASD 1 after eight weeks neuronal differentiation, H(2)=7.6, n>35. (D) Mean number of counted cells 
after eight weeks neuronal differentiation, H(2)=25.7, n>35. (B, C, D) Kruskal-Wallis Test and Dunn’s 
post hoc test, p<0.05*, p<0.01**, p<0.001***, Error bars are s.e.m. 
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Fig. 12: Test of high content analysis of neurite outgrowth in iPSC-derived neurons. (A) Procedure 
of neurite outgrowth experiments: staining using -III-tubulin antibody and Hoechst, automated imaging 
via ImageXpress micro XL and segmentation with the MetaXpress Software. Scale bar: 100 µm (B) 
Percentage of neurons with outgrowing neurites >10 µm of iPSC-derived neurons from donor CTR 1 
after treatment with DMSO or ROCK inhibitor. DMSO served as solvent control. (C) Percentage of mean 
neurite length of iPSC-derived neurons from donor CTR 1 after treatment with DMSO or ROCK inhibitor. 
(B,C) Data normalised to DMSO, Mann-Whitney U-Test, p<0.05*, n=3. 
 
After four days of neuronal differentiation, neurite length and percentage of neurons with 
neurites were calculated to analyse the ability of neurite development. Processes longer than 
10 µm were defined as neurites. Suitable measurable differences between iPSC-derived 
neurons from patients and healthy individuals have to be identified. Y-27632 (ROCK inhibitor) 
was used as test substance to calibrate the system. A stimulating effect on neurite outgrowth 
is already known from literature [143-145]. Treatment with ROCK inhibitor allows the 
measurement of neurite outgrowth under controlled conditions. Pure DMSO served as dilution 
control. Two parameters were calculated, which reproduce the stimulating effect of neurite 
outgrowth after ROCK inhibitor treatment: percentage of neurons with neurites and mean 
neurite length. Hoechst staining was used to determine the number of total cells. Number of 
cells with a neurite outgrowth >10 µm was calculated via -III-tubulin channel. Percentage of 
neuron with neurites >10 µm was generated for each donor and each experiment.  
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Fig. 12B shows a significant higher number of neurons with neurites after ROCK inhibitor 
treatment (167 %) in comparison to DMSO. The stimulating effect of ROCK inhibitor on neurite 
outgrowing can be positively measured. As additional parameter the mean neurite length of 
outgrowing neurites was analysed. The lengths of all measured neurites >10 µm were summed 
up and divided by the number of analysed cells with neurites >10 µm. Mean neurite length was 
calculated per donor and individual experiment. Fig. 12C shows a significant higher mean 
neurite length (158 %) for four days old neurons after ROCK inihibitor treatment in comparison 
to DMSO. To sum up an automated analysis using ImageXpress micro XL microscope for 
imaging and MetaXpress software for automated analysis positively measured the known 
stimulating effect of ROCK inhibitor on neurite formation and neurite length. These findings 
indicate the validity of this method and was used as tool to compare potential differences of 
neurite formation and the mean neurite length between healthy individuals and patients with 
schizophrenia or autism.  According to the previous described procedure iPSC-derived 
neurons from patients with schizophrenia, autism and healthy individuals were differentiated 
for four days, fixed, stained and analysed with regard to neurite induction and length. Potential 
differences in early neuronal development have to be tested. 
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Fig. 13: High content analysis of neurite outgrowth in iPSC-derived neurons. (A) Percentage of 
neurons with neurites > 10 µm of iPSC-derived neurons from healthy donors (CTR 1-3), patients with 
schizophrenia (SZ 1-3) and patients with autism (ASD 1-3), H(2)=11.3. (B) Mean neurite length of iPSC-
derived neurons from healthy donors (CTR 1-3), patients with schizophrenia (SZ 1-3) and patients with 
autism (ASD 1-3), H(2)=21.6 (A,B) CTR 1 served as normalization control for each experiment, six 
independent experiments are shown in box-and-whisker plots: filled dots = data points, dot unfilled = 
mean, line in the box = median, lower end of the box = 25 % of all values are smaller, upper end of the 
box = 75 % of values are smaller, range of the whiskers = 95 %, dot outside box and whisker = spike, 
Statistic was performed group wise, n=18, Kruskal-Wallis Test and Dunn’s post hoc test, p<0.05*, 
p<0.01**, p<0.001***, Error bars are s.e.m. 
 
Fig. 13 shows the results of experiments measuring neurite induction and mean neurite length 
of donors with schizophrenia or autism compared to healthy individuals. In total six 
independent experiments were performed for each donor. Exemplarily, immunocytochemical 
staining of iPSC-derived neurons from donor CTR 1-3, SZ 1-3 and ASD 1-3 against -III-
tubulin is shown in Supplement Fig. 4. All values were normalized to CTR 1 in each experiment 
which was set 100%. Each single experiment is shown as dot in the diagram. For statistical 
analysis, data obtained from each donor were combined in one group and subsequently 
evaluated statistically. 
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The percentage of neurons extending neurites for all donors is shown in Fig. 13A. Neurons 
derived from patients with schizophrenia extended significant less neurites compared to the 
group of healthy individuals. The percentage of neurons with neurites was reduced by 39 %. 
In case of the patients with schizophrenia, only donor SZ 1 (51 %) and SZ 3 (65 %) showed a 
higher reduction of the percentage of neurons with neurites than the mean of all donors (67 %). 
In SZ 2 average 85 % of neurons elaborate neurites. This percentage is lower than the lowest 
value of donors from the healthy control group. iPSC-derived neurons from patients with autism 
extend significant less neurons with neurites >10 µm in comparison to healthy individuals, too. 
The percentage in case of autism was reduced by 33 %. Lowest level of neurons with neurites 
was measured for ASD 3 (46 %). 87 % of iPSC-derived neurons from donor ASD 1 and ASD 2 
extend neurites. Highest variability between experiments was observed for donor CTR 3. 
Percentage of neurons with neurites from each healthy individual (CTR 1:100 %, CTR 2: 
105 %, CTR 3: 98 %) was bigger than in patient-derived cells. 
 
As second parameter, the mean neurite length was calculated for all donors in the same six 
independent neuronal differentiations as described above (Fig. 13B). Mean neurite length of 
iPSC-derived neurons from patients with schizophrenia and autism was significantly reduced 
by 23 % in comparison to neurons derived from healthy individuals. Again, donor SZ 1 (74 %) 
and SZ 3 (73 %) showed a more reduced mean neurite length in comparison to SZ 2 (84 %). 
But mean neurite length of SZ 2 was shorter than every mean neurite length of a healthy 
individuals. Mean neurite length of donor ASD 3 (66 %) exhibited the highest reduction in 
comparison to ASD 1 (80 %) and ASD 2 (84 %). Highest experimental variability was 
measured for donor CTR 3 again. Mean neurite length of iPSC-derived neurons from healthy 
individuals (CTR 1: 100 %, CTR 2:123 %, CTR 3: 96%) was longer than in patient-derived 
cells. 
 
Percentages of neurons with neurites >10 µm as well as the mean neurite lengths were 
significantly reduced in iPSC-derived neurons from patients with schizophrenia. Both 
parameters indicate an impaired neurite outgrowth in case of schizophrenia. 
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3.5 Significant reduced PSD95 clusters density in iPSC-derived 
neurons from patients with schizophrenia 
iPSC-derived neurons from patients with schizophrenia exhibited significant reduced mean 
neurite length. Decreased capacity for neurite outgrowth may result in delayed neuronal 
development or reduced morphological plasticity which may impair proper formation of 
neuronal network. Formation of synapses is a prominent process of early neuronal 
development and is important for synaptic functionality. Potential changes in synapse 
formation have to be investigated. iPSC-derived neurons from all donors were differentiated 
for eight weeks, fixed and stained against postsynaptic marker PSD95 and presynaptic marker 
VGluT (Fig. 14A). Hoechst solution was used for nuclei staining. Whole cell surface was 
marked using -III-tubulin staining. The cluster densities of PSD95 and PSD95/VGluT co-
localization were analysed for dendritic fragments of each donor (Fig. 14B). 
 
First step was the segmentation of a 20 µm neuritic region of interest using the -III-tubulin 
staining. This ROI was used to generate new channels for PSD95 and VGluT staining. 
According to size and fluorescence intensity, number of synaptic spots was automatically 
determined via Imaris software. Double positive spots were marked as PSD95-VGluT co-
localization. In total, 40 segments per donor and experiment were analysed without knowing 
the classification of the donor. To find a differentiation time with significant measurable 
differences, iPSC-derived neurons were differentiated up to 12 weeks. First time point with 
significant measurable differences in PSD95 cluster density between single donors should be 
selected. PSD95 cluster density was analysed for one donor per group after four, eight and 12 
weeks of neuronal differentiation (Fig. 14C). 
 
Data were normalised to the PSD95 cluster density after one week of differentiation for each 
donor, individually. Donor CTR 1, SZ 1 and ASD 1 exhibited the highest PSD95 cluster density 
after 12 weeks of differentiation. At this time point, iPSC-derived neurons from SZ 1 (152 %) 
and ASD 1 (166 %) exhibited significant less PSD95 cluster than CTR 1 (230 %). The 
percentage of PSD95 cluster density continuously increased for donor CTR 1 and ASD 1 over 
time. Rise of PSD95 cluster density from donor SZ 1 stagnated at time point eight weeks of 
differentiation. First differences of PSD95 cluster density were measured at time point four 
weeks of differentiation. Patient with autism (125 %) showed a significant higher PSD95 cluster 
density in comparison to the healthy control group (113 %). PSD95 cluster density of SZ 1 
(125 %) was higher than at time point 1 week but did not increased significantly. The time point 
eight weeks of neuronal differentiation was the first time point with significant differences in 
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both disease groups in comparison to CTR 1. CTR 1 exhibited the highest level of PSD95 
cluster density (176 %) in comparison to SZ 1 (121 %) and ASD 1 (152 %). 
 
For further analyses, neurons were differentiated for eight weeks because both donors showed 
significant differences in PSD95 cluster density. Additionally, the quality of neuronal culture 
and following analyses were better than after twelve weeks differentiation. PSD95 cluster 
density of three different iPSC clones derived from donor CTR 1 was compared to test clonal 
variability. After differentiation for eight weeks and analysis of PSD95 cluster density, iPSC 
clone a, b, and c showed no significant differences (Fig. 14D). For following experiments only 
one clone per donor was selected, differentiated for eight weeks and analysed concerning 
cluster density of PSD95 and PSD95/VGluT co-localization. 
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Fig. 14: Validation of PSD95 cluster density analysis. (A) Immunocytochemical staining against 
synaptic marker PSD95, VGluT and neuronal marker -III-tubulin. Hoechst was used for nuclei staining. 
Scale bars: 10 µm. (B) Analysis of synaptic and neuronal marker expressions using Imaris software. 
Scale bars: 10 µm. (C) PSD95 cluster density of iPSC-derived neuron from CTR 1, SZ 1 and ASD 1 
during twelve weeks differentiation. Data is normalised to one week value per donor. 4W: H(2)=9.6, 
8W:H(2)= 54.7, 12W:H(2)=70.1, n=40. (D) PSD95 cluster density of iPSC-derived neurons from three 
different iPSC clones from donor CTR 1 after eight weeks differentiation. Data normalised to clone a, 
H(2)=8.8, n=50. (C,D) Kruskal-Wallis Test and Dunn’s post hoc test, p<0.05*, p<0.001***, n.s.= not 
significant, error bars are s.e.m. 
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Fig. 15: PSD95 and PSD95/VGluT cluster density analysis in iPSC-derived neurons. (A) PSD95 
cluster density of iPSC-derived neurons from donors CTR 1-3, SZ 1-3 and ASD 1-3 after eight weeks of 
differentiation, H(2)=62.4. (B) PSD95/VGluT cluster density of iPSC-derived neurons from donors 
CTR 1-3, SZ 1-3 and ASD 1-3 after eight weeks differentiation, H(2)=24.4. (A,B) Statistic is performed 
group wise. Data is normalised to CTR 1 in each experiment, three independent experiments are 
performed, Kruskal-Wallis Test and Dunn’s post hoc test, p<0.05*, p<0.01**, p<0.001***, n.s.= not 
significant, n=360, error bars are s.e.m. 
 
Potential changes in early neurodevelopmental processes like synapse formation of iPSC-
derived neurons from patients with schizophrenia have to be tested. According to previous 
results, iPSC-derived neurons of one clone per donor were differentiated for eight weeks, fixed 
and stained against -III-tubulin, PSD95 and VGlut. Imaris software helped to analyse PSD95 
as well as PSD95/VGluT cluster density. Statistics of cluster densities were performed in 
groups related to disease group or non-disease group. Fig. 15 shows the PSD95 and 
PSD95/VGluT cluster density in iPSC-derived neurons from CTR 1-3, SZ 1-3 and ASD 1-3 
after eight weeks of differentiation. PSD95 cluster densities of patients with schizophrenia and 
autism were significantly reduced in comparison to healthy individuals (Fig. 15A). The mean 
PSD95 cluster density of patients with schizophrenia was reduced by 5 %. Even if the reduction 
was significant, amounts of reduction measured in the neurite outgrowth experiment were not 
reached, based on the high variability of reduction between donors of one group. For example, 
donor SZ 2 (100 %) showed no reduction. PSD95 cluster density from SZ 1 (93 %) and SZ 3 
64   RESULTS 
(88 %) were more reduced than SZ 2. The mean PSD95 cluster density of patients with autism 
was reduced by 12 %. Variability is less and all donor exhibited a reduced PSD95 cluster 
density: ASD 1=91 %, ASD 2=86 % and ASD 3=83 %. PSD95 cluster density of each healthy 
donor (CTR 1=100 %, CTR 2=98 %, CTR 3=98 %) was higher and more consistent than levels 
of patients.  
 
A synapse is characterised by closely co-located post- and presynaptic parts. An overlap of 
synaptic markers of the post- and presynaptic side was used, to identify potential synapses in 
iPSC-derived neurons. In addition to previous experiments, PSD95/VGluT co-localization was 
analysed in the same differentiation experiments. To analyse cluster density, PSD95/VGluT 
double positive spots were counted per 20 µm neuritic segment. Fig. 15B shows the 
PSD95/VGluT cluster densities for iPSC-derived neurons from CTR 1-3, SZ 1-3 and ASD 1-3 
after eight weeks of neuronal differentiation. PSD95/VGluT density of patients with 
schizophrenia was not significantly changed in comparison to healthy individuals in contrast to 
a significant reduction of 9 % in iPSC-derived neurons from patients with autism. Values of the 
healthy control group exhibited highest similarity: CTR 1=100 %, CTR 2=102 % and 
CTR 3=98 %. PSD95/VGluT cluster densities of patients with schizophrenia differed a lot. 
Donor SZ 2 exhibited the highest cluster density of 106 % in comparison to SZ 1 (97 %) and 
SZ 3 (99 %). PSD95/VGluT cluster density of ASD 2 was highest (99 %) in comparison to 
ASD 1 (94 %) and ASD 3 (81%).  
 
In addition to the percentage of neurons with neurites and the mean neurite length, mean 
PSD95 cluster density was significantly reduced in iPSC-derived neurons from patients with 
schizophrenia. PSD95/VGluT co-localization showed no significant differences. Based on 
these findings both experimental procedures showed an impaired early neuronal development 
in iPSC-derived neurons from patients with schizophrenia.  
3.6 Transcriptome analysis of iPSC-derived neurons 
Analysis of mRNA expression profiles of iPSC-derived neurons was performed to supplement 
the phenotypic assays. Experimental work of transcriptome analysis was done by the industrial 
partner CeGaT in Tübingen. For transcriptome analysis iPSC-derived neurons from all donors 
(CTR 1-3, SZ 1-3, ASD 1-3) were differentiated for four weeks into cortical neurons, harvested 
and sent for analysis. Transcriptome analysis should identify potential gene expression 
similarities and differences in iPSC-derived neurons. Potential differences of gene expression 
of genes related to neurodevelopmental, synaptic, immune activation or functional processes 
were focused and may relate to disease relevant mechanisms. Whole transcriptomes of iPSC-
derived neurons were analysed to test the specificity of gene expression changes. Gene 
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expression of donor within one group should exhibited a stronger accordance than to donor of 
other groups. After transcriptome analysis similarity of gene expression was compared via 
hierarchical clustering. Fig. 16 shows the hierarchical clustering of all samples based on 
similarity of expression data (Spearman's rank correlation coefficient) of all genes which are 
significantly changed in a group comparison. Donors exhibited small changes in gene 
expression clustered closer than donors with big differences. iPSC-derived neurons from 
patients with schizophrenia or autism and healthy individuals clustered according to their 
disease or non-disease origin. Observed changes in transcriptome analysis were disease 
specific. The Dendrogram shows, RNA expression profiles of patients with schizophrenia were 
more closely related to the healthy control group than those of patients with autism. In addition 
to a hierarchical clustering RNA expression of healthy individuals and patients with 
schizophrenia was compared to identify significantly deregulated genes.  
 
 
Fig. 16: Hierarchical clustering of all samples. The dendrogram shows the clustering of all donors 
based on similarity of RNA expression.  
 
Tab. 20: Significant deregulated genes after group comparison of SZ and CTR. 
gene ID gene name log2 Fold-Change 
AC104809.3 homo sapiens BAC clone RP11-637O3 from 2 3.2 
ARHGAP36 rho GTPase activating protein 36 -3.5 
ASPN asporin 3.4 
C22orf42 chromosome 22 open reading frame 42 -3.2 
CDC20B cell division cycle 20B 4.1 
CLEC2L c-type lectin domain family 2 member L -3.1 
COL22A1 collagen type XXII alpha 1 chain 2.6 
CPM carboxypeptidase M 3.4 
CYP4F24P cytochrome P450 family 4 subfamily F member 
24, pseudogene 
3.7 
DCT dopachrome tautomerase 3.3 
EEF1GP1 eukaryotic translation elongation factor 1 
gamma pseudogene 1 
3.7 
ENTPD2 ectonucleoside triphosphate 
diphosphohydrolase 2 
2.9 
FAM156A family with sequence similarity 156 member A -2.8 
FNDC9 fibronectin type III domain containing 9 -2.9 
GALNTL6 polypeptide N-acetylgalactosaminyltransferase 
like 6 
-2.4 
ITGA2 integrin subunit alpha 2 3.4 
LEF1 lymphoid enhancer binding factor 1 3.4 
LINC00473 long intergenic non-protein coding RNA 473 -3.4 
NGB neuroglobin -3.5 
RIT2 Ras like without CAAX 2 -2.8 
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RP11-19O2.2 pre-mRNA processing factor 31 -3.4 
RP11-209K10.2 pre-mRNA processing factor 31 -3.8 
RP11-262H14.5 pre-mRNA processing factor 31 -2.8 
RP1-293L6.1 RP1, axonemal microtubule associated -3.3 
SPOCK3 SPARC/osteonectin, cwcv and kazal like 
domains proteoglycan 3 
-2.4 
ZPLD1 zona pellucida like domain containing 1 -3.3 
 
Tab. 20 shows all deregulated genes after comparing all donors of the healthy control group 
with all donors with schizophrenia. The gene ID is shown on the left side, followed by the 
extended gene name and log2 Fold-change, which indicates the kind of deregulation. Detailed 
table is added as Supplement Tab. 1. All in all 26 genes indicated major differences in the 
transcriptomic profile (p<0,05), 11 genes were upregulated and 15 genes were downregulated. 
Transcriptomic changes were investigated in genes related to various signalling pathways or 
functional units. The 26 deregulated genes were submitted to panther gene ontology analysis 
version 12.0 (http://pantherdb.org). Statistical overrepresentation test showed no significant 
result (p<0,05). The functional classification tool grouped genes according to specific 
pathways, functionality or cellular compartments. Having a closer look to the ontology 
“Molecular function”, 8 out of 26 genes belonged to “catalytic activity” (GO:0003824) and 5 out 
26 genes were members of the “binding category” (GO:0005488). Only 1 gene belonged to 
“structural molecule activity” (GO:0005198) and another gene to “transporter activity” 
(GO:0005215). The two prominent categories after selecting the ontology term “Biological 
Process” were “cellular process” (GO:0009987) (8 genes out of 26) and “metabolic process” 
(GO:0008152) (7 genes out of 26). The ontologies “Cellular Component”, “Protein Class” and 
“Pathways” exhibited no category with more than 4 genes. However, some of the deregulated 
genes identified were previously shown to be linked to SZ. For example the upregulated ecto-
nucleosidase ENTPD2 was mentioned before in an antipsychotic study for schizophrenia 
[146]. As a member of the Ras-signaling family, RIT2 is important for neuronal development. 
In 2010 Glessner et al. analysed copy number variations in patients with schizophrenia and 
found also aberrations in the RIT2 gene [147]. Among these genes related to schizophrenia, 
upregulation of LEF1 was identified indicating aberrations in the WNT-signalling pathway [148]. 
During the last years, several papers described the WNT pathway as a crucial pathway in the 
pathogenesis of schizophrenia [149, 150]. 
 
Minor difference in transcriptome analysis after comparing healthy individuals with patients 
with schizophrenia may result on big gene expression differences between individual donors 
in each group. Each donor with schizophrenia (SZ 1, SZ 2 and SZ 3) was compared separately 
with the group of all healthy control individuals. Numbers of deregulated genes observed for 
each patient are depicted in Fig. 17. The transcriptomic profile of donor SZ 1 showed the 
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highest number of deregulated genes (149) in comparison to the healthy control group.  Donor 
SZ 2 (49) and SZ 3 (37) exhibited less deregulated genes. Only two deregulated genes (ASPN, 
EEF1GP1) mentioned in previous studies were again significantly deregulated comparing 
single patients with schizophrenia with the healthy control group. 
 
Indicating the big genetic variability between donors of one group, most deregulated genes 
were not shared among transcriptomic profiles. Only 4 identical genes were deregulated in 
SZ 1 and SZ 2, SZ 2 and SZ 3 shared only one deregulated gene. Most similarity existed 
between SZ 3 and SZ 1 (16 identical deregulated genes). For details of deregulated genes see 
Supplement Tab. 2-4. Analysis of shared deregulated genes using the PANTHER 
Overrepresentation Test showed no enrichment of any genes. But detailed analysis of the 149 
deregulated genes between SZ 1 and CTR 1-3 exhibited significantly overrepresented genes. 
Genes involved in “muscle contraction” (GO:0006936) revealed 19.77-fold enrichment (p=9.21 
x 10-16) and genes important for “actin cytoskeleton” (GO:0015629) a 10.56-fold enrichment 
(p=1.33 x 10-7, Bonferroni correction). Genes related to “calcium ion binding” (GO:0005509) 
and “cell differentiation” (GO:0030154) were significantly enriched, too. 8 deregulated genes 
belonged to “Wnt signaling pathway” (P00057), 30 genes to “developmental process” 
(GO:0032502), 8 genes to “calcium-binding protein” (PC00060) and 1 gene belonged to 
“synapse” (GO:0045202). 
 
49 deregulated genes were found after a detailed comparison of SZ 2 and CTR 1-3. PANTHER 
overrepresentation test identified an enrichment of genes greater than 100-fold involved in 
antigen processing and presentation of peptide or polysaccharide antigen via MHC class II 
(GO:0002504) (p=5.36 x 10-16). Here 7 out of 49 genes belonging to category “developmental 
process” (GO:0032502). Genes related to calcium or WNT-signalling were not found.  
 
Only 53 deregulated genes were found in transcriptome profile analysis of SZ 3 and the healthy 
control group. Deregulated genes were analysed via PANTHER overrepresentation test. 
Genes involved in “nervous system development” (GO:0007399) showed a 6.72-fold 
significant enrichment (p=0.00494). 12 genes were grouped to the category “developmental 
process” (GO:0032502), 1 gene to category “calcium-binding protein” (PC00060) and 2 genes 
belonged to category “Wnt signaling pathway” (P00057). Deregulated genes were found a 
variety of signalling and functional processes. These findings indicate the high diversity of 
patients with schizophrenia at the transcriptome level.  
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Fig. 17: Number of deregulated genes after transcriptomic profile comparison. Individual patients 
with schizophrenia are compared with the healthy control group. Numbers indicate deregulated genes 
belonging to major differences in transcriptomic profile (p<0.05). 
 
Since group comparisons revealed only few differences, a paired comparison of one individual 
chosen from the healthy (CTR1) and the schizophrenia (SZ2) group was conducted. 1146 
significantly deregulated genes (Supplement Tab. 5), found after transcriptome sequencing, 
were analysed with PANTHER overrepresentation test. Deregulated genes of following 
ontology groups were significantly deregulated (p=<0,05): “calcium-dependent phospholipid 
binding” (GO:0005544) (p=0.029), “antigen processing and presentation of peptide or 
polysaccharide antigen via MHC class II” (GO:0002504) (p= 0.000014), “nervous system 
development” (GO:0007399) (p=8.05 x 10-9) and “synaptic transmission” (GO:0007268) (p= 
0.00345). Functional classification analysis identified 18 genes important for “calcium-binding 
proteins” (PC00060), 21 genes related to “Wnt signaling pathway” (P00057), 9 genes to 
“synapse” (GO:0045202), 159 genes to “developmental process” (GO:0032502) and 51 genes 
to “immune system process” (GO:0002376). 
 
In conclusion, gene expression of patients with schizophrenia and healthy individuals exhibited 
big differences. Minimization and specification of analysed groups resulted in an increased 
number of significantly deregulated genes. Overrepresentation test and functional annotation 
figured out gene clusters, related to calcium signalling, cell development and MHC class II.   
3.7 Reduced calcium mobilization in iPSC-derived neurons from 
patient with schizophrenia SZ 2  
As mentioned in the previous chapter, a group of genes related to calcium binding was 
significant enriched. Since calcium ions are involved in neuronal transmission, aberrant 
calcium influx may account for functional defects observed in schizophrenia. 
 
To test potential changes in calcium mobilization iPSC-derived neurons were differentiated for 
eight weeks and analysed regarding intracellular calcium mobilization. Cal520® AM was used 
as fluorescence-based assay to detect intracellular calcium ions in neurons. According to the 
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fluorescence intensity an influx and outflux of calcium were measured and analysed. As shown 
in Fig. 18A fluorescence intensity of Cal520® AM differs at different time point of the recording. 
Neuronal cells showed spontaneous activity and exhibited a changed amount of calcium ions 
inside the cell body. Exemplarily, quantification of Cal520® AM fluorescence intensity of iPSC-
derived neurons from ASD 1 is shown in Fig. 18B. This visualization was used to count the 
frequency of calcium peaks and the length of a peak. Three independent experiments were 
performed for CTR 1, SZ 2 and ASD 1 to analyse potential differences in case of 
schizophrenia. As shown in Fig. 18C frequency in iPSC-derived neurons from patients with 
schizophrenia and autism is significantly reduced. In each experiment data were normalised 
to CTR 1. iPSC-derived neurons from donor SZ 2 significantly showed less mobilization of 
calcium ions. In comparison to healthy individuals, frequency was reduced by more than one-
half (53 %). Frequency of iPSC-derived neuron from donor ASD 1 is also significantly 
diminished to 61 %.  In contrast to the frequency, the length of a calcium peak is not 
significantly affected in iPSC-derived neuron from patients with schizophrenia (147 %) or 
autism (142 %) (Fig. 18D). Results of three independent experiments exhibited a high 
variability.  
 
As supposed after transcriptomic analysis, calcium influx is affected in patients with 
schizophrenia. iPSC-derived neurons from patients with schizophrenia obtained a significant 
reduced frequency of calcium influx. The lengths of the calcium peaks were not affected.  
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Fig. 18: Calcium mobilization in iPSC-derived neurons. (A) Fluorescence dye Cal520® AM is used 
to visualize intracellular calcium ions. Images of stained iPSC-derived neurons from donor CTR 1 are 
shown for time points 40, 60 and 80 seconds. Scale bar: 10 µm (B) Fluorescence intensity of Cal50® 
AM during a 120 second recording of iPSC-derived neurons from donor ASD 1. (C) Frequency of peaks 
measuring Cal520® AM fluorescence intensity in iPSC-derived neurons from CTR 1, SZ 2 and ASD 1. 
Data is normalised to CTR 1. H(2)=13.7, n>14. (D) Peak length normalised to CTR 1 during a Cal520® 
AM recording in iPSC-derived neurons from CTR 1, SZ 2 and ASD 1. H(2)=1.9, n>33. (C, D) Kruskal-
Wallis Test and Dunn’s post hoc test, p<0.01**, n.s.= not significant, error bars are s.e.m. 
3.8 Increased MHCII expression in iPSC-derived NPCs and neurons 
from patient with schizophrenia SZ 2  
In addition to deregulated calcium binding genes, transcriptome analysis identified an 
enrichment of MHCII related antigens. MHCII complex can be found on antigen presenting 
cells which are important for initiating the immune response. The formation and potential 
changes in MHCII complex expression have to be investigated in iPSC-derived NPC and 
neurons from patients with schizophrenia or autism in comparison to healthy individuals. 
 
To test whether the upregulation of MHCII complexes is initiated early in neuronal 
development, MHCII expression in NPCs was analysed. Therefore, NPCs from SZ 2 and 
CTR 1 were stained with the Tü39 antibody specific for HLA-DR, DP and DQ heterodimeric 
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cell surface glycoproteins of the MHCII complex, without permeabilization. Cell nuclei were 
stained with Hoechst. Analysis focussed on a round shaped area surrounding the cell nucleus. 
Tü39 intensity of each ROI was measured automatically using the open source software Fiji. 
Mean intensity of Tü39 was calculated for 50 different cells for each donor and normalised to 
CTR 1 (100%). As shown in Fig. 19A the mean intensity of Tü39 is significantly upregulated 
by 29 % in iPSC-derived NPCs from SZ 2 (129 %). iPSC-derived NPCs from SZ 2 expressed 
significantly more MHCII complexes at their cell surfaces than CTR1. For further neuronal 
differentiation gene expression of MHCII has to be investigated. iPSC-derived NPC from 
patient with schizophrenia and healthy individual were differentiated to cortical neuronal cell 
for four weeks. The MHCII expression was analysed with immunocytochemical staining with 
Tü39 antibody. For exposure to the first antibody, neurons were not fixed and permeabilised 
to enable detection of functional MHCII complexes at the cell surface. Images show neuronal 
cells with typical neuron morphology (Fig. 19B). Cell nuclei were stained with Hoechst solution. 
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Fig. 19: MHCII expression in iPSC-derived cells. (A) Quantification of mean intensity of MHCII 
expression of NPCs from donor CTR 1 and SZ 2. Data is normalised to CTR 1. Mann-Whitney U-Test, 
p<0.001***, n=50, error bars are s.e.m. (B) Immunocytochemical staining of living four weeks old 
neurons from donor CTR 1 and SZ 2. Hoechst staining is done as nuclei staining. Scale bars: 10 µm.  
3.9 Olanzapine and haloperidol significantly reduced early neurite 
outgrowth of iPSC-derived neurons from donor CTR 1 
As mentioned before early neuronal development of iPSC-derived neurons from patients with 
schizophrenia is changed. Neurons exhibited deficits in the percentages of neurons with 
neurites and mean neurite length. Measuring the neurite outgrowth offers a robust method to 
investigate early neurodevelopmental processes. The effect of three known and three new 
substances on neurite outgrowth of iPSC-derived neurons was tested, to find new drugs for 
the treatment of schizophrenia. In the beginning, common drugs used for the treatment of 
schizophrenia were selected. One first generation antipsychotic haloperidol and two atypical 
antipsychotics clozapine and olanzapine were chosen. Mode of action differs between drugs. 
Second generation antipsychotics have a higher affinity to serotonin receptors and first 
generation antipsychotics bind preferentially more to dopamine receptors. 
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iPSC-derived neurons from donor CTR 1 and SZ 2 were differentiated for 72 hours and treated 
with different concentrations of antipsychotics for the subsequent 48 hours. Finally, cells were 
fixed, stained against surface marker -III-tubulin and neurite outgrowth was automatically 
analysed with the ImageXpress system. The percentage of neurons with neurites >10 µm and 
the mean neurite length of all measured neurons were calculated for 75 images per individual 
experiment.  Analysis was performed for CTR 1 and SZ 2 in three independent experiments. 
Effects of drugs on neurite outgrowth were tested in concentrations up to 4 µM.  
 
Fig. 20A shows the percentage of neurons developing neurites after treatment with clozapine 
in the range from 0.15 µM up to 4 µM. All values were normalised to CTR 1 untreated. As 
shown before, the percentage of neurons with neurites from the patient with schizophrenia 
SZ 2 (59 %) was in untreated condition significant lower than percentage in the healthy control 
group (100 %). Significance was tested for drug treated versus untreated conditions 
individually per donor. The drug clozapine did not influence the percentage of neurites per 
neuron in any case independently of the drug concentration and the donor. Despite no 
significant results, little effects on the ability to form neurites could be observed. Low 
concentration of 0.15 µM clozapine had a negative effect on the ability of neurite formation in 
both donors (CTR 1=88 %, SZ 2=48 %). Higher concentration supported the percentages of 
neurons with neurites and increased the value for donor CTR 1 at 1 µM to a maximum of 115 % 
and for SZ 2 at 4 µM up to 75 %. Observed changes were not significant. 
 
Olanzapine (Fig. 20B) had a significantly negative effect on neurite formation of donor CTR 1. 
The percentage of neurons with neurites from CTR 1 was significantly reduced after treatment 
with 0.125, 0.5 and 1 µM olanzapine in comparison to the untreated control. Highest reduction 
was measured after cultivation with 0.5 µM olanzapine. Neurite formation was significantly 
reduced by 36 %. In addition to CTR 1, the curve of the percentage of neurons with neurites 
from SZ 2 after olanzapine treatment showed a U shape with higher amounts of neurites in the 
low and high drug concentrations. Comparing untreated and drug treated conditions, iPSC-
derived neurons from SZ 2 showed no significant differences.  
 
The treatment with haloperidol (Fig. 20C) from 0.005 µM up to 4 µM had also a significantly 
negative effect on the formation of neurites from CTR 1. The percentage of neurons with 
neurites was significantly reduced in iPSC-derived neurons from CTR 1 after treatment with 
0.027 and 0.067 µM haloperidol. In comparison to the untreated control highest reduction by 
43 % was measured after treatment with 0.067 µM haloperidol. iPSC-derived neurons from 
SZ 2 exhibited no significant changes in neurite formation after treatment with haloperidol.  
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Fig. 20: Percentage neurons with neurites of iPSC-derived neurons from CTR 1 and SZ 2 after 
drug treatment. iPSC-derived neurons from patient with schizophrenia SZ 2 (blue) and healthy 
individual CTR 1 (black) were treated with clozapine (A, 0.15, 0.62, 1, 1.5, 2, 4 µM), olanzapine (B, 
0.125, 0.25, 0.5,1,2,4 µM) and haloperidol (C, 0.005, 0.027, 0.067, 0.133, 1.3, 4 µM) for 48 hours and 
percentage of neurons with neurites was calculated for 75 images per individual experiment. Only 
significant spots are marked. Kruskal-Wallis Test and Dunn’s post hoc test, p<0.05*, p<0.01**, 
p<0.001***, CTR 1 Clozapine H(6)=8.3, CTR 1 Olanzapine H(6)=22.8, CTR 1 Haloperidol H(6)=25.2, 
SZ 2 Clozapine H(6)=10.9, SZ 2 Olanzapine H(6)=12.6, SZ 2 Haloperidol H(6)=10.6, n=75, error bars 
are s.e.m. 
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In addition to neurite formation the mean neurite length was calculated after treatment with 
clozapine, olanzapine and haloperidol up to 4 µM. Treatment with clozapine showed no 
significant changes in neurite outgrowth in comparison to the untreated control for both donors 
(Fig. 21A).  
 
Fig. 21B shows the mean neurite length of iPSC-derived neurons from CTR 1 and SZ 2 after 
treatment with olanzapine with the same concentration as described above. Mean neurite 
length of donor CTR 1 was significantly reduced after treatment with 0.125, 0.5, 1 and 2 µM 
olanzapine. Highest reduction (39 %) was measured after treatment with 1 µM olanzapine. 
iPSC-derived neurons from SZ 2 exhibited no significant changes.  
 
Treatment with haloperidol also significantly reduced the mean neurite length in iPSC-derived 
neurons from CTR 1. A significant reduction of the mean neurite length was measured for 
donor CTR 1 after treatment with 0.027, 0.067, 0.133, 1.3 and 4 µM haloperidol. The mean 
neurite length of iPSC-derived neurons from CTR 1 was minimal reduced by 43 % after 
treatment with 0.067 µM haloperidol. In comparison to the untreated control, iPSC-derived 
neurons from SZ 2 showed no significant differences in neurite outgrowth.  
 
Despite of the same affinity profiles clozapine and olanzapine showed no comparable effects 
on the ability to form neurites. Clozapine did not significantly influence the neurite formation 
and the mean neurite length at any concentrations. The drugs olanzapine and haloperidol 
significantly inhibited the process of neurite outgrowth for donor CTR 1. Reduction of neurons 
with neurites and mean neurite length followed a U-shaped turn suggesting compensatory 
effects at higher concentrations as described by hormetic drug response models [151]. 
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Fig. 21: Mean neurite length of iPSC-derived neurons from CTR 1 and SZ 2 after drug treatment. 
iPSC-derived neurons from patient with schizophrenia SZ 2 (blue) and healthy individual CTR 1 (black) 
were treated with clozapine (A, 0.15, 0.62, 1, 1.5, 2, 4 µM), olanzapine (B, 0.125, 0.25, 0.5,1,2,4 µM) 
and haloperidol (C, 0.005, 0.027, 0.067, 0.133, 1.3, 4 µM) for 48 hours and mean neurite outgrowth of 
all cells was calculated for 75 images per individual experiment. Only significant spots are marked. 
Kruskal-Wallis Test and Dunn’s post hoc test, p<0.05*, p<0.01**, p<0.001***, CTR 1 Clozapine 
H(6)=10.6, CTR 1 Olanzapine H(6)=23.2, CTR 1 Haloperidol H(6)=27.3, SZ 2 Clozapine H(6)=11.9, 
SZ 2 Olanzapine H(6)=17, SZ 2 Haloperidol H(6)=9.1, n=75, error bars are s.e.m. 
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3.10 Increased percentage of neurons with neurites after treatment 
with mimetic peptides was not peptide specific 
Three different mimetic peptides were added to the neuronal differentiation of iPSC-derived 
cells to test the influence on the neurite outgrowth, too.  Narpin, neurexide and FN4-NF3 are 
synthetic mimetic peptides which target important receptors for neuronal development, like the 
FGF receptor.   
 
The glycoprotein neuroplastin 55 was basis for the synthesis of the mimetic peptide narpin. 
Neuroplastin 55 is one isoform of neuroplastin which belongs to the immunoglobulin 
superfamily of cell adhesion molecules (CAMs). The mimetic peptide neurexide has the same 
sequence as the heterophilic neuroligin-1 binding site of neurexin 1. Neurexin 1 is a 
presynaptic membrane protein and its interaction with neurexin is essential for a neuron-
neuron interaction and the formation of a synapse. The mimetic peptide FN4-NF3 is 
synthesised on basis of the sequence for neurofascin which is important for the synaptic 
development, too. Neurofascin is a cell adhesion molecule important for axon targeting in 
neuronal development.  
 
Effects of mimetic peptides narpin, neurexide and FN4-NF3 in different concentrations were 
tested in iPSC-derived neurons from a healthy individual (CTR 1) and a patient with 
schizophrenia (SZ 2). According to the drug treatment, application of peptides started 24 hours 
after initiating neuronal differentiation and lasted for 48 hours. Cells were fixed, stained with -
III-tubulin antibody and Hoechst solution and automatically analysed using the MetaXpress 
system. Three experiments were performed independently. Data was normalised to the 
untreated value of CTR 1 or SZ 2 in each experiment. As experimental control, the neurite 
outgrowth after ROCK inhibitor treatment was analysed. An enhanced neurite outgrowth after 
ROCK inhibitor was shown before. Compared to DMSO, percentage of neurons with neurites 
after ROCK inhibitor treatment was significantly increased in iPSC-derived neurons from 
CTR 1 (73 %) and SZ 2 (70 %). An enhancing effect of the ROCK inhibitor on neurite outgrowth 
was confirmed. A scrambled version of the peptide was applied in the same concentration as 
control for a peptide specific effect. Fig. 22 shows the percentage of neurons with neurites after 
treatment with a scrambled version of the peptides and a functional version of the peptides 
narpin (A), neurexide (B) and FN4-NF3 (C). Independent of the treatment or the donor the 
number of neurons elaborating neurites was enhanced. Even if the percentage is significantly 
increased in some cases after peptide treatment in comparison to the untreated control, the 
effect was not peptide specific. Number of neurites was increased after treatment with the 
scrambled version of the peptide, too. A comparison between the percentage of neurons with 
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neurites after treatment with the scrambled version of the peptide and the functional version of 
the peptide showed no significant differences at any concentration.  
 
Even if results were not significant little tendency could be observed. Only in neurons from 
patients with schizophrenia, treatment with narpin had a supportive effect. Effect was not 
peptide specific but increased by 46 % in SZ 2 after treatment with 12 µM narpin. A treatment 
with 12 µM scrambled narpin increased the number of neurons with neurites by 45 %. In 
comparison, highest level of neurons with neurites in CTR 1 was 116 % after treatment with 
3 µM narpin.  
 
Treatment of iPSC-derived neurons from donor SZ 2 and CTR 1 with scrambled or functional 
neurexide had a supportive effect on neurite formation, too. iPSC-derived neurons from CTR 1 
exhibited nearly the same number of neurites (~123 %) after treatment with the three peptide 
concentrations. After treatment with the scrambled version of neurexide percentage of neurons 
with neurites was increased up to 127 %.  Highest level of neurons with neurites (153 %) was 
reached after treatment with 9 µM neurexide for donor SZ 2. 9 µM scrambled neurexide 
increased number of neurons with neurites by 41 %. Difference was not significant and a 
peptide specific effect was excluded. Higher concentrations 27 µM and 50 µM neurexide did 
not increased the neurite formation as much as 9 µM neurexide.  
 
Treatment of iPSC-derived neurons from CTR 1 with 3 µM FN4-NF3 had the most positive 
effect and increased the percentage of neurons with neurites up to 143 %. After treatment with 
3 µM scrambled FN4-NF3 the number of neurons with neurites was enhanced by 32 %. 
Highest percentage of neurons with neurites (148 %) was measured after treatment with 18 µM 
in iPSC-derived neurons from SZ 2. Treatment with the same concentration of scrambled FN4-
NF3 showed only an increase of neurites up to 128 %. Differences after treatment with 
scrambled or functional peptide were not significant and a peptide specific effect for neurite 
formation of FN4-NF3 was excluded.   
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Fig. 22: Percentage of neurons with neurites of iPSC-derived neurons after treatment with 
mimetic peptides. iPSC-derived neurons from CTR 1 (grey bars) and SZ 2 (blue bars) are 
differentiated for 72 hours and treated with DMSO, ROCK inhibitor (10 µM) and different concentrations 
of narpin (A, 3, 9, 12 µM), neurexide (B, 9, 27, 50 µM) or FN4-NF3 (C, 3, 9, 18 µM) during the last 48 
hours. Data is normalised to DMSO or the untreated control. s=scrambled peptide, p=peptide, Kruskal-
Wallis Test and Dunn’s post hoc test, p<0.001***, n.s.= not significant, narpin CTR 1:H(5)=1.2, narpin 
SZ 2:H(5)=2.3, neurexide CTR 1:H(5)=1.1, neurexide SZ 2:H(5)=1.5, FN4-NF3 CTR 1:H(5)=2.1, FN4-
NF3 SZ 2:H(5)=2.8, n=75, error bars are s.e.m.    
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3.11 Knock-out of DISC1 generated same phenotypical 
characteristics as obtained in neurons from patients SZ 1-3 
DISC1 is a known risk gene for schizophrenia and its functionality and interaction with other 
proteins is important for neurite development [152]. The influence of a DISC1 knock-out in 
iPSC-derived neurons on early neurodevelopmental processes has to be investigated. Exon 2 
in iPSC derived from CTR 1 was deleted using CRISPR/Cas9 technology. Two self-designed 
guide RNAs targeted unique sequences in the beginning and in the end of exon 2 of the DISC1 
gene (Fig 23A). gRNAs and Cas9 plasmid were delivered via electroporation to single cell 
iPSCs. Successful mutation of DISC 1 resulted in a deletion of 851 base pairs in exon 2. iPSC 
cells were cultivated until stable clonal growing occur again. iPSC of mutated donor CTR 1 (C-
CTR 1) were differentiated to cortical neurons, via embryoid body formation and NPC 
generation. iPSC clones and NPCs were checked for a deletion of exon 2 in the DISC1 gene 
via genomic PCR. Experiments were performed by Kathrina Haag during her master thesis. 
Fig. 23B shows the results of genomic PCR of iPSC from CTR 1 and C-CTR 1 and NPC from 
C-CTR 1. PCR product of DISC 1 specific primers used for genomic PCR had a length of 1850 
base pairs. After the deletion of exon 2 with a length of 851 base pairs the mutated fragment 
had a length of 999 base pairs. Wild type fragment of DISC1 gene was verified in samples of 
iPSCs from CTR 1. A second band with the length of 999 base pairs was present in samples 
of iPSCs and NPCs from mutated CTR 1. The wild type form of the DISC1 gene was still 
present, based on a CRISPR event only in one allele. The deletion of exon 2 which leads to a 
knock-out of DISC1 was shown in iPSCs and NPCs. Exon 2 of the DISC 1 gene in iPSC from 
donor CTR 1 was successfully deleted. Potential changes of morphological and functional 
characteristics of iPSC, NPC and cortical neurons in case of a DISC 1 mutation were analysed.  
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Fig. 23: Verification of DISC1 knockout in iPSCs and NPCs from donor CTR 1. (A) Schematic 
overview of the DISC1 coding sequence and induced cutting sides. (B) Agarose gel of genomic PCR 
products of iPSCs from CTR 1 and iPSCs and NPCs from C-CTR 1. Arrows indicate expected genomic 
PCR product length of wildtype and mutated Exon 2 fragments of the DISC 1 gene. 
 
After testing of DISC 1 mutation iPSC were cultivated and passaged until the typical clonal 
morphology occurred. Stem cell specific marker expression was analysed via 
immunofluorescence staining against SSEA 4 and Tra 1-81. iPSC from C-CTR 1 show clonal 
growing and stem cell specific marker expression (Fig. 24A, B). Changes in growing abilities 
and marker expression in comparison to iPSC from CTR 1 (see Fig. 6) were not observed. In 
addition to immunocytochemical stainings, the expression of induced exogenous genes and 
typical endogenous embryonic stem cell marker genes were analysed in iPSC from C-CTR 1 
by RT-PCR (Fig 24C). Exogenous genes OCT3/4, SOX 2, KLF4 and c-Myc induced during 
reprogramming process were still silenced. Endogenous gene expression of 17 embryonic 
stem cell marker genes were shown. NTERA cell line served as control for stem cell specific 
genes. In comparison to iPSC from CTR 1 less endogenous genes were expressed (see 
Fig. 7).  
 
Based on morphological analysis and immunocytochemical staining no changes were 
observed in iPSC from C-CTR 1. Gene expression analysis showed minor differences in gene 
expression in comparison to iPSC from CTR 1. iPSC were used for neuronal differentiation, 
producing embryoid bodies and neuronal progenitor cells as described before. 
82   RESULTS 
 
Fig. 24: Immunocytochemical staining and RT-PCR of mutated iPSC from donor CTR 1. 
Immunocytochemical staining of mutated iPSCs from CTR 1 (C-CTR 1) against stem cell specific 
marker genes SSEA 4 (A) and Tra 1-81 (B). Scale bars: 100 µm (C) RT-PCR of embryonic stem cell 
specific marker genes of mutated iPSCs from donor CTR 1. The silenced expression of exogenous 
markers can be confirmed. NTERA serves as positive control. NTERA=human embryonal carcinoma 
cell line.    
 
As first step in the neuronal differentiation neuronal progenitor cells (NPC) were generated 
using high quality iPSC clones carrying DISC 1 mutation. To confirm a NPC phenotype, cells 
were stained against NPC marker genes ZO 1, PAX 6, Nestin and SOX 1 as described above. 
Results of immunocytochemical staining are shown in Fig. 25. Immunocytochemistry revealed 
that PAX 6 and SOX 1 were enriched in cell nuclei. ZO 1 and Nestin immunoreactivity was 
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spread all over the cell soma. Only some of the stained cells express NPC specific marker. 
Based on positive immunocytochemical staining, stem cell specific marker expression of iPSC-
derived NPCs from C-CTR 1 is comparable to non-mutated NPCs (see Fig. 9). Number of cells 
expressing NPC marker seems to be reduced. In face of this changed abilities NPCs were 
used for final neuronal differentiation. Already after a short differentiation time cells exhibited 
neuronal morphology and built neurites.  
 
 
Fig. 25: Immunocytochemical staining of mutated donor CTR 1 against Neuronal Progenitor Cell 
marker genes ZO 1, PAX 6, Nestin and SOX 1. In (A) cell surface marker ZO 1 and transcription factor 
PAX 6 and in (B) Nestin and transcription factor SOX 1 were stained as NPC marker genes in NPCs of 
mutated cell from donor CTR 1. ZO 1=Zona Occludens 1, PAX 6=Paired box gene 6, SOX 1=SRY box 
1, Scale bars: 100 µm. 
 
As indicator for early neuronal developmental neurite formation and mean neurite length were 
analysed. Fig. 26A shows an immunocytochemical staining of three days old iPSC-neurons 
from CTR 1 and C-CTR 1 using cell surface marker -III-tubulin and cell nuclei marker 
Hoechst. In contrast to CTR 1, iPSC-derived neurons from donor C-CTR 1 showed more cells 
with a NPC morphology than neuronal morphology. Cell bodies were flatter and expanded and 
the neuronal network was very limited. An impaired neuronal differentiation and development 
was tested via neurite outgrowth experiment. iPSC-derived neurons from C-CTR 1 were 
differentiated into cortical neurons for four days, fixed and stained. Percentage of neurons with 
neurites > 10 µm and mean neurite length was analysed as described before. Finding was 
confirmed in a quantification of three independent experiments. iPSC-derived neurons from 
CTR 1 served as control cells. Results of neurite outgrowth experiments are shown in Fig. 26B 
and C. iPSC-derived neurons from C-CTR 1 showed significantly reduced percentage of 
neurons with neurites (Fig. 26B). The percentage was significantly reduced by 67 %. The mean 
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neurite length of iPSC-neurons from C-CTR 1 was significantly reduced by 34 % (Fig. 26C). 
Differences in neurite outgrowth were observed in iPSC-derived neurons from C-CTR 1. 
Changes in early neuronal development resulted of DISC1 mutation in iPSC-derived neurons. 
In comparison to neurite outgrowth of iPSC-derived neurons from patients with schizophrenia 
(SZ 1-3), percentage of neurons with neurites and mean neurite length of iPSC-derived 
neurons from CTR 1 was more reduced. Mutated iPSC-derived neurons from donor CTR 1 




Fig. 26: High content analysis of neurite outgrowth of mutated iPSC-derived neurons from donor 
CTR 1. (A) Immunocytochemical staining using b-III-tubulin antibody and Hoechst in iPSC-derived 
neurons from CTR 1 (left) and mutated iPSC-derived neurons from CTR 1 (right). Scale bars: 100 µm 
Effect of DISC1 knock-out is shown via percentage of neurons with neurites (B) and mean neurite 
outgrowth (C) in three days old neurons derived from non-mutated and mutated iPSCs from donor 
CTR 1. (B, C) Data is normalised to CTR 1. Mann-Whitney U-Test, n=3, p<0.05*. 
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4. DISCUSSION 
In the context of this thesis, an iPSC-derived neuronal system was developed to study changes 
in early neuronal development in case of schizophrenia. Therefore, fibroblasts from three 
healthy individuals, three patients with schizophrenia and three patients with autism were 
reprogrammed into high quality iPSC. These clones were differentiated into cortical neuronal 
cells and characterised for disease-specific properties. Beside neurite outgrowth, PSD95 
cluster density and the calcium flux were decreased in iPSC-derived neurons from patients 
with schizophrenia. Transcriptome analysis identified changes in neuronal and synapse-
specific genes and aberrations in the expression of genes related to calcium signalling and 
MHC clusters in case of schizophrenia. Treatment with antipsychotic drugs like olanzapine and 
haloperidol resulted in a reduced neurite outgrowth in iPSC-derived neurons from CTR 1. In 
the following section the observed results are critically discussed and compared with the 
current state of the literature in the field of iPSC technology for neurodevelopmental diseases. 
4.1 Reprogramming of fibroblasts into iPSC  
First part of this thesis focus on the generation of nine iPSC lines out of human fibroblasts from 
preselected patients with schizophrenia or autism and healthy individuals. Fibroblasts were 
reprogrammed via retroviral transduction using the four Yamanaka factors Sox2, OCT3/4, 
KLF4, and c-Myc and relevant genomic aberrations could be excluded in all iPSC lines. Only 
characterised iPSC clones with a typical stem cell morphology, right marker expression, and 
proof of pluripotency were used as starting material for a neuronal differentiation. 
 
In 2007, the group of Yamanaka was the first one describing the successful reprogramming of 
human fibroblasts into iPSC [123]. Retroviral transduction was the first method to deliver the 
reprogramming factors into the host genome. Despite the high reprogramming efficiency, some 
problems developed using this system. The reprogramming viruses can randomly integrate 
into the genome and thereby induce changes in gene expression, de novo somatic coding 
mutations, copy number variations and chromosomal abnormalities [153-156]. Unpredictable 
genomic changes, aberrant transgene expression or tumor formation can occur. The induction 
of genetic aberration is very problematic, because reprogramming can affect undiscovered 
genetic modifications and epigenetic memory of schizophrenia. To circumvent genomic 
aberrations after retroviral transduction, alternative reprogramming strategies using non-
integrative viruses like Sendai viruses [157], episomal vectors [158], modified mRNA 
transcripts [159] or proteins [160] have been developed. Another method is the direct lineage 
reprogramming, where an adult somatic cell is transformed into another lineage without going 
through the pluripotent state [161]. Generation of induced neurons (iN) directly out of iPSC 
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could be a valid alternative for modelling schizophrenia [162]. On one hand, direct conversion 
does not erase cellular ageing markers [163] and allows modelling of sporadic and epigenetic 
diseases. The process is much faster than retroviral transduction. On the other hand, it has 
limitations like a low reprogramming efficiency and a reduced neuronal maturation reflected in 
a small competence in synapse formation [164, 165]. The number of cells is limited to the 
amount of starting material and cannot be infinitely expanded like during the stem cell state. 
Direct reprogramming skips the pluripotent and neuronal progenitor stages [166] and make the 
modelling of early neurodevelopmental processes difficult. Because the cellular starting 
material was limited and the development and differentiation of neuronal progenitor cells were 
also focused on this thesis, retroviral reprogramming was chosen. Additionally, the 
reprogramming efficiency is high and this robust method enables the generation of iPSC 
independent from the genetic background of the patient. To exclude genomic aberrations 
because of viral integration, a non-integrative method should be selected for reprogramming 
in future. 
4.2 Differentiation of iPSC into cortical neuronal cells 
To study early neurodevelopmental processes of patients with schizophrenia, high quality 
iPSC were differentiated into cortical neurons with embryoid body formation and NPC 
generation. In addition to the manufacturer protocol, Dorsomorphin dihydrochloride, 
SB 431542 and recombinant Human Noggin Fc Chimera Protein were added to the medium 
to improve the generation of pure NPC. As described by Chambers et al. [167] dual inhibition 
of SMAD signalling using Noggin and SB 431542 leads to highly efficient neural conversion of 
iPSCs and an increase of NPC marker expression. Soluble BMP antagonists such as noggin, 
limit BMP signalling by ligand sequestration resulting in disturbed receptor heterodimerization. 
SB 431542 inhibits TGF- signaling via blocking type I receptor activity which leads to a 
reduced phosphorylation and nuclear translocation of the SMADs. Additionally, the small 
molecule dorsomorphin inhibits SMAD-dependent BMP signal by directly disturbing the binding 
of SMAD 1/5/8 to its receptor [168]. A combination of these three factors enable the generation 
of pure NPCs. Every NPC line of each donor was immunocytochemically tested for the 
expression of relevant NPC markers to check the quality of the NPC culture. Only NPC cultures 
with the expression of all four NPC marker genes PAX 6, SOX 1, ZO 1 and Nestin were used 
for further differentiation into cortical neurons.  
 
Cortical neuronal differentiation was performed according to the protocol of Shi et al., which 
followed all steps of the human brain development [140]. This way of differentiation is more 
precise to the early in vivo process. Transcriptome analysis of 4-weeks old iPSC-derived 
neuronal cells from healthy individuals as well as patients with schizophrenia and autism 
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showed typical gene expression of neuronal cells like calcium, synapse and nervous system-
related genes. As shown by Handel et al., differentiated iPSC-derived neurons resembled cells 
of the fetal brain and can be used for modelling young stages of the disease phenotype [169]. 
They used a broad range of neuronal markers for single-cell transcriptomics to characterise 
different layer identities in iPSC-derived cortical neuronal cultures. After differentiation of iPSC 
into neuronal cells 93.6 % of single cells expressed genes indicate neuronal identity, mostly 
excitatory glutamatergic receptor and synaptic genes. In comparison to single-cell RNA-
sequencing data from primary human brain tissue, iPSC-derived cortical neurons, 
differentiated cells recapitulate the single-cell transcriptomic signature of human fetal cortical 
neurons, and expressed many genes associated with neuronal and synaptic function [169]. 
Based on these findings, iPSC-derived cortical neurons are a suitable source to investigate 
changes in gene expression in early neuronal developmental stages. 
 
Following, the protocol of Shi et al. enables a differentiation into a mixture of cortical neurons, 
which may have variable roles in disease pathogenesis. A variety of neuronal markers of 
excitatory, inhibitory neurons and astrocytes were observed after immunocytochemical 
staining. Exact percentage proportion was not determined but a variety of neuronal cell types 
were obvious. The experimental diversity complicated a comparison between diverse 
differentiation approaches. Additionally, the generation of disease relevant cell types in a 
defined amount may improve the modelling because of a better representation of the disease 
phenotype. The establishment of lineage-specific differentiation enables the production of 
specific subtype of neuronal cells [170]. But lineage-specific differentiation and investigations 
using only one neuronal subtype do not represent the heterogeneous in vivo conditions and 
the complex disease phenotype. Further improvement of the differentiation protocol and 
standardization will increase the comparability between different experiments and in vivo 
conditions.  
 
Besides a proper differentiation protocol, the duration of neuronal differentiation is essential 
for marker gene expression and neuronal functionality. To follow neurodevelopmental 
processes, iPSC-derived neurons were positively stained against brain layer V marker gene 
Ctip2. Brain layer V is the second developed brain layer during cortex maturation and exhibiting 
subcortical projection neurons expressing Ctip2 [141]. The time point of marker expression of 
neurons from CTR 1 was comparable to studies performed by Shi et al. [140] and increased 
with further differentiation time. The expression of Ctip2 verified the differentiation into the 
targeted neuronal layer and indicated early stages of neuronal development. Functionality of 
iPSC-derived neuronal cells was tested using calcium imaging with an immunofluorescent 
calcium dye. Spontaneous calcium influx and efflux were positively tested in all iPSC-derived 
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neuronal cultures after eight weeks differentiation. In addition to a correct neuronal marker 
expression, the functionality of the neuronal cells is essential for studying neurodevelopmental 
diseases like schizophrenia with iPSC-derived neurons. Until today, iPSC-derived neurons 
failed to fully recapitulate the whole three-dimensional brain architecture [171], cellular 
maturation and aging [172] even after an extended cultivation time. The differentiation time in 
an in vitro culture from 14 to greater than 100 days [140, 167, 173] is much shorter than the 
human neurodevelopment of the brain. Therefore, the study of later disease phases for 
example early adolescence would be much more difficult. Focus of this thesis was to 
investigate potential changes in early neuronal development of iPSC-derived neurons from 
patients with schizophrenia, therefore the expression of early neuronal markers and first 
neuronal functionality is sufficient. All these characteristics were observed after eight weeks of 
neuronal differentiation in iPSC derived cells from healthy individuals as well as patients with 
schizophrenia or autism. Only neuronal cultures exhibiting all morphological and functional 
neuronal characteristics were selected for experiments to study neurodevelopmental changes. 
4.3 Expression of disease relevant characteristics like neurite 
outgrowth and synaptic formation 
iPSC-derived neurons from patients with schizophrenia were used to study changes in early 
neurodevelopmental processes in comparison to iPSC-derived neurons from healthy 
individuals. Proliferation, differentiation of precursor cells into neuronal cells, migration and 
elaboration of neurites are some of the key cellular processes of neuronal development [174]. 
Important for a normal development of the nervous system is a dynamic process and 
coordinated expression of molecular and cellular events at the correct time and place [175, 
176]. The neurite outgrowth experiment is a simplified model to investigate processes of 
nervous system development in a 2D system. As indicator for early neuronal development the 
percentage of neurons with neurites and the mean neurite length were selected as 
phenotypical assay. Both values were significantly decreased in neurons derived from patients 
with schizophrenia in comparison to healthy individuals. Neurite outgrowth is the most 
performed assay because it is directly linked with cellular function and cellular health [177-
179]. In brain development, a reduced neurite development can lead to a diminished formation 
of the neurite network and reduced maturation. Changes in dendritic arborizations were 
already observed in studies of post-mortem brains from patients with schizophrenia [62]. 
Additionally, iPSC showed high potential in phenotypical screenings like neurite outgrowth 
because pathophysiology of the disease is focused [180]. Brennand et al. observed reduced 
neurite outgrowth in iPSC-derived neurons from patients with schizophrenia [68]. In contrast 
to the experimental procedure described in this thesis, Brennand et al. differentiated iPSC-
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derived neurons for three-months in a co-culture with astrocytes. For the analysis they counted 
the number of neurites growing out of the cell soma in iPSC-derived neurons from patients 
with schizophrenia. Despite varied differentiation periods and analysis methods in both cases 
a diminished ability to form neurites was observed and could be linked to neurons with a 
schizophrenic genetic background. Even if the percentage of neurons with neurites was 
significantly reduced in group wise comparison, the percentage of reduction differs. Cultivation 
and differentiation method were identical, and differences may be based on genetic 
heterogeneity between individual donors. The generation of an isogenetic disease cell line may 
increase the comparability of mutation related effects. For this thesis, a schizophrenic disease 
cell line was generated with inducing a mutation in the known risk gene DISC1 [181] in iPSC 
from donor CTR 1 using CRIPSR/Cas9 technology. Genome editing with CRIPSR/Cas9 is an 
easy tool to induce specific mutation or to correct known aberrations [182]. With this, each cell 
line can serve as its own control because of a shared genetic origin. Specific morphological 
changes can be investigated regarding the induction of a known mutation in this case DISC1 
knock-out. Off-target effects should be studied and excluded before using a cell line.  
 
DISC1 is an important gene for neuronal differentiation, signalling and synaptic function [183], 
that is why changes in neurite outgrowth were analysed using the neurite outgrowth 
experiment. As expected the percentage of neurons with neurites and the mean neurite 
outgrowth were significantly reduced in comparison to CTR 1. Mice lines with DISC1 mutation 
showed alterations in neuronal architecture for example a reduction in the apical dendrite 
length of layer V pyramidal neurons [184]. Wen et al. reprogrammed somatic cells of individuals 
carrying a DISC1 mutation and differentiated them into forebrain-specific neuronal cells. For 
each donor two independent iPSC lines were generated. As control somatic cells of unaffected 
relatives were reprogrammed and differentiated. Similar to immunocytochemical staining used 
in this thesis, Wen et al. did not observe any changes in iPSC or NPC generation. Neurite 
outgrowth was analysed as total dendritic length of forebrain neurons derived from each 
individual at one up to four weeks of neuronal differentiation. In contrast to the mean neurite 
outgrowth after three days of neuronal differentiation of iPSC-derived neurons carrying an 
artificial induced DISC1 mutation, Wen et al. observed an increased total dendritic length 
during the first two weeks of neuronal differentiation. Effects became indistinguishable from 
control iPSC cell lines after three and four weeks. Various differentiation and analysis 
procedures as well as diverse analysis time points make a comparison between both 
experiments difficult. Both experiments showed the relevance of DISC1 in neuronal 
development. Described findings support theories of changed neurite outgrowth observed in 
previous studies of patients with schizophrenia. 
90   DISCUSSION 
A reduced neuronal development may lead to aberrations in synaptogenesis and cellular 
connectivity. As representative marker gene of the postsynaptic density, the formation of 
PSD95 clusters were analysed in 8-weeks old iPSC-derived neurons. Significant reduction 
was observed in the number of PSD95 cluster density of iPSC-derived cortical neurons from 
individual patients. Key finding of a reduced synaptic density was already described by Roberts 
et al. using electron microscopy [185]. Additionally, this observation correlates with the findings 
of Brennand et al., who observed a diminished PSD95-protein level in iPSC-derived neurons, 
even if the analysis was performed for the whole PSD95:MAP2 ratio of all stained neurons 
[68]. Furthermore, Wen et al. analysed reduced synaptic density indicated by PSD95/Synapsin 
1 (SYN1) co-staining in iPSC-derived neurons carrying DISC1 mutation in comparison to 
healthy family members. Diminished PSD95 protein expression can also lead to changes with 
interaction partners like NMDA receptor or neuregulin 1 [186]. A reduced PSD95 expression 
was described in several publications and seems to be a characteristic of neuronal cells 
derived from patients with schizophrenia. Additionally, a decreased PSD95 cluster density may 
cause dysregulation of synaptic function and structure. Synapses are the basic functional units 
of the brain and are important for signalling processes with neurotransmitter. Neurotransmitter 
are important for the intracellular signalling processes like gating calcium channels and with 
this regulating the synaptic activity. Calcium ions have a large concentration gradient among 
the plasma membrane of all cells [187]. In neurons calcium ions regulate the electrical activity 
by opening and closing sodium and potassium channels, inducing action potentials [188].  
 
In this work, spontaneous calcium influx and efflux of eight weeks old iPSC-derived neurons 
were significantly reduced in case of schizophrenia. The immature neuronal phenotype of all 
neurons independent of the genetic origin were indicated by a low frequency of calcium peaks 
and missing synchronism. Aberrations in calcium signalling was correlated to the molecular 
pathology of schizophrenia before [189]. Functional imaging studies and post-mortem studies 
identified brain and synapse deficits in prefrontal cortex region of patients with schizophrenia 
[63, 66]. The publication of Wen et al. observed iPSC-derived forebrain neurons carrying a 
DISC1 mutation with reduced synaptic boutons after four and six weeks differentiation and 
deficits in synaptic vesicle release [98]. Similar to the results of iPSC-derived neurons from 
patients with schizophrenia described in this thesis, the frequency of excitatory spontaneous 
synaptic currents was reduced in iPSC-derived neurons with DISC1 mutation in comparison 
to neurons derived from healthy family members. Brennand et al. did not observe any changes 
in spontaneous calcium transient imaging in iPSC-derived neurons [68]. In contrast to these 
experiments, they used the calcium dye Fluo-4AM to visualise calcium traces of fluorescent 
intensity from three-month-old iPSC-derived neurons co-cultured with astrocytes. The spike 
amplitude of spontaneous calcium transients and the total number of calcium transients 
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showed no significant differences. Potentially correlated to the age, iPSC-derived neuronal 
cells were more synchronic in co-culture.   
 
Maybe based on different genetic backgrounds and various differentiation procedures, results 
of calcium transients differed between individual approaches. In all experiments spontaneous 
calcium release was measured to analyse calcium influx and efflux indicating the functionality 
of generated neuronal cells. Even if a changed calcium release needs more experimental 
explanations, first steps in the generation of functional cortical neuronal cells were made. Next 
step would be the quantification of firing response to current injections, stimulation or inhibitory 
substances to get a better understanding of the synaptic function and processes related to 
calcium signalling. Additionally, the number of analysed patients per functional analysis should 
be increased to exclude individuum specific results. A genetic predisposition in the family 
seemed to be a relevant selection criteria to see differences in functional assays and should 
be maintained.   
4.4 Transcriptome analysis identify changes in MHC locus in case 
of schizophrenia  
iPSC technology offers an easy system for studying the expression profile of 
neurodevelopmental and cellular processes in the pathophysiology of schizophrenia. A lot of 
changes in the transcriptome, including gene expression of synapse, calcium signalling and 
cell development are known for schizophrenia until today. Four weeks-old iPSC-derived 
neurons from SZ 2 exhibited a significant upregulation of HLA related genes like HLA-DM, 
HLA-DQ and HLA-DR, in comparison to CTR 1 after transcriptome analysis. 
Immunocytochemical staining of NPC derived from SZ 2 confirmed an increased amount of 
functional MHCII expression at early stages of neuronal development. Transcriptome analysis 
was performed to identify new relevant changes in gene expression in neuronal cells in case 
of schizophrenia. Aberrations may explain neurodevelopmental or phenotypical changes. 
 
First evidence for a changed Human Leukocyte Antigen (HLA) locus in schizophrenia was 
published in 1974 from Cazzullo et al. [190]. Since then, several HLA alleles like HLA-DRB1 
and HLA-DQB1 were directly linked to schizophrenia. HLA-DRB1 is important for antigen 
presentation and processing and build with HLA-DPA1 a dimer of the MHCII complex [191]. 
Multiple alleles and polymorphism of the HLA-DRB1 promotor makes the gene expression 
complex. The rheumatoid arthritism which negatively correlated with the incidence of 
schizophrenia, is related to the expression of the HLA-DRB1 allele [192, 193].   
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In 2009 the International Schizophrenia Consortium performed a GWAS using 3,322 European 
individuals with schizophrenia and 3,587 healthy controls. The HLA locus was identified as 
most powerful region of association for schizophrenia. Aberrations in genes involved in the 
antigen presentation shows a close link to innate and adaptive immune functions [91]. 
Furthermore, other studies figure the HLA locus out as one of the most significant determinant 
of susceptibility for schizophrenia [194, 195]. Most prominent SNPs were identified in regions 
near immune-related genes [194]. MHCII genes have important roles in the immune response 
and a variation in its density influences the intensity of the T-cell response. Its interaction with 
the T-cell receptor results in an activation and stimulation of CD4 T-cells [196]. An increase of 
the MHCII density would result in hyperactive T-cells resulting in increased immune reactions. 
These findings correlate to the enteropathogenesis. Dysregulation of innate and adaptive 
immune systems was described before by different working groups [197-199]. Prenatal 
infections [27], an increased risk for autoimmune diseases [200] and altered levels of 
inflammatory biomarkers [75] have been found as well in schizophrenia pathology. 
 
Beside immunological functionality, the MHC locus is also linked to non-immune functions. For 
example, the MHCI complex is involved in fundamental functions of the CNS, including 
neuronal differentiation, maturation and synaptic plasticity [201-203]. In 2016 Sekar et al. 
identified a linearly relation between the risk of schizophrenia and the expression of MHC 
region gene C4 [204]. The expression of C4 leads to an excessive synaptic pruning in neurons, 
giving straightforward evidence that the expression of an immune gene influences brain 
development. Another study observed significant SNPs closely to the gene NOTCH4 
(neurogenic locus notch homolog 4) [205, 206]. NOTCH4 codes for a transmembrane protein 
which is critical for neurodevelopment. Because NOTCH4 is a non-HLA gene that only maps 
to the HLA locus may suggest non-immune function as well. 
 
iPSC-derived neuronal cells showed same transcriptomic changes as described in previous 
studies indicating the explanatory power of these cells as cellular system to detect disease 
specific genomic changes. Findings support the relevance of gene expression aberrations in 
MHC-related genes in case of schizophrenia. In contrast to GWAS performed with somatic 
cells, the differentiation into neuronal cells and following transcriptome analysis enables 
investigations of disease relevant cell types. Schizophrenia is known as polygenetic disease 
and the disease origin cannot be only related to changes in one genomic region [80]. The 
genetic complexity of the disease has to be investigated in future to fully understand all 
observed genetic changes.  
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4.5 iPSC technology as cellular system for drug development of   
neurodevelopmental diseases 
In addition to morphological and functional tests, iPSC can be used to test drug effects in vitro 
and to identify new drug targets or molecular predictors in pharmacogenomics [180]. Animal 
models and post-mortem studies were mostly used for the investigation of schizophrenia but 
have limitations in qualified drug testing. Animal models can be used for the analysis of 
disease-specific molecular pathways or neuronal circuits, but fail to fully recapitulate all 
features of the psychiatric disorder schizophrenia. Changes in brain morphology, neuronal 
network, and synapse plasticity are already described using post-mortem brain tissue. Studies 
with post-mortem tissue only investigate the endpoint of the disease. Effects of drugs on early 
neuronal developmental or signalling processes can be better studied using living cells. 
Phenotypical assays for drug development must be relevant for clinical diagnosis and robust 
in therapeutic screenings [180]. The parameter neurite outgrowth of neuronal cells exhibit 
these properties and can be used as an indicator for the action of drugs or chemical 
compounds in developmental processes [178].  
 
To investigate the effect of antipsychotics on early neuronal development, drugs were applied 
after 24 hours of differentiation and neurite outgrowth of iPSC-derived neurons from CTR 1 
and SZ 2 was analysed after 72 hours. One first generation antipsychotic drug, haloperidol, 
and a second-generation antipsychotic drug, namely olanzapine, significantly reduced neurite 
outgrowth of iPSC-derived neurons from CTR 1. The antipsychotic clozapine had no effect on 
the neurite outgrowth. iPSC-derived neurons from SZ 2 were not significantly changed in 
neurite outgrowth after treatment with clozapine, olanzapine or haloperidol.  
 
Intrinsic and extrinsic factors which regulate the assembly of cytoskeletal elements, control the 
initiation and elongation of neurites [207, 208]. Additionally, changes in gene expression, 
membrane receptors, ion channels and complex intracellular signalling processes can result 
in aberrant neurite initiation and growth [209]. The complex nature of the regulation of neurite 
outgrowth, causes a wide range of potential targets to perturb this process.  
 
All three antipsychotics bind as antagonists with a moderate affinity to the dopamine D1 
receptor. Olanzapine has the highest affinity in comparison to Haloperidol and Clozapine. The 
DRD1 receptor is highly expressed in the prefrontal brain region [210] and dopamine plays a 
prominent role in the pathophysiology of schizophrenia [211, 212]. Already post-mortem 
studies identified a decreased expression of DRD1 receptor [213] in patients with 
schizophrenia mostly linked with an impairment of cognitive function and the presence of 
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negative symptoms [214, 215]. The functionality of DRD1 is directly linked to the control of 
working memory [216, 217], which dysfunction is a prominent feature in schizophrenia [218].  
The dopamine D1 receptor belongs to the heptahelical receptor family which modulated the 
activity of adenylate cyclase by activating specific G-proteins. The stimulation of DRD1 leads 
to the activation of adenyl cyclase (AC) which increases the production of cyclic adenosine 
monophosphate (cAMP). A higher cAMP activation increased the activation of protein kinase 
A (PKA). Both molecules play an extensive role in neuronal development and neuroplasticity 
[219]. For example, neurite outgrowth [220], neuronal differentiation [221] and survival [222] 
are mediated by cAMP in neurons. Stronger activation of the cAMP/PKA pathway promotes 
the neurite outgrowth in human embryonal carcinoma stem cells [223]. The application of an 
DRD1 antagonist such as olanzapine [224] and haloperidol [225] decreased the neurite 
outgrowth as expected. Despite the inhibitory effect on DRD1 of clozapine, the application of 
this drug resulted in no significant changes of neurite outgrowth. A reduction was only observed 
in iPSC-derived neurons from healthy individuals. Transcriptome analysis showed a reduced 
DRD2 expression in iPSC-derived neurons from donor SZ 2. Changes in DRD1 expression 
were not detected. In contrast to DRD1 the activation of DRD2 receptor inhibits AC [226] and 
may result in a decreased amount of cAMP. The proportions of DRD1:DRD2 receptors are 
essential for the cAMP activation and may be the reason for different effects in neurite 
outgrowth after drug application.   
 
Brennand et al. studied also neuronal development of iPSC-derived neurons from patients with 
schizophrenia after treatment with antipsychotics. Treatment with loxapine improved neuronal 
connectivity and gene expression, similar Clozapine and olanzapine had no effect on neuronal 
connectivity after adding during the last three weeks of neuronal differentiation [68]. Loxapine 
has a strong binding affinity for dopamine D4 and serotonin 5-HT2 receptors [227] and mode 
of action differs to other antipsychotics. Above described results are difficult to compare to the 
results of this thesis because differentiation protocol and time point of analysis differed. 
Furthermore, the co-cultivation with astrocytes may have an impact on the neuronal 
development of iPSC-derived cells which may lead to different experimental results.  
 
After an extended period without new developments, some new drugs are already in clinical 
trial phases II and III. At the CNS summit 2016 efforts of the new drug named ITI-007 
manufactured by IntraCellular Therapies were presented. ITI-007 showed significant 
improvements in comparison to the placebo control and reduce positive and negative 
symptoms in acute and residual schizophrenia (compare clinical trials gov. Identifier: 
NCT02469155, [228]). Comparable to further drugs ITI-007 mode of action includes the D2 
dopamine receptor and is agonist at the presynaptic side and antagonist at the postsynaptic 
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side. Additionally, it has serotonin antagonistic effects and increases the phosphorylation of 
GluN2B [229]. The appearance of side effects is limited under ITI-007 treatment. 
4.6 Outlook 
In this thesis the development of an iPSC-based cellular system for modelling schizophrenia 
is described using patient-derived cells. Modelling of complex neurodevelopmental disease in 
vitro is still challenging because of missing maturation of neuronal cells and robust analysis 
systems.  
 
The development of 3-dimensional cerebral organoids as described by Lancaster et al. [230] 
mimics the in vivo conditions in a more specific way and recapitulate fundamental mechanisms 
of human brain development, neuronal circuits and neuronal interaction partners. Organoids 
were successfully used to model a neuron specific disease phenotype and supports the 
development of disease-specific drugs. Pasca et al. developed a method to generate human 
cortical spheroids using pluripotent stem cell, which mimic the cerebral cortex structure of a 
human brain [231]. Developed structures contain cell types of deep and superficial cortical 
layers. Transcriptome analysis data correlated with results of fetal derived cells. Beside 
morphological characteristics, functionality of neurons was observed by electrophysiological 
experiments which display spontaneous activity and functional synapses.  
 
With the improvement of differentiation also the analysis setup of prominent neuronal network 
formation has to be more robust, efficient and replicable. The multielectrode array (MEA) 
technology offers a perfect tool to measure neuronal network activity. Here, iPSC-derived 
neurons are cultivated of an electrode field enable a non-invasive measurement of connectivity 
of functional neural networks during the whole cultivation time. Aspects of development, 
maturation, as well as, responses to pharmaceuticals can be investigated in a long-term 
culture.  
 
To increase the explanatory power of the cellular system with patient-specific cells an 
automation and upscaling is necessary, potentially with automatization. Although it will be very 
challenging to optimize and standardize the differentiation protocols, culture conditions and 
differentiation strategies to produce more mature, healthy and stable neurons at a much faster 
time scale. 
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5. SUPPLEMENT 
5.1 Supplement figures 
 
Supplement Fig. 1: Immunocytochemical staining of iPSCs from all donors against stem cell 
marker genes SSEA 4 and Tra 1-81. iPSC clones of donor CTR 1-3, SZ 1-3 and ASD 1-3 are shown. 
The expression of stem cell marker genes SSEA 4 (left) and Tra 1-81 (right) is demonstrated with 
immunocytochemical staining. Scale bars: 100 µm. 
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Supplement Fig. 2: Immunocytochemical staining of NPCs from all donors against marker 
genes ZO 1 and PAX 6. Expression of NPC marker genes like cell surface marker ZO 1 and 
transcription factor PAX 6 was validated via immunocytochemical staining of NPCs derived from donor 
CTR 1-3, SZ 1-3 and ASD 1-3. ZO 1=Zona Occludens 1, PAX 6=Paired box gene 6, Scale bars: 
100 µm. 
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Supplement Fig. 3: Immunocytochemical staining of NPCs from all donors against marker 
genes Nestin and SOX 1. Expression of NPC marker genes like Nestin and transcription factor 
SOX 1 was validated via immunocytochemical staining of NPCs derived from donor CTR 1-3, SZ 1-3 
and ASD 1-3. SOX 1=SRY box 1, Scale bars: 100 µm. 
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Supplement Fig. 4: Immunocytochemical staining of iPSC-derived neurons from all donors 
against -III-tubulin. iPSC-derived neurons from CTR 1-3, SZ 1-3 and ASD 1-3 were differentiated 
for four days and stained against -III-tubulin. Hoechst solution was used for nuclei staining. Images 
were automatically obtained by ImageXpress micro XL microscope and used for segmentation with 
the MetaXpress Software. Scale bars: 100 µm. 
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Supplement Fig. 5: Immunocytochemical staining of iPSC-derived neurons against synaptical 
and neuronal markers. Immunocytochemical staining of eight weeks old iPSC-derived neurons from 
donor CTR 1-3, SZ 1-3 and ASD 1-3 against synaptic marker PSD95, VGluT and neuronal marker -
III-tubulin. Hoechst was used for nuclei staining. Scale bars: 10 µm. 
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5.2 Supplement tables 
Supplement Tab. 1: Significant deregulated genes of iPSC-derived neurons from all SZ versus 
all CTR after transcriptome analysis. 
gene ID gene log2FoldChange pvalue padj 
ENSG00000226321 AC104809.3 3.2 4.73E-05 4.60E-02 
ENSG00000147256 ARHGAP36 -3.5 2.53E-06 9.13E-03 
ENSG00000106819 ASPN 3.4 3.34E-05 3.67E-02 
ENSG00000205856 C22orf42 -3.2 1.27E-05 2.01E-02 
ENSG00000164287 CDC20B 4.1 1.16E-06 7.64E-03 
ENSG00000236279 CLEC2L -3.1 9.38E-06 1.69E-02 
ENSG00000169436 COL22A1 2.6 4.22E-05 4.26E-02 
ENSG00000135678 CPM 3.4 1.72E-08 4.33E-04 
ENSG00000267594 CYP4F24P 3.7 1.08E-05 1.81E-02 
ENSG00000080166 DCT 3.3 4.84E-06 1.35E-02 
ENSG00000186676 EEF1GP1 3.7 1.21E-06 7.64E-03 
ENSG00000054179 ENTPD2 2.9 1.87E-05 2.78E-02 
ENSG00000182646 FAM156A -2.8 3.91E-05 4.12E-02 
ENSG00000172568 FNDC9 -2.9 7.56E-06 1.47E-02 
ENSG00000174473 GALNTL6 -2.4 2.55E-05 3.22E-02 
ENSG00000164171 ITGA2 3.4 1.57E-06 7.92E-03 
ENSG00000138795 LEF1 3.4 1.70E-07 2.15E-03 
ENSG00000223414 LINC00473 -3.4 2.20E-05 2.93E-02 
ENSG00000165553 NGB -3.5 3.21E-06 1.01E-02 
ENSG00000152214 RIT2 -2.8 3.08E-05 3.54E-02 
ENSG00000250448 RP11-19O2.2 -3.4 2.74E-05 3.30E-02 
ENSG00000259203 RP11-209K10.2 -3.8 5.36E-06 1.35E-02 
ENSG00000229422 RP11-262H14.5 -2.8 7.44E-06 1.47E-02 
ENSG00000234688 RP1-293L6.1 -3.3 6.07E-06 1.39E-02 
ENSG00000196104 SPOCK3 -2.4 1.99E-05 2.80E-02 
ENSG00000170044 ZPLD1 -3.3 2.05E-06 8.62E-03 
 
Supplement Tab. 2: Significant deregulated genes of iPSC-derived neurons from SZ 1 versus 
all CTR after transcriptome analysis. 
gene ID gene log2FoldChange pvalue padj 
ENSG00000234281 AC007970.1 4.7 1.15E-05 3.33E-03 
ENSG00000143632 ACTA1 4.1 4.91E-05 1.09E-02 
ENSG00000159251 ACTC1 4.8 2.73E-06 1.11E-03 
ENSG00000077522 ACTN2 4.2 1.22E-05 3.50E-03 
ENSG00000157510 AFAP1L1 3.7 1.28E-04 2.38E-02 
ENSG00000165092 ALDH1A1 5.6 2.18E-08 2.37E-05 
ENSG00000147256 ARHGAP36 -4.4 8.32E-06 2.55E-03 
ENSG00000005981 ASB4 3.8 1.94E-04 3.30E-02 
ENSG00000164122 ASB5 4.1 8.87E-05 1.77E-02 
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ENSG00000106819 ASPN 4.3 1.67E-06 7.91E-04 
ENSG00000101892 ATP1B4 6.6 2.03E-10 4.06E-07 
ENSG00000043039 BARX2 5.3 4.73E-07 2.82E-04 
ENSG00000182492 BGN 3.8 2.68E-05 6.94E-03 
ENSG00000177354 C10orf71 4.6 1.47E-05 4.04E-03 
ENSG00000161992 C16orf11 5.1 1.69E-06 7.91E-04 
ENSG00000180999 C1orf105 4.4 1.53E-05 4.15E-03 
ENSG00000169085 C8orf46 -3.4 1.96E-04 3.30E-02 
ENSG00000077274 CAPN6 4.7 5.31E-06 1.86E-03 
ENSG00000118729 CASQ2 4.6 6.88E-07 3.79E-04 
ENSG00000164287 CDC20B 5.0 3.48E-06 1.32E-03 
ENSG00000129910 CDH15 4.6 3.43E-07 2.36E-04 
ENSG00000135902 CHRND 5.1 1.75E-06 8.03E-04 
ENSG00000104879 CKM 4.6 1.31E-05 3.66E-03 
ENSG00000159212 CLIC6 4.6 1.81E-05 4.87E-03 
ENSG00000187955 COL14A1 4.0 6.80E-06 2.24E-03 
ENSG00000105664 COMP 7.8 1.06E-15 7.77E-12 
ENSG00000129170 CSRP3 5.7 2.26E-08 2.37E-05 
ENSG00000268518 CTD-2545M3.8 5.6 2.84E-08 2.84E-05 
ENSG00000186377 CYP4X1 -3.6 3.36E-04 4.97E-02 
ENSG00000067048 DDX3Y 6.2 2.40E-09 3.59E-06 
ENSG00000175084 DES 4.4 1.51E-06 7.54E-04 
ENSG00000231764 DLX6-AS1 -4.2 3.57E-05 8.74E-03 
ENSG00000121570 DPPA4 -4.0 8.29E-06 2.55E-03 
ENSG00000186676 EEF1GP1 3.5 1.34E-04 2.46E-02 
ENSG00000198692 EIF1AY 7.3 1.21E-13 6.65E-10 
ENSG00000127507 EMR2 3.8 3.13E-04 4.69E-02 
ENSG00000108515 ENO3 4.5 5.06E-07 2.94E-04 
ENSG00000065361 ERBB3 4.0 3.27E-05 8.25E-03 
ENSG00000157554 ERG 4.4 2.17E-05 5.76E-03 
ENSG00000106038 EVX1 3.9 1.23E-04 2.31E-02 
ENSG00000122176 FMOD 5.7 2.61E-09 3.59E-06 
ENSG00000143140 GJA5 3.9 2.13E-04 3.53E-02 
ENSG00000177291 GJD4 5.5 1.53E-07 1.22E-04 
ENSG00000132975 GPR12 -3.6 5.59E-05 1.22E-02 
ENSG00000130600 H19 4.6 1.84E-06 8.27E-04 
ENSG00000164107 HAND2 5.2 2.91E-07 2.07E-04 
ENSG00000237125 HAND2-AS1 5.1 2.38E-06 1.03E-03 
ENSG00000204287 HLA-DRA -4.0 1.14E-05 3.33E-03 
ENSG00000130528 HRC 4.6 1.10E-06 5.79E-04 
ENSG00000157219 HTR5A -3.4 2.56E-04 3.99E-02 
ENSG00000167244 IGF2 4.6 3.83E-07 2.51E-04 
ENSG00000115221 ITGB6 3.6 1.05E-04 2.01E-02 
ENSG00000241859 KALP 5.0 2.58E-06 1.07E-03 
ENSG00000182255 KCNA4 -3.5 1.79E-04 3.12E-02 
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ENSG00000185774 KCNIP4 -3.5 2.27E-04 3.71E-02 
ENSG00000115474 KCNJ13 4.0 2.38E-04 3.83E-02 
ENSG00000012817 KDM5D 6.6 5.51E-11 1.35E-07 
ENSG00000168427 KLHL30 3.9 7.44E-05 1.53E-02 
ENSG00000157119 KLHL40 4.6 1.40E-06 7.20E-04 
ENSG00000239474 KLHL41 4.8 4.00E-07 2.51E-04 
ENSG00000131650 KREMEN2 3.6 4.97E-05 1.09E-02 
ENSG00000122367 LDB3 4.1 8.84E-06 2.67E-03 
ENSG00000262152 LINC00514 4.9 4.48E-06 1.62E-03 
ENSG00000233117 LINC00702 4.1 1.88E-04 3.26E-02 
ENSG00000249378 LINC01060 4.2 9.48E-05 1.85E-02 
ENSG00000170807 LMOD2 4.0 1.49E-04 2.67E-02 
ENSG00000214548 MEG3 8.4 2.00E-16 2.20E-12 
ENSG00000265142 MIR1-2 4.3 6.99E-05 1.47E-02 
ENSG00000211574 MIR770 4.9 7.42E-06 2.37E-03 
ENSG00000136297 MMD2 -3.5 2.47E-04 3.91E-02 
ENSG00000086967 MYBPC2 4.0 7.98E-05 1.61E-02 
ENSG00000111049 MYF5 6.0 2.03E-08 2.36E-05 
ENSG00000109063 MYH3 5.4 2.75E-07 2.02E-04 
ENSG00000168530 MYL1 4.2 6.74E-05 1.44E-02 
ENSG00000160808 MYL3 3.7 1.36E-04 2.48E-02 
ENSG00000198336 MYL4 4.8 4.31E-06 1.58E-03 
ENSG00000180209 MYLPF 4.8 3.39E-06 1.31E-03 
ENSG00000133454 MYO18B 4.1 3.13E-05 8.02E-03 
ENSG00000129152 MYOD1 6.1 6.82E-10 1.25E-06 
ENSG00000122180 MYOG 5.0 3.24E-06 1.30E-03 
ENSG00000142661 MYOM3 4.8 7.01E-06 2.27E-03 
ENSG00000172399 MYOZ2 3.7 4.60E-05 1.05E-02 
ENSG00000138347 MYPN 5.2 2.73E-07 2.02E-04 
ENSG00000183091 NEB 3.6 3.19E-04 4.75E-02 
ENSG00000087303 NID2 3.8 3.91E-05 9.30E-03 
ENSG00000122585 NPY 4.0 3.95E-05 9.30E-03 
ENSG00000226306 NPY6R 4.2 1.07E-04 2.04E-02 
ENSG00000106809 OGN 4.1 4.73E-05 1.06E-02 
ENSG00000183801 OLFML1 3.7 1.26E-04 2.35E-02 
ENSG00000188269 OR7A5 4.0 2.43E-04 3.89E-02 
ENSG00000171540 OTP -4.6 3.37E-06 1.31E-03 
ENSG00000108405 P2RX1 4.0 3.12E-04 4.69E-02 
ENSG00000253537 PCDHGA7 3.8 2.80E-04 4.29E-02 
ENSG00000069011 PITX1 6.4 7.50E-11 1.65E-07 
ENSG00000147588 PMP2 -3.7 1.43E-04 2.59E-02 
ENSG00000099725 PRKY 4.7 6.08E-06 2.03E-03 
ENSG00000172179 PRL 5.8 3.25E-08 3.11E-05 
ENSG00000171864 PRND 4.4 2.43E-06 1.03E-03 
ENSG00000165917 RAPSN 5.0 1.58E-06 7.75E-04 
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ENSG00000254202 RP11-120I21.2 5.0 3.72E-06 1.39E-03 
ENSG00000269994 RP11-276H19.2 -3.3 2.80E-04 4.29E-02 
ENSG00000254586 RP11-358H18.3 4.3 9.29E-05 1.83E-02 
ENSG00000253619 RP11-369K17.1 4.5 3.29E-05 8.25E-03 
ENSG00000269466 RP11-432M8.17 4.5 4.28E-05 9.94E-03 
ENSG00000257951 RP11-554D14.4 4.9 5.17E-06 1.84E-03 
ENSG00000267287 RP11-567M16.1 4.2 7.42E-05 1.53E-02 
ENSG00000258732 RP11-603B24.1 4.0 2.59E-04 4.02E-02 
ENSG00000259669 RP11-643A5.2 4.5 3.47E-05 8.59E-03 
ENSG00000248713 RP11-766F14.2 3.9 1.96E-04 3.30E-02 
ENSG00000259847 RP11-95H3.1 4.0 2.91E-04 4.43E-02 
ENSG00000129824 RPS4Y1 7.2 2.07E-13 9.12E-10 
ENSG00000070031 SCT 3.9 2.20E-04 3.62E-02 
ENSG00000108823 SGCA 4.9 6.78E-07 3.79E-04 
ENSG00000126778 SIX1 3.9 5.72E-05 1.23E-02 
ENSG00000091482 SMPX 4.1 8.93E-05 1.77E-02 
ENSG00000115593 SMYD1 5.0 1.55E-07 1.22E-04 
ENSG00000185739 SRL 5.2 6.38E-09 7.81E-06 
ENSG00000184343 SRPK3 3.8 2.01E-04 3.36E-02 
ENSG00000139874 SSTR1 -3.5 1.57E-04 2.79E-02 
ENSG00000166317 SYNPO2L 5.1 7.44E-08 6.31E-05 
ENSG00000163630 SYNPR -4.0 1.30E-05 3.66E-03 
ENSG00000092377 TBL1Y 4.5 3.90E-05 9.30E-03 
ENSG00000135111 TBX3 3.9 2.49E-04 3.92E-02 
ENSG00000121075 TBX4 4.2 3.97E-05 9.30E-03 
ENSG00000188681 TEKT4P2 5.7 3.94E-08 3.62E-05 
ENSG00000142910 TINAGL1 4.8 5.40E-06 1.86E-03 
ENSG00000187616 TMEM8C 5.2 4.05E-07 2.51E-04 
ENSG00000154620 TMSB4Y 6.2 2.53E-09 3.59E-06 
ENSG00000101470 TNNC2 4.5 8.33E-06 2.55E-03 
ENSG00000159173 TNNI1 5.3 4.72E-09 6.12E-06 
ENSG00000130598 TNNI2 5.3 4.93E-08 4.35E-05 
ENSG00000105048 TNNT1 3.8 4.44E-05 1.02E-02 
ENSG00000118194 TNNT2 4.5 2.44E-05 6.40E-03 
ENSG00000130595 TNNT3 5.1 2.00E-06 8.81E-04 
ENSG00000186439 TRDN 3.9 7.56E-05 1.54E-02 
ENSG00000147573 TRIM55 4.1 6.83E-05 1.45E-02 
ENSG00000158022 TRIM63 4.0 1.59E-04 2.80E-02 
ENSG00000155657 TTN 4.2 5.75E-06 1.95E-03 
ENSG00000118271 TTR 4.6 9.84E-06 2.93E-03 
ENSG00000176728 TTTY14 5.3 4.09E-07 2.51E-04 
ENSG00000233864 TTTY15 8.6 5.71E-18 1.26E-13 
ENSG00000131002 TXLNG2P 7.2 8.45E-13 3.10E-09 
ENSG00000141161 UNC45B 5.2 7.44E-07 4.00E-04 
ENSG00000114374 USP9Y 6.8 6.54E-12 2.02E-08 
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ENSG00000181408 UTS2R 3.9 9.90E-05 1.91E-02 
ENSG00000183878 UTY 6.8 7.35E-12 2.02E-08 
ENSG00000135925 WNT10A 3.6 1.89E-04 3.26E-02 
ENSG00000163092 XIRP2 4.0 2.33E-04 3.78E-02 
ENSG00000067646 ZFY 6.2 1.99E-09 3.38E-06 
 
Supplement Tab. 3: Significant deregulated genes of iPSC-derived neurons from SZ 2 versus 
all CTR after transcriptome analysis. 
gene ID gene log2FoldChange pvalue padj 
ENSG00000224911 AC015936.3 4.2 3.64E-05 2.19E-02 
ENSG00000106819 ASPN 4.1 5.44E-06 4.72E-03 
ENSG00000125730 C3 4.3 1.28E-05 9.24E-03 
ENSG00000151062 CACNA2D4 4.1 2.02E-05 1.37E-02 
ENSG00000019582 CD74 6.0 2.08E-10 1.51E-06 
ENSG00000164287 CDC20B 6.0 1.16E-08 2.28E-05 
ENSG00000133048 CHI3L1 5.8 6.09E-10 2.21E-06 
ENSG00000179583 CIITA 5.7 1.30E-09 4.03E-06 
ENSG00000115844 DLX2 4.2 1.04E-05 8.39E-03 
ENSG00000105880 DLX5 4.2 1.08E-05 8.39E-03 
ENSG00000006377 DLX6 4.0 7.31E-05 3.78E-02 
ENSG00000231764 DLX6-AS1 5.1 1.33E-08 2.41E-05 
ENSG00000070886 EPHA8 -3.5 8.75E-05 4.36E-02 
ENSG00000164308 ERAP2 5.4 1.78E-08 2.76E-05 
ENSG00000230316 FEZF1-AS1 4.4 4.01E-05 2.35E-02 
ENSG00000143631 FLG 4.6 2.72E-05 1.73E-02 
ENSG00000164694 FNDC1 3.7 5.29E-05 3.02E-02 
ENSG00000134612 FOLH1B 5.6 2.29E-07 2.62E-04 
ENSG00000176165 FOXG1 4.1 1.05E-04 4.82E-02 
ENSG00000117226 GBP3 4.2 9.92E-06 8.29E-03 
ENSG00000131095 GFAP 3.8 3.04E-05 1.89E-02 
ENSG00000184674 GSTT1 -4.8 1.66E-07 2.00E-04 
ENSG00000206337 HCP5 4.3 1.14E-05 8.50E-03 
ENSG00000204257 HLA-DMA 4.2 3.12E-06 2.83E-03 
ENSG00000242574 HLA-DMB 4.5 5.40E-07 5.86E-04 
ENSG00000204252 HLA-DOA 6.3 1.66E-11 1.80E-07 
ENSG00000231389 HLA-DPA1 5.6 3.18E-10 1.56E-06 
ENSG00000196735 HLA-DQA1 5.5 6.88E-09 1.49E-05 
ENSG00000237541 HLA-DQA2 5.2 7.06E-07 7.30E-04 
ENSG00000232629 HLA-DQB2 6.0 4.75E-09 1.15E-05 
ENSG00000204287 HLA-DRA 5.5 3.59E-10 1.56E-06 
ENSG00000196126 HLA-DRB1 4.0 5.46E-05 3.04E-02 
ENSG00000198502 HLA-DRB5 4.3 1.32E-05 9.24E-03 
ENSG00000229391 HLA-DRB6 5.6 2.49E-08 3.60E-05 
ENSG00000204642 HLA-F 3.8 1.07E-04 4.82E-02 
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ENSG00000132204 LINC00470 4.7 2.13E-06 2.10E-03 
ENSG00000012223 LTF 6.8 6.85E-12 1.49E-07 
ENSG00000053438 NNAT -4.7 1.01E-07 1.29E-04 
ENSG00000111331 OAS3 4.2 2.47E-06 2.33E-03 
ENSG00000160951 PTGER1 3.9 8.83E-05 4.36E-02 
ENSG00000198774 RASSF9 3.7 5.68E-05 3.08E-02 
ENSG00000250138 RP11-848G14.5 4.3 9.73E-05 4.70E-02 
ENSG00000177409 SAMD9L 3.7 1.02E-04 4.82E-02 
ENSG00000126778 SIX1 3.8 1.09E-04 4.82E-02 
ENSG00000226287 TMEM191A -3.7 6.81E-05 3.61E-02 
ENSG00000150244 TRIM48 6.2 2.17E-09 5.89E-06 
ENSG00000148704 VAX1 5.7 1.77E-08 2.76E-05 
ENSG00000106018 VIPR2 -4.2 2.19E-05 1.44E-02 
ENSG00000197134 ZNF257 5.8 5.21E-08 7.08E-05 
 
Supplement Tab. 4: Significant deregulated genes of iPSC-derived neurons from SZ 3 versus 
all CTR after transcriptome analysis. 
gene ID gene log2FoldChange pvalue padj 
ENSG00000251621 AC009487.5 4.9 8.98E-05 3.92E-02 
ENSG00000178522 AMBN 8.6 2.92E-19 3.13E-15 
ENSG00000004848 ARX 4.6 3.55E-06 2.62E-03 
ENSG00000169085 C8orf46 -3.9 5.23E-05 2.49E-02 
ENSG00000117266 CDK18 4.1 1.39E-05 8.37E-03 
ENSG00000168539 CHRM1 5.2 2.34E-06 1.79E-03 
ENSG00000259436 CTC-378H22.2 -4.8 2.01E-05 1.16E-02 
ENSG00000250377 CTC-467M3.3 6.1 4.02E-07 3.44E-04 
ENSG00000080166 DCT 4.2 1.18E-04 4.86E-02 
ENSG00000067048 DDX3Y 7.6 9.36E-12 1.43E-08 
ENSG00000142700 DMRTA2 7.2 1.28E-12 2.11E-09 
ENSG00000186676 EEF1GP1 5.3 2.79E-08 2.84E-05 
ENSG00000198692 EIF1AY 7.9 4.08E-14 8.72E-11 
ENSG00000170370 EMX2 8.5 1.55E-15 5.35E-12 
ENSG00000229847 EMX2OS 8.8 3.73E-16 1.99E-12 
ENSG00000163064 EN1 -5.2 1.66E-06 1.32E-03 
ENSG00000163508 EOMES 5.0 7.00E-06 4.68E-03 
ENSG00000153266 FEZF2 8.3 4.46E-18 3.18E-14 
ENSG00000176165 FOXG1 6.5 2.51E-08 2.68E-05 
ENSG00000144820 GPR128 7.5 7.10E-11 1.01E-07 
ENSG00000164171 ITGA2 4.4 1.10E-05 6.92E-03 
ENSG00000241859 KALP 5.2 1.41E-05 8.37E-03 
ENSG00000012817 KDM5D 7.6 6.10E-13 1.09E-09 
ENSG00000138795 LEF1 4.4 4.10E-06 2.83E-03 
ENSG00000106689 LHX2 6.1 1.07E-08 1.21E-05 
ENSG00000214548 MEG3 7.0 2.64E-10 3.53E-07 
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ENSG00000111341 MGP -4.4 3.45E-05 1.84E-02 
ENSG00000164600 NEUROD6 3.9 4.10E-05 2.04E-02 
ENSG00000133636 NTS 4.5 4.04E-06 2.83E-03 
ENSG00000171540 OTP -5.6 2.30E-07 2.14E-04 
ENSG00000163803 PLB1 -4.6 4.21E-05 2.05E-02 
ENSG00000099725 PRKY 6.2 3.65E-08 3.54E-05 
ENSG00000134438 RAX 4.7 1.04E-04 4.45E-02 
ENSG00000185304 RGPD2 5.5 7.27E-06 4.71E-03 
ENSG00000152214 RIT2 -4.1 3.83E-05 2.00E-02 
ENSG00000263711 RP11-169F17.1 6.8 1.16E-09 1.46E-06 
ENSG00000260197 RP11-424G14.1 5.2 3.18E-05 1.74E-02 
ENSG00000205663 RP11-706O15.5 5.7 1.02E-06 8.38E-04 
ENSG00000231227 RP11-85O21.4 4.8 7.68E-05 3.49E-02 
ENSG00000129824 RPS4Y1 8.1 3.04E-15 8.13E-12 
ENSG00000066230 SLC9A3 4.9 2.60E-05 1.46E-02 
ENSG00000136535 TBR1 8.0 5.16E-14 1.00E-10 
ENSG00000157150 TIMP4 -4.4 1.18E-04 4.86E-02 
ENSG00000154620 TMSB4Y 6.1 2.78E-07 2.48E-04 
ENSG00000176728 TTTY14 4.7 1.21E-04 4.86E-02 
ENSG00000233864 TTTY15 9.7 1.22E-19 2.61E-15 
ENSG00000131002 TXLNG2P 8.3 1.97E-14 4.68E-11 
ENSG00000262519 TXNP4 -4.4 6.97E-05 3.24E-02 
ENSG00000114374 USP9Y 8.2 1.75E-15 5.35E-12 
ENSG00000183878 UTY 8.4 1.17E-15 5.00E-12 
ENSG00000227165 WDR11-AS1 -4.6 4.04E-05 2.04E-02 
ENSG00000204186 ZDBF2 -4.4 8.31E-05 3.70E-02 
ENSG00000067646 ZFY 6.6 8.84E-09 1.05E-05 
 
Supplement Tab. 5: Significant deregulated genes of iPSC-derived neurons from SZ 2 versus 
CTR 1 after transcriptome analysis. 
gene ID gene log2FoldChange pvalue 
ENSG00000175899 A2M 2.5 1.63E-02 
ENSG00000181409 AATK -2.2 2.81E-02 
ENSG00000108846 ABCC3 3.3 2.84E-03 
ENSG00000006071 ABCC8 -2.7 1.18E-02 
ENSG00000154175 ABI3BP 3.0 5.24E-03 
ENSG00000163995 ABLIM2 -2.0 4.53E-02 
ENSG00000173210 ABLIM3 -2.5 1.59E-02 
ENSG00000187905 AC002472.13 2.8 1.15E-02 
ENSG00000188477 AC003003.5 3.4 2.66E-03 
ENSG00000261790 AC005606.14 -2.4 3.59E-02 
ENSG00000261342 AC006538.1 -2.2 3.62E-02 
ENSG00000236544 AC008060.8 2.4 4.29E-02 
ENSG00000223642 AC008277.1 2.6 2.60E-02 
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ENSG00000224911 AC015936.3 3.2 3.89E-03 
ENSG00000234710 AC060834.3 3.0 1.10E-02 
ENSG00000228528 AC068057.1 -2.6 2.56E-02 
ENSG00000229267 AC072062.1 2.5 2.87E-02 
ENSG00000222043 AC079305.10 -2.4 4.37E-02 
ENSG00000204460 AC079586.1 -2.8 1.62E-02 
ENSG00000229370 AC092635.1 -2.7 2.23E-02 
ENSG00000226321 AC104809.3 2.5 3.47E-02 
ENSG00000236710 AC108448.2 -2.6 2.49E-02 
ENSG00000232938 AC139099.3 -2.9 1.30E-02 
ENSG00000197142 ACSL5 2.4 4.11E-02 
ENSG00000154930 ACSS1 2.3 2.68E-02 
ENSG00000159251 ACTC1 -2.6 1.56E-02 
ENSG00000163017 ACTG2 2.7 1.12E-02 
ENSG00000077080 ACTL6B -2.1 3.61E-02 
ENSG00000073670 ADAM11 -2.3 2.56E-02 
ENSG00000148848 ADAM12 2.0 4.73E-02 
ENSG00000138316 ADAMTS14 2.4 2.16E-02 
ENSG00000145536 ADAMTS16 2.9 5.87E-03 
ENSG00000158859 ADAMTS4 2.2 3.89E-02 
ENSG00000134917 ADAMTS8 -2.3 3.53E-02 
ENSG00000105963 ADAP1 -2.9 6.97E-03 
ENSG00000141433 ADCYAP1 -2.4 1.83E-02 
ENSG00000118492 ADGB 2.7 1.83E-02 
ENSG00000106624 AEBP1 2.2 2.86E-02 
ENSG00000135439 AGAP2 -2.3 2.45E-02 
ENSG00000255737 AGAP2-AS1 2.1 4.68E-02 
ENSG00000165923 AGBL2 2.7 1.96E-02 
ENSG00000124942 AHNAK 2.4 1.97E-02 
ENSG00000106546 AHR 2.0 4.79E-02 
ENSG00000154027 AK5 -2.0 4.76E-02 
ENSG00000162641 AKNAD1 2.8 1.06E-02 
ENSG00000151632 AKR1C2 -2.7 1.00E-02 
ENSG00000179148 ALOXE3 -2.6 2.79E-02 
ENSG00000104899 AMH -2.5 1.78E-02 
ENSG00000167772 ANGPTL4 2.1 4.74E-02 
ENSG00000187984 ANKRD19P -2.8 1.92E-02 
ENSG00000230006 ANKRD36BP2 -2.2 3.81E-02 
ENSG00000164512 ANKRD55 -2.3 3.02E-02 
ENSG00000230062 ANKRD66 3.0 9.60E-03 
ENSG00000011426 ANLN 2.0 4.94E-02 
ENSG00000131620 ANO1 2.3 3.31E-02 
ENSG00000231991 ANXA2P2 2.0 4.92E-02 
ENSG00000273295 AP000350.5 -2.6 2.50E-02 
ENSG00000213983 AP1G2 -2.3 2.55E-02 
SUPPLEMENT  109 
ENSG00000107282 APBA1 -2.0 4.33E-02 
ENSG00000198768 APCDD1L 2.6 1.97E-02 
ENSG00000134817 APLNR 2.5 2.00E-02 
ENSG00000239713 APOBEC3G 2.3 4.42E-02 
ENSG00000130203 APOE 2.6 1.21E-02 
ENSG00000100342 APOL1 3.0 1.07E-02 
ENSG00000221963 APOL6 2.6 1.43E-02 
ENSG00000198576 ARC -2.3 2.41E-02 
ENSG00000081181 ARG2 -2.1 3.79E-02 
ENSG00000198826 ARHGAP11A 2.5 1.68E-02 
ENSG00000187951 ARHGAP11B 2.1 4.07E-02 
ENSG00000137727 ARHGAP20 -2.2 3.14E-02 
ENSG00000137962 ARHGAP29 2.1 3.99E-02 
ENSG00000147256 ARHGAP36 -2.9 7.61E-03 
ENSG00000242173 ARHGDIG -3.2 3.42E-03 
ENSG00000165309 ARMC3 3.1 4.75E-03 
ENSG00000172995 ARPP21 -2.1 3.53E-02 
ENSG00000140450 ARRDC4 2.2 3.21E-02 
ENSG00000004848 ARX 3.0 6.38E-03 
ENSG00000108684 ASIC2 -2.3 2.28E-02 
ENSG00000108381 ASPA 2.7 2.13E-02 
ENSG00000174939 ASPHD1 -2.3 2.52E-02 
ENSG00000066279 ASPM 3.0 5.02E-03 
ENSG00000106819 ASPN 3.1 4.06E-03 
ENSG00000179774 ATOH7 -2.8 1.58E-02 
ENSG00000118322 ATP10B 2.3 2.75E-02 
ENSG00000105409 ATP1A3 -2.3 2.33E-02 
ENSG00000067842 ATP2B3 -2.4 2.17E-02 
ENSG00000180389 ATP5EP2 -2.2 3.22E-02 
ENSG00000132932 ATP8A2 -2.0 4.11E-02 
ENSG00000081923 ATP8B1 2.2 3.81E-02 
ENSG00000178999 AURKB 2.0 4.80E-02 
ENSG00000176383 B3GNT4 -2.6 1.60E-02 
ENSG00000086062 B4GALT1 2.5 1.53E-02 
ENSG00000181790 BAI1 -2.4 2.08E-02 
ENSG00000198604 BAZ1A 2.0 4.35E-02 
ENSG00000166546 BEAN1 -2.4 2.13E-02 
ENSG00000183092 BEGAIN -2.2 3.04E-02 
ENSG00000133169 BEX1 -2.1 3.90E-02 
ENSG00000133134 BEX2 -2.1 3.90E-02 
ENSG00000184515 BEX5 -2.3 2.68E-02 
ENSG00000182492 BGN 2.8 8.09E-03 
ENSG00000139618 BRCA2 2.4 2.16E-02 
ENSG00000136492 BRIP1 2.1 4.09E-02 
ENSG00000160469 BRSK1 -2.0 4.89E-02 
110   SUPPLEMENT 
ENSG00000169679 BUB1 2.2 2.86E-02 
ENSG00000137691 C11orf70 2.3 2.84E-02 
ENSG00000183644 C11orf88 2.6 1.83E-02 
ENSG00000188596 C12orf55 2.2 3.01E-02 
ENSG00000177875 C12orf68 -2.1 3.91E-02 
ENSG00000156206 C15orf26 2.9 8.77E-03 
ENSG00000221916 C19orf73 -2.4 3.34E-02 
ENSG00000203963 C1orf141 2.3 4.62E-02 
ENSG00000157330 C1orf158 2.6 1.39E-02 
ENSG00000163263 C1orf189 2.3 4.59E-02 
ENSG00000188931 C1orf192 2.1 3.62E-02 
ENSG00000142609 C1orf222 2.6 1.68E-02 
ENSG00000228594 C1orf233 -2.2 3.05E-02 
ENSG00000162598 C1orf87 2.5 3.33E-02 
ENSG00000144119 C1QL2 -2.6 1.42E-02 
ENSG00000172247 C1QTNF4 -2.3 2.28E-02 
ENSG00000159403 C1R 2.7 1.12E-02 
ENSG00000139178 C1RL 2.1 4.03E-02 
ENSG00000205885 C1RL-AS1 2.8 1.13E-02 
ENSG00000182326 C1S 2.1 3.92E-02 
ENSG00000171695 C20orf201 -2.9 9.81E-03 
ENSG00000198547 C20orf203 -2.8 1.16E-02 
ENSG00000182912 C21orf90 -2.9 1.05E-02 
ENSG00000154642 C21orf91 2.5 1.56E-02 
ENSG00000205856 C22orf42 -2.3 2.95E-02 
ENSG00000183186 C2CD4C -2.0 4.26E-02 
ENSG00000125730 C3 3.2 4.34E-03 
ENSG00000224389 C4B 2.4 2.27E-02 
ENSG00000181577 C6orf223 2.4 3.10E-02 
ENSG00000164746 C7orf57 2.6 1.44E-02 
ENSG00000160401 C9orf117 2.4 2.39E-02 
ENSG00000204352 C9orf129 -2.7 1.45E-02 
ENSG00000204711 C9orf135 2.3 4.40E-02 
ENSG00000188523 C9orf171 2.2 3.44E-02 
ENSG00000063180 CA11 -2.3 2.38E-02 
ENSG00000157782 CABP1 -2.7 1.36E-02 
ENSG00000141837 CACNA1A -2.0 4.88E-02 
ENSG00000006283 CACNA1G -2.1 3.41E-02 
ENSG00000100346 CACNA1I -2.9 7.21E-03 
ENSG00000007402 CACNA2D2 -2.0 4.15E-02 
ENSG00000157445 CACNA2D3 -2.3 2.55E-02 
ENSG00000151062 CACNA2D4 3.0 6.70E-03 
ENSG00000166862 CACNG2 -2.2 3.24E-02 
ENSG00000104327 CALB1 -2.4 2.08E-02 
ENSG00000172137 CALB2 -2.3 2.23E-02 
SUPPLEMENT  111 
ENSG00000122786 CALD1 2.0 4.66E-02 
ENSG00000130643 CALY -3.0 5.75E-03 
ENSG00000070808 CAMK2A -2.4 1.90E-02 
ENSG00000058404 CAMK2B -2.7 1.02E-02 
ENSG00000163888 CAMK2N2 -2.4 1.88E-02 
ENSG00000076826 CAMSAP3 -2.2 2.93E-02 
ENSG00000180881 CAPS2 2.5 1.96E-02 
ENSG00000152611 CAPSL 2.5 2.27E-02 
ENSG00000204397 CARD16 2.6 2.27E-02 
ENSG00000137812 CASC5 2.6 1.24E-02 
ENSG00000167971 CASKIN1 -2.6 1.27E-02 
ENSG00000137752 CASP1 2.2 3.20E-02 
ENSG00000196954 CASP4 2.4 3.02E-02 
ENSG00000121691 CAT 3.9 6.46E-04 
ENSG00000105974 CAV1 2.5 1.72E-02 
ENSG00000102924 CBLN1 -2.9 6.48E-03 
ENSG00000141668 CBLN2 3.5 2.88E-03 
ENSG00000054803 CBLN4 3.0 9.67E-03 
ENSG00000105479 CCDC114 2.3 3.32E-02 
ENSG00000159625 CCDC135 2.3 2.62E-02 
ENSG00000120262 CCDC170 2.2 3.08E-02 
ENSG00000213085 CCDC19 2.4 2.32E-02 
ENSG00000173421 CCDC36 2.7 2.38E-02 
ENSG00000186710 CCDC42B 2.3 3.47E-02 
ENSG00000135127 CCDC64 -2.3 2.45E-02 
ENSG00000055813 CCDC85A -2.0 4.92E-02 
ENSG00000110148 CCKBR -2.5 2.13E-02 
ENSG00000131142 CCL25 -2.4 3.57E-02 
ENSG00000151882 CCL28 3.1 8.15E-03 
ENSG00000145386 CCNA2 2.1 3.89E-02 
ENSG00000156535 CD109 3.0 5.91E-03 
ENSG00000120217 CD274 2.2 4.38E-02 
ENSG00000174059 CD34 2.2 3.81E-02 
ENSG00000019582 CD74 3.9 5.72E-04 
ENSG00000153563 CD8A -2.1 3.84E-02 
ENSG00000010278 CD9 2.4 1.97E-02 
ENSG00000117399 CDC20 2.1 4.09E-02 
ENSG00000164287 CDC20B 3.5 3.09E-03 
ENSG00000231007 CDC20P1 2.2 3.73E-02 
ENSG00000184661 CDCA2 2.3 2.77E-02 
ENSG00000163814 CDCP1 2.7 1.55E-02 
ENSG00000149654 CDH22 -2.3 2.45E-02 
ENSG00000187492 CDHR4 2.5 3.50E-02 
ENSG00000170312 CDK1 2.0 4.44E-02 
ENSG00000171450 CDK5R2 -2.2 2.90E-02 
112   SUPPLEMENT 
ENSG00000124762 CDKN1A -2.0 4.48E-02 
ENSG00000147889 CDKN2A 2.1 4.27E-02 
ENSG00000129355 CDKN2D -2.5 1.76E-02 
ENSG00000186567 CEACAM19 -2.2 3.29E-02 
ENSG00000007129 CEACAM21 -3.1 5.56E-03 
ENSG00000093072 CECR1 2.0 4.55E-02 
ENSG00000101489 CELF4 -2.6 1.27E-02 
ENSG00000161082 CELF5 -2.1 3.51E-02 
ENSG00000184524 CEND1 -2.4 1.89E-02 
ENSG00000117724 CENPF 2.6 1.22E-02 
ENSG00000151725 CENPU 2.0 4.80E-02 
ENSG00000138180 CEP55 2.8 8.61E-03 
ENSG00000188452 CERKL 2.1 4.66E-02 
ENSG00000205403 CFI 2.1 3.95E-02 
ENSG00000003402 CFLAR 3.7 9.59E-04 
ENSG00000138028 CGREF1 -2.0 4.72E-02 
ENSG00000186940 CHCHD2P9 -3.1 5.84E-03 
ENSG00000116254 CHD5 -2.3 2.49E-02 
ENSG00000100604 CHGA -2.6 1.41E-02 
ENSG00000089199 CHGB -2.5 1.54E-02 
ENSG00000133048 CHI3L1 3.8 8.12E-04 
ENSG00000064886 CHI3L2 3.1 4.89E-03 
ENSG00000154645 CHODL 3.7 1.40E-03 
ENSG00000101204 CHRNA4 -3.2 3.32E-03 
ENSG00000175264 CHST1 -2.2 2.81E-02 
ENSG00000179583 CIITA 3.9 6.84E-04 
ENSG00000125931 CITED1 -2.0 4.52E-02 
ENSG00000169607 CKAP2L 2.0 4.71E-02 
ENSG00000223572 CKMT1A -2.3 2.73E-02 
ENSG00000237289 CKMT1B -2.6 1.47E-02 
ENSG00000013297 CLDN11 2.3 3.16E-02 
ENSG00000164007 CLDN19 2.5 2.52E-02 
ENSG00000160318 CLDND2 -2.2 4.37E-02 
ENSG00000105472 CLEC11A -2.2 3.46E-02 
ENSG00000261210 CLEC19A 2.8 1.50E-02 
ENSG00000236279 CLEC2L -3.5 1.95E-03 
ENSG00000239265 CLRN1-AS1 -3.1 7.94E-03 
ENSG00000070729 CNGB1 -2.6 1.41E-02 
ENSG00000146910 CNPY1 3.2 3.91E-03 
ENSG00000060718 COL11A1 2.0 4.89E-02 
ENSG00000111799 COL12A1 3.0 4.89E-03 
ENSG00000187955 COL14A1 2.4 1.83E-02 
ENSG00000108821 COL1A1 2.4 2.12E-02 
ENSG00000169436 COL22A1 2.2 3.41E-02 
ENSG00000144810 COL8A1 2.3 2.57E-02 
SUPPLEMENT  113 
ENSG00000049089 COL9A2 2.0 4.36E-02 
ENSG00000092758 COL9A3 2.9 6.86E-03 
ENSG00000158270 COLEC12 2.5 1.61E-02 
ENSG00000105664 COMP 3.5 2.23E-03 
ENSG00000106789 CORO2A -2.2 3.52E-02 
ENSG00000258981 COX5AP2 -3.0 9.84E-03 
ENSG00000047457 CP 3.2 3.31E-03 
ENSG00000128510 CPA4 2.8 9.55E-03 
ENSG00000168993 CPLX1 -3.2 3.71E-03 
ENSG00000124772 CPNE5 -2.7 1.07E-02 
ENSG00000178773 CPNE7 -3.0 5.61E-03 
ENSG00000166426 CRABP1 -3.1 4.33E-03 
ENSG00000143320 CRABP2 2.1 3.45E-02 
ENSG00000175874 CREG2 -2.5 1.69E-02 
ENSG00000147571 CRH -2.2 4.81E-02 
ENSG00000120088 CRHR1 -2.3 3.11E-02 
ENSG00000146215 CRIP3 -2.3 4.82E-02 
ENSG00000095713 CRTAC1 -2.9 6.76E-03 
ENSG00000109846 CRYAB 2.8 8.43E-03 
ENSG00000233280 CRYBG3 2.9 7.57E-03 
ENSG00000080200 CRYBG3 2.1 3.55E-02 
ENSG00000183117 CSMD1 2.9 8.95E-03 
ENSG00000173546 CSPG4 2.5 2.03E-02 
ENSG00000114646 CSPG5 -1.9 4.92E-02 
ENSG00000273287 CTA-268H5.14 -2.7 1.41E-02 
ENSG00000260708 CTA-29F11.1 -2.1 4.26E-02 
ENSG00000259871 CTA-363E6.1 2.9 1.36E-02 
ENSG00000268262 CTC-246B18.8 -2.4 3.82E-02 
ENSG00000269814 CTC-273B12.10 -2.3 4.63E-02 
ENSG00000259436 CTC-378H22.2 -2.6 1.81E-02 
ENSG00000247311 CTC-441N14.2 2.2 4.97E-02 
ENSG00000267481 CTC-559E9.5 2.6 2.44E-02 
ENSG00000232615 CTD-2012J19.1 2.3 4.17E-02 
ENSG00000267121 CTD-2020K17.1 -2.6 2.27E-02 
ENSG00000233175 CTD-2020K17.3 -2.4 2.22E-02 
ENSG00000261439 CTD-2050B12.2 -2.6 2.78E-02 
ENSG00000253525 CTD-2114J12.1 3.1 6.65E-03 
ENSG00000267890 CTD-2126E3.4 -2.9 1.04E-02 
ENSG00000267254 CTD-2162K18.5 3.2 5.81E-03 
ENSG00000271743 CTD-2541M15.3 -2.1 4.95E-02 
ENSG00000267640 CTD-2554C21.2 3.2 6.43E-03 
ENSG00000229481 CTD-2554C21.3 3.6 2.09E-03 
ENSG00000268119 CTD-2561J22.5 2.2 4.37E-02 
ENSG00000268041 CTD-2575K13.6 -2.6 1.55E-02 
ENSG00000267522 CTD-2621I17.6 -2.7 2.05E-02 
114   SUPPLEMENT 
ENSG00000234773 CTD-2666L21.1 2.4 2.71E-02 
ENSG00000255372 CTD-3064C13.1 -2.3 3.86E-02 
ENSG00000180458 CTD-3064H18.4 2.6 2.63E-02 
ENSG00000188897 CTD-3088G3.8 2.2 4.10E-02 
ENSG00000103811 CTSH 3.0 5.51E-03 
ENSG00000158290 CUL4B -2.5 1.61E-02 
ENSG00000107562 CXCL12 3.1 4.13E-03 
ENSG00000081041 CXCL2 2.4 3.11E-02 
ENSG00000165164 CXorf22 2.5 3.02E-02 
ENSG00000188011 CXXC11 -2.0 4.94E-02 
ENSG00000071967 CYBRD1 2.4 2.17E-02 
ENSG00000161544 CYGB -2.9 7.30E-03 
ENSG00000138061 CYP1B1 2.1 3.52E-02 
ENSG00000187553 CYP26C1 -3.8 9.29E-04 
ENSG00000036530 CYP46A1 -2.2 3.25E-02 
ENSG00000187048 CYP4A11 -2.5 3.01E-02 
ENSG00000186377 CYP4X1 -2.1 4.22E-02 
ENSG00000173198 CYSLTR1 2.5 3.47E-02 
ENSG00000166265 CYYR1 2.8 9.63E-03 
ENSG00000153071 DAB2 2.1 4.15E-02 
ENSG00000126733 DACH2 -2.1 3.49E-02 
ENSG00000164488 DACT2 2.6 1.20E-02 
ENSG00000123977 DAW1 2.6 1.26E-02 
ENSG00000163673 DCLK3 -2.4 2.33E-02 
ENSG00000237737 DCTN1-AS1 -2.2 4.20E-02 
ENSG00000145358 DDIT4L 2.5 1.91E-02 
ENSG00000203797 DDO 2.7 2.09E-02 
ENSG00000137628 DDX60 2.1 4.18E-02 
ENSG00000024526 DEPDC1 2.7 1.09E-02 
ENSG00000175084 DES 2.7 1.10E-02 
ENSG00000273164 DGCR10 -2.7 2.08E-02 
ENSG00000204466 DGKK -2.0 4.72E-02 
ENSG00000139734 DIAPH3 2.1 4.03E-02 
ENSG00000116544 DLGAP3 -2.0 4.74E-02 
ENSG00000126787 DLGAP5 2.4 2.22E-02 
ENSG00000144355 DLX1 2.0 4.50E-02 
ENSG00000115844 DLX2 3.0 5.37E-03 
ENSG00000105880 DLX5 3.3 3.11E-03 
ENSG00000006377 DLX6 3.5 2.31E-03 
ENSG00000231764 DLX6-AS1 3.8 7.16E-04 
ENSG00000161249 DMKN -2.1 4.56E-02 
ENSG00000176399 DMRTA1 2.5 2.02E-02 
ENSG00000158856 DMTN -2.4 2.02E-02 
ENSG00000105877 DNAH11 2.8 1.11E-02 
ENSG00000174844 DNAH12 2.6 1.69E-02 
SUPPLEMENT  115 
ENSG00000149927 DOC2A -2.3 2.38E-02 
ENSG00000272636 DOC2B -2.6 1.47E-02 
ENSG00000141096 DPEP3 2.7 2.19E-02 
ENSG00000143196 DPT -2.3 4.26E-02 
ENSG00000188641 DPYD 2.7 1.05E-02 
ENSG00000149295 DRD2 -2.3 2.80E-02 
ENSG00000046604 DSG2 2.9 6.61E-03 
ENSG00000163840 DTX3L 2.4 2.03E-02 
ENSG00000158050 DUSP2 -2.6 1.66E-02 
ENSG00000158560 DYNC1I1 -2.2 2.73E-02 
ENSG00000165891 E2F7 2.0 4.50E-02 
ENSG00000129173 E2F8 2.1 4.01E-02 
ENSG00000106823 ECM2 2.3 2.69E-02 
ENSG00000114346 ECT2 2.2 3.21E-02 
ENSG00000101210 EEF1A2 -2.3 2.18E-02 
ENSG00000186676 EEF1GP1 2.5 2.27E-02 
ENSG00000034239 EFCAB1 2.6 1.20E-02 
ENSG00000185055 EFCAB10 2.6 1.65E-02 
ENSG00000115380 EFEMP1 2.7 9.38E-03 
ENSG00000143590 EFNA3 -2.0 4.28E-02 
ENSG00000198759 EGFL6 -2.4 2.15E-02 
ENSG00000255150 EID3 2.5 3.06E-02 
ENSG00000166897 ELFN2 -2.6 1.30E-02 
ENSG00000158711 ELK4 2.0 4.65E-02 
ENSG00000227295 ELL2P1 2.3 4.55E-02 
ENSG00000049540 ELN 2.4 1.83E-02 
ENSG00000230314 ELOVL2-AS1 -2.4 2.93E-02 
ENSG00000134531 EMP1 2.0 4.41E-02 
ENSG00000170370 EMX2 2.8 1.11E-02 
ENSG00000229847 EMX2OS 2.8 1.55E-02 
ENSG00000164778 EN2 3.0 4.82E-03 
ENSG00000119888 EPCAM -2.4 2.13E-02 
ENSG00000183317 EPHA10 -2.5 1.55E-02 
ENSG00000070886 EPHA8 -3.3 2.56E-03 
ENSG00000177106 EPS8L2 -2.4 2.08E-02 
ENSG00000164308 ERAP2 3.9 6.53E-04 
ENSG00000171320 ESCO2 2.2 3.29E-02 
ENSG00000143845 ETNK2 -2.0 4.64E-02 
ENSG00000134954 ETS1 2.8 8.13E-03 
ENSG00000115363 EVA1A 2.4 2.83E-02 
ENSG00000106038 EVX1 -3.1 8.16E-03 
ENSG00000174279 EVX2 -3.2 6.48E-03 
ENSG00000110723 EXPH5 2.2 3.97E-02 
ENSG00000057593 F7 -3.0 1.13E-02 
ENSG00000165591 FAAH2 -2.2 4.26E-02 
116   SUPPLEMENT 
ENSG00000121769 FABP3 -2.0 4.75E-02 
ENSG00000172782 FADS6 -2.4 4.02E-02 
ENSG00000135472 FAIM2 -2.1 3.99E-02 
ENSG00000189057 FAM111B 2.3 2.54E-02 
ENSG00000135842 FAM129A 2.7 9.80E-03 
ENSG00000185519 FAM131C -2.8 9.87E-03 
ENSG00000147724 FAM135B 3.7 1.27E-03 
ENSG00000182646 FAM156A -2.9 1.27E-02 
ENSG00000182183 FAM159A -2.5 2.79E-02 
ENSG00000196990 FAM163B -2.6 1.66E-02 
ENSG00000215187 FAM166B 2.8 1.59E-02 
ENSG00000186973 FAM183A 2.2 3.44E-02 
ENSG00000104059 FAM189A1 -2.1 3.74E-02 
ENSG00000219438 FAM19A5 -3.9 6.39E-04 
ENSG00000179813 FAM216B 3.4 2.33E-03 
ENSG00000250486 FAM218A -2.2 3.45E-02 
ENSG00000183508 FAM46C 2.3 3.36E-02 
ENSG00000149926 FAM57B -2.0 4.11E-02 
ENSG00000142530 FAM71E1 -2.5 1.90E-02 
ENSG00000153347 FAM81B 2.3 2.76E-02 
ENSG00000153789 FAM92B 2.2 4.29E-02 
ENSG00000078098 FAP 2.6 1.79E-02 
ENSG00000180178 FAR2P1 -3.1 4.97E-03 
ENSG00000188573 FBLL1 -2.4 1.83E-02 
ENSG00000166147 FBN1 2.0 4.15E-02 
ENSG00000138829 FBN2 2.1 3.41E-02 
ENSG00000127585 FBXL16 -2.1 3.67E-02 
ENSG00000156804 FBXO32 2.1 3.85E-02 
ENSG00000163013 FBXO41 -2.0 4.85E-02 
ENSG00000101311 FERMT1 2.3 3.28E-02 
ENSG00000128610 FEZF1 3.1 7.55E-03 
ENSG00000230316 FEZF1-AS1 3.0 8.37E-03 
ENSG00000154783 FGD5 -2.3 2.91E-02 
ENSG00000129682 FGF13 -2.2 2.97E-02 
ENSG00000158815 FGF17 -2.4 2.24E-02 
ENSG00000162344 FGF19 2.8 1.61E-02 
ENSG00000138675 FGF5 3.1 5.96E-03 
ENSG00000143631 FLG 2.8 1.84E-02 
ENSG00000102755 FLT1 2.7 1.91E-02 
ENSG00000122025 FLT3 -2.7 1.70E-02 
ENSG00000248905 FMN1 2.6 1.78E-02 
ENSG00000184922 FMNL1 -2.2 3.35E-02 
ENSG00000115414 FN1 3.3 2.26E-03 
ENSG00000164694 FNDC1 2.8 9.17E-03 
ENSG00000172568 FNDC9 -2.9 8.65E-03 
SUPPLEMENT  117 
ENSG00000134612 FOLH1B 3.1 8.48E-03 
ENSG00000110195 FOLR1 2.8 1.15E-02 
ENSG00000204612 FOXB2 -3.2 5.80E-03 
ENSG00000129654 FOXJ1 2.0 4.74E-02 
ENSG00000254685 FPGT 2.0 4.44E-02 
ENSG00000139926 FRMD6 2.3 2.60E-02 
ENSG00000156869 FRRS1 2.7 1.42E-02 
ENSG00000237637 FRY-AS1 -2.3 4.73E-02 
ENSG00000174951 FUT1 -2.6 2.07E-02 
ENSG00000180549 FUT7 -2.7 1.87E-02 
ENSG00000089327 FXYD5 2.7 1.09E-02 
ENSG00000221946 FXYD7 -2.2 3.04E-02 
ENSG00000163251 FZD5 2.2 3.24E-02 
ENSG00000109458 GAB1 2.0 4.56E-02 
ENSG00000136928 GABBR2 -2.0 4.80E-02 
ENSG00000011677 GABRA3 -2.2 2.92E-02 
ENSG00000186297 GABRA5 -2.5 1.71E-02 
ENSG00000146276 GABRR1 -2.6 2.37E-02 
ENSG00000182870 GALNT9 -2.3 3.00E-02 
ENSG00000174473 GALNTL6 -2.6 1.23E-02 
ENSG00000223460 GAPDHP69 2.3 4.19E-02 
ENSG00000139354 GAS2L3 2.5 1.52E-02 
ENSG00000117228 GBP1 3.3 3.00E-03 
ENSG00000162645 GBP2 3.1 5.18E-03 
ENSG00000117226 GBP3 3.7 9.74E-04 
ENSG00000187210 GCNT1 2.2 3.75E-02 
ENSG00000140297 GCNT3 -2.3 4.70E-02 
ENSG00000119125 GDA 2.1 3.85E-02 
ENSG00000131095 GFAP 3.1 3.91E-03 
ENSG00000099998 GGT5 2.6 1.72E-02 
ENSG00000121743 GJA3 2.4 3.97E-02 
ENSG00000165474 GJB2 2.3 3.46E-02 
ENSG00000101958 GLRA2 -2.4 1.79E-02 
ENSG00000135423 GLS2 -2.4 2.05E-02 
ENSG00000130755 GMFG -2.5 2.86E-02 
ENSG00000205835 GMNC 3.5 1.80E-03 
ENSG00000155265 GOLGA7B -2.4 2.15E-02 
ENSG00000269783 GOLGA7B -2.5 2.31E-02 
ENSG00000174567 GOLT1A -2.6 2.44E-02 
ENSG00000136235 GPNMB 2.6 1.42E-02 
ENSG00000256925 GPR123-AS1 -2.2 4.89E-02 
ENSG00000144230 GPR17 2.7 1.63E-02 
ENSG00000156097 GPR61 -2.3 2.64E-02 
ENSG00000173698 GPR64 -2.1 4.29E-02 
ENSG00000164199 GPR98 2.3 2.36E-02 
118   SUPPLEMENT 
ENSG00000155324 GRAMD3 2.2 3.29E-02 
ENSG00000166923 GREM1 2.1 3.59E-02 
ENSG00000176884 GRIN1 -2.2 3.39E-02 
ENSG00000198785 GRIN3A 3.7 1.22E-03 
ENSG00000144596 GRIP2 -2.4 1.89E-02 
ENSG00000124493 GRM4 -2.5 1.81E-02 
ENSG00000196277 GRM7 3.5 2.26E-03 
ENSG00000104518 GSDMD 2.7 1.33E-02 
ENSG00000169181 GSG1L -2.6 1.40E-02 
ENSG00000177602 GSG2 2.1 4.13E-02 
ENSG00000184674 GSTT1 -3.6 1.52E-03 
ENSG00000180613 GSX2 3.0 1.00E-02 
ENSG00000145736 GTF2H2 2.1 4.84E-02 
ENSG00000253203 GUSBP3 2.8 1.62E-02 
ENSG00000132702 HAPLN2 -2.4 2.41E-02 
ENSG00000105509 HAS1 -2.4 2.93E-02 
ENSG00000099822 HCN2 -2.9 6.22E-03 
ENSG00000206337 HCP5 3.4 2.26E-03 
ENSG00000121764 HCRTR1 -2.5 2.18E-02 
ENSG00000173706 HEG1 1.9 4.92E-02 
ENSG00000127311 HELB 2.1 4.74E-02 
ENSG00000019991 HGF 3.0 7.24E-03 
ENSG00000223345 HIST2H2BA 2.5 3.47E-02 
ENSG00000159399 HK2 2.4 2.08E-02 
ENSG00000234745 HLA-B 2.7 9.24E-03 
ENSG00000204525 HLA-C 2.3 2.26E-02 
ENSG00000204257 HLA-DMA 3.5 1.45E-03 
ENSG00000242574 HLA-DMB 3.4 2.40E-03 
ENSG00000204252 HLA-DOA 3.9 6.03E-04 
ENSG00000231389 HLA-DPA1 3.9 5.89E-04 
ENSG00000223865 HLA-DPB1 3.5 1.70E-03 
ENSG00000196735 HLA-DQA1 3.9 8.37E-04 
ENSG00000237541 HLA-DQA2 3.8 9.29E-04 
ENSG00000179344 HLA-DQB1 3.2 3.73E-03 
ENSG00000232629 HLA-DQB2 3.7 1.37E-03 
ENSG00000204287 HLA-DRA 3.9 6.21E-04 
ENSG00000196126 HLA-DRB1 3.9 5.66E-04 
ENSG00000198502 HLA-DRB5 3.9 6.63E-04 
ENSG00000229391 HLA-DRB6 3.9 7.02E-04 
ENSG00000204592 HLA-E 2.2 3.11E-02 
ENSG00000204642 HLA-F 3.8 8.61E-04 
ENSG00000143341 HMCN1 3.2 3.52E-03 
ENSG00000149948 HMGA2 2.7 1.11E-02 
ENSG00000072571 HMMR 2.5 1.81E-02 
ENSG00000233429 HOTAIRM1 -3.3 3.44E-03 
SUPPLEMENT  119 
ENSG00000253293 HOXA10 -3.5 2.09E-03 
ENSG00000253187 HOXA10-AS -2.6 2.42E-02 
ENSG00000105996 HOXA2 -3.7 1.52E-03 
ENSG00000106004 HOXA5 -3.6 1.78E-03 
ENSG00000106006 HOXA6 -2.7 2.22E-02 
ENSG00000122592 HOXA7 -3.8 1.08E-03 
ENSG00000078399 HOXA9 -3.7 1.36E-03 
ENSG00000253552 HOXA-AS2 -2.5 3.12E-02 
ENSG00000173917 HOXB2 -3.0 6.07E-03 
ENSG00000120093 HOXB3 -3.5 1.85E-03 
ENSG00000182742 HOXB4 -3.1 7.22E-03 
ENSG00000120075 HOXB5 -3.8 9.79E-04 
ENSG00000108511 HOXB6 -3.6 1.89E-03 
ENSG00000260027 HOXB7 -3.7 1.56E-03 
ENSG00000120068 HOXB8 -3.5 2.66E-03 
ENSG00000170689 HOXB9 -3.8 9.99E-04 
ENSG00000230148 HOXB-AS1 -2.4 3.52E-02 
ENSG00000198353 HOXC4 -2.7 2.02E-02 
ENSG00000037965 HOXC8 -3.1 7.64E-03 
ENSG00000128710 HOXD10 -3.1 7.52E-03 
ENSG00000128652 HOXD3 -3.2 4.95E-03 
ENSG00000128709 HOXD9 -3.0 9.59E-03 
ENSG00000121905 HPCA -2.6 1.32E-02 
ENSG00000115756 HPCAL1 -2.2 3.17E-02 
ENSG00000116983 HPCAL4 -2.1 3.36E-02 
ENSG00000101180 HRH3 -2.1 4.39E-02 
ENSG00000122254 HS3ST2 -2.3 2.75E-02 
ENSG00000171004 HS6ST2 -2.0 4.83E-02 
ENSG00000141854 hsa-mir-1199 -2.6 1.42E-02 
ENSG00000237973 hsa-mir-6723 -3.0 5.46E-03 
ENSG00000102878 HSF4 -2.3 2.62E-02 
ENSG00000004776 HSPB6 2.2 4.14E-02 
ENSG00000142798 HSPG2 2.3 2.40E-02 
ENSG00000157219 HTR5A -2.8 1.02E-02 
ENSG00000090339 ICAM1 3.4 1.97E-03 
ENSG00000163565 IFI16 2.3 2.68E-02 
ENSG00000159217 IGF2BP1 2.0 4.66E-02 
ENSG00000163453 IGFBP7 2.6 1.35E-02 
ENSG00000204869 IGFL4 -3.1 7.25E-03 
ENSG00000142549 IGLON5 -2.1 3.59E-02 
ENSG00000147255 IGSF1 -2.3 2.42E-02 
ENSG00000110324 IL10RA -2.5 2.22E-02 
ENSG00000115594 IL1R1 2.5 1.87E-02 
ENSG00000091181 IL5RA 2.6 1.74E-02 
ENSG00000168685 IL7R 2.3 4.23E-02 
120   SUPPLEMENT 
ENSG00000139269 INHBE 2.3 2.74E-02 
ENSG00000168918 INPP5D -2.9 9.26E-03 
ENSG00000124313 IQSEC2 -2.1 4.06E-02 
ENSG00000120645 IQSEC3 -2.7 9.37E-03 
ENSG00000164675 IQUB 2.3 2.70E-02 
ENSG00000128604 IRF5 -2.2 4.15E-02 
ENSG00000113430 IRX4 -2.4 2.36E-02 
ENSG00000159387 IRX6 -2.6 1.61E-02 
ENSG00000100593 ISM2 -2.7 1.76E-02 
ENSG00000213949 ITGA1 2.7 1.19E-02 
ENSG00000137809 ITGA11 2.4 1.97E-02 
ENSG00000164171 ITGA2 3.1 5.10E-03 
ENSG00000132470 ITGB4 2.3 2.62E-02 
ENSG00000198542 ITGBL1 2.5 2.00E-02 
ENSG00000123243 ITIH5 2.9 7.48E-03 
ENSG00000184916 JAG2 -2.1 3.94E-02 
ENSG00000152969 JAKMIP1 -2.1 3.61E-02 
ENSG00000154118 JPH3 -2.5 1.68E-02 
ENSG00000092051 JPH4 -2.0 4.43E-02 
ENSG00000186994 KANK3 -2.3 3.21E-02 
ENSG00000169282 KCNAB1 -2.1 3.86E-02 
ENSG00000166006 KCNC2 -2.6 1.38E-02 
ENSG00000131398 KCNC3 -3.0 5.56E-03 
ENSG00000116396 KCNC4 -2.5 1.48E-02 
ENSG00000162975 KCNF1 -2.4 2.14E-02 
ENSG00000135519 KCNH3 -2.5 1.67E-02 
ENSG00000089558 KCNH4 -2.3 3.74E-02 
ENSG00000162728 KCNJ9 -2.1 4.13E-02 
ENSG00000171303 KCNK3 -2.1 3.87E-02 
ENSG00000169427 KCNK9 -2.1 3.46E-02 
ENSG00000197584 KCNMB2 -2.2 3.46E-02 
ENSG00000107147 KCNT1 -2.9 7.56E-03 
ENSG00000104756 KCTD9 2.0 4.84E-02 
ENSG00000100196 KDELR3 2.0 4.79E-02 
ENSG00000235750 KIAA0040 3.2 3.94E-03 
ENSG00000255103 KIAA0754 2.1 3.86E-02 
ENSG00000122733 KIAA1045 -2.8 8.82E-03 
ENSG00000103888 KIAA1199 2.4 2.12E-02 
ENSG00000138160 KIF11 2.2 2.83E-02 
ENSG00000118193 KIF14 2.6 1.28E-02 
ENSG00000163808 KIF15 2.0 4.24E-02 
ENSG00000121621 KIF18A 2.3 2.69E-02 
ENSG00000112984 KIF20A 2.2 3.25E-02 
ENSG00000138182 KIF20B 2.1 4.17E-02 
ENSG00000150361 KLHL1 -2.0 4.66E-02 
SUPPLEMENT  121 
ENSG00000272079 LA16c-380H5.5 -3.1 7.03E-03 
ENSG00000125869 LAMP5 -2.3 2.63E-02 
ENSG00000138136 LBX1 -3.9 7.45E-04 
ENSG00000227128 LBX1-AS1 -3.8 9.22E-04 
ENSG00000166796 LDHC 2.4 4.07E-02 
ENSG00000138795 LEF1 2.0 4.90E-02 
ENSG00000143768 LEFTY2 2.3 2.74E-02 
ENSG00000168481 LGI3 -3.2 3.92E-03 
ENSG00000156959 LHFPL4 -2.3 2.36E-02 
ENSG00000106852 LHX6 3.4 3.22E-03 
ENSG00000162624 LHX8 3.0 9.42E-03 
ENSG00000104863 LIN7B -2.6 1.45E-02 
ENSG00000178947 LINC00086 -2.0 4.11E-02 
ENSG00000196421 LINC00176 -2.1 4.28E-02 
ENSG00000180422 LINC00304 -2.5 2.47E-02 
ENSG00000153363 LINC00467 2.0 4.99E-02 
ENSG00000132204 LINC00470 3.5 2.33E-03 
ENSG00000223414 LINC00473 -2.5 2.53E-02 
ENSG00000259714 LINC00594 -2.2 3.91E-02 
ENSG00000250337 LINC01021 -2.8 1.26E-02 
ENSG00000232903 LINC01166 -2.7 1.73E-02 
ENSG00000169783 LINGO1 -2.3 2.36E-02 
ENSG00000101670 LIPG 2.0 4.71E-02 
ENSG00000225110 LL0XNC01-16G2.1 -2.7 1.31E-02 
ENSG00000142235 LMTK3 -1.9 4.99E-02 
ENSG00000072201 LNX1 -2.1 3.61E-02 
ENSG00000134013 LOXL2 2.2 2.92E-02 
ENSG00000138131 LOXL4 2.2 3.39E-02 
ENSG00000198670 LPA -2.7 2.07E-02 
ENSG00000145012 LPP 2.0 4.32E-02 
ENSG00000128011 LRFN1 -2.0 4.28E-02 
ENSG00000156564 LRFN2 -2.7 1.07E-02 
ENSG00000155530 LRGUK 2.2 3.58E-02 
ENSG00000186648 LRRC16B -2.2 2.96E-02 
ENSG00000163827 LRRC2 2.7 1.27E-02 
ENSG00000171757 LRRC34 2.5 1.87E-02 
ENSG00000176809 LRRC37A3 -2.0 4.90E-02 
ENSG00000162494 LRRC38 -3.0 1.08E-02 
ENSG00000229356 LRRC3-AS1 -2.8 1.69E-02 
ENSG00000171962 LRRC48 2.2 3.58E-02 
ENSG00000127399 LRRC61 -2.9 7.48E-03 
ENSG00000160838 LRRC71 2.8 1.80E-02 
ENSG00000171017 LRRC8E 2.8 1.61E-02 
ENSG00000131951 LRRC9 2.1 4.30E-02 
ENSG00000133640 LRRIQ1 2.0 4.31E-02 
122   SUPPLEMENT 
ENSG00000162620 LRRIQ3 2.8 1.40E-02 
ENSG00000166159 LRTM2 -2.3 3.35E-02 
ENSG00000111321 LTBR 2.9 9.07E-03 
ENSG00000012223 LTF 3.8 1.11E-03 
ENSG00000150556 LYPD6B -2.2 4.06E-02 
ENSG00000180660 MAB21L1 -2.8 7.74E-03 
ENSG00000181541 MAB21L2 -2.9 6.97E-03 
ENSG00000182759 MAFA -2.3 3.25E-02 
ENSG00000111837 MAK 3.1 4.53E-03 
ENSG00000176601 MAP3K19 2.8 8.28E-03 
ENSG00000184368 MAP7D2 -2.3 2.33E-02 
ENSG00000181085 MAPK15 2.2 3.14E-02 
ENSG00000186868 MAPT -2.2 2.72E-02 
ENSG00000264589 MAPT-AS1 -2.3 3.72E-02 
ENSG00000105613 MAST1 -2.1 3.36E-02 
ENSG00000007264 MATK -2.8 8.84E-03 
ENSG00000166603 MC4R -3.2 4.44E-03 
ENSG00000214548 MEG3 2.7 1.74E-02 
ENSG00000134138 MEIS2 -2.6 1.20E-02 
ENSG00000166823 MESP1 -2.1 3.95E-02 
ENSG00000111341 MGP -2.0 4.92E-02 
ENSG00000204516 MICB 2.9 1.34E-02 
ENSG00000240972 MIF -2.1 3.75E-02 
ENSG00000215417 MIR17HG 2.3 4.26E-02 
ENSG00000264063 MIR3687 2.6 2.09E-02 
ENSG00000129534 MIS18BP1 2.2 3.15E-02 
ENSG00000187098 MITF 2.3 2.83E-02 
ENSG00000148773 MKI67 2.6 1.30E-02 
ENSG00000150051 MKX 2.4 2.31E-02 
ENSG00000146147 MLIP 2.2 3.98E-02 
ENSG00000096395 MLN -2.6 2.98E-02 
ENSG00000009950 MLXIPL -3.3 4.18E-03 
ENSG00000136297 MMD2 -2.2 3.88E-02 
ENSG00000196611 MMP1 2.5 3.64E-02 
ENSG00000137745 MMP13 2.5 3.57E-02 
ENSG00000123342 MMP19 2.4 2.18E-02 
ENSG00000125966 MMP24 -2.0 4.05E-02 
ENSG00000100985 MMP9 2.5 3.07E-02 
ENSG00000138722 MMRN1 2.1 3.76E-02 
ENSG00000138587 MNS1 2.7 1.28E-02 
ENSG00000075643 MOCOS 3.0 8.26E-03 
ENSG00000161647 MPP3 -2.1 3.58E-02 
ENSG00000153029 MR1 3.3 3.23E-03 
ENSG00000254305 MRPL9P1 -2.8 1.21E-02 
ENSG00000178860 MSC 2.5 2.03E-02 
SUPPLEMENT  123 
ENSG00000087250 MT3 -3.0 6.24E-03 
ENSG00000162576 MXRA8 2.1 3.64E-02 
ENSG00000133055 MYBPH -2.3 4.40E-02 
ENSG00000214114 MYCBP 2.3 2.81E-02 
ENSG00000109063 MYH3 -2.0 4.95E-02 
ENSG00000133020 MYH8 -3.2 5.80E-03 
ENSG00000168530 MYL1 -2.9 1.36E-02 
ENSG00000198336 MYL4 -2.5 2.89E-02 
ENSG00000065534 MYLK 2.1 3.50E-02 
ENSG00000180209 MYLPF -3.4 3.27E-03 
ENSG00000122180 MYOG -3.0 1.16E-02 
ENSG00000145911 N4BP3 -2.1 3.79E-02 
ENSG00000177694 NAALADL2 2.3 3.16E-02 
ENSG00000173559 NABP1 2.2 3.49E-02 
ENSG00000187556 NANOS3 -2.7 1.16E-02 
ENSG00000125814 NAPB -2.0 4.50E-02 
ENSG00000158747 NBL1 -2.1 3.61E-02 
ENSG00000154654 2 3.8 1.09E-03 
ENSG00000103034 NDRG4 -2.0 4.56E-02 
ENSG00000103154 NECAB2 -2.7 1.02E-02 
ENSG00000139350 NEDD1 2.0 4.84E-02 
ENSG00000104725 NEFL -2.0 4.36E-02 
ENSG00000104722 NEFM -2.1 3.49E-02 
ENSG00000107954 NEURL1 -2.2 2.91E-02 
ENSG00000171532 NEUROD2 -2.2 3.33E-02 
ENSG00000123307 NEUROD4 3.1 4.46E-03 
ENSG00000181965 NEUROG1 2.7 2.09E-02 
ENSG00000178403 NEUROG2 2.0 4.62E-02 
ENSG00000101096 NFATC2 2.2 3.52E-02 
ENSG00000165553 NGB -3.6 1.43E-03 
ENSG00000066248 NGEF -2.3 2.68E-02 
ENSG00000171786 NHLH1 2.1 4.03E-02 
ENSG00000177551 NHLH2 2.4 2.26E-02 
ENSG00000185942 NKAIN3 2.0 4.65E-02 
ENSG00000148826 NKX6-2 2.5 1.79E-02 
ENSG00000022556 NLRP2 3.8 9.95E-04 
ENSG00000123609 NMI 2.0 4.65E-02 
ENSG00000053438 NNAT -3.8 7.32E-04 
ENSG00000166741 NNMT 3.0 6.22E-03 
ENSG00000089250 NOS1 -2.6 1.46E-02 
ENSG00000183793 NPIPA5 -2.4 2.70E-02 
ENSG00000158806 NPM2 -2.4 2.31E-02 
ENSG00000163273 NPPC -2.4 3.15E-02 
ENSG00000187258 NPSR1 2.3 4.19E-02 
ENSG00000171246 NPTX1 -2.4 1.95E-02 
124   SUPPLEMENT 
ENSG00000221890 NPTXR -2.1 3.63E-02 
ENSG00000122585 NPY 2.6 1.72E-02 
ENSG00000112333 NR2E1 3.4 3.70E-03 
ENSG00000154146 NRGN -2.1 3.82E-02 
ENSG00000110076 NRXN2 -2.1 3.31E-02 
ENSG00000168824 NSG1 -2.2 2.97E-02 
ENSG00000170091 NSG2 -2.1 3.44E-02 
ENSG00000143228 NUF2 2.4 1.87E-02 
ENSG00000184923 NUTM2A -2.2 4.48E-02 
ENSG00000130950 NUTM2F -2.8 1.45E-02 
ENSG00000144227 NXPH2 -2.2 3.95E-02 
ENSG00000182575 NXPH3 -2.7 1.15E-02 
ENSG00000089127 OAS1 2.3 3.04E-02 
ENSG00000111331 OAS3 3.3 2.62E-03 
ENSG00000130558 OLFM1 -2.6 1.37E-02 
ENSG00000125510 OPRL1 -2.2 3.15E-02 
ENSG00000196071 OR2L13 3.2 4.47E-03 
ENSG00000238243 OR2W3 2.2 4.74E-02 
ENSG00000183444 OR7E38P 2.4 3.10E-02 
ENSG00000145623 OSMR 2.6 1.36E-02 
ENSG00000165899 OTOGL 2.8 1.12E-02 
ENSG00000182447 OTOL1 -2.5 3.18E-02 
ENSG00000115507 OTX1 2.5 2.14E-02 
ENSG00000165588 OTX2 3.2 4.81E-03 
ENSG00000083454 P2RX5 -2.7 1.63E-02 
ENSG00000149380 P4HA3 2.2 3.71E-02 
ENSG00000124507 PACSIN1 -2.7 1.15E-02 
ENSG00000137843 PAK6 -2.7 1.17E-02 
ENSG00000100767 PAPLN 2.7 1.37E-02 
ENSG00000059378 PARP12 2.1 4.74E-02 
ENSG00000173193 PARP14 2.0 4.64E-02 
ENSG00000138964 PARVG -2.5 3.26E-02 
ENSG00000075891 PAX2 -3.3 2.78E-03 
ENSG00000135903 PAX3 2.5 1.61E-02 
ENSG00000125618 PAX8 -2.4 2.38E-02 
ENSG00000250120 PCDHA10 2.2 3.59E-02 
ENSG00000239389 PCDHA13 -2.7 1.64E-02 
ENSG00000113248 PCDHB15 2.2 2.96E-02 
ENSG00000255622 PCDHB17 2.3 3.00E-02 
ENSG00000113209 PCDHB5 3.9 5.93E-04 
ENSG00000253873 PCDHGA11 2.9 1.02E-02 
ENSG00000254245 PCDHGA3 3.9 7.03E-04 
ENSG00000248485 PCP4L1 -2.2 2.89E-02 
ENSG00000102109 PCSK1N -2.0 4.65E-02 
ENSG00000197646 PDCD1LG2 2.2 4.27E-02 
SUPPLEMENT  125 
ENSG00000105650 PDE4C -2.9 8.01E-03 
ENSG00000134853 PDGFRA 2.0 4.83E-02 
ENSG00000104213 PDGFRL 2.6 1.56E-02 
ENSG00000185615 PDIA2 -3.0 4.78E-03 
ENSG00000101327 PDYN -2.8 1.07E-02 
ENSG00000186862 PDZD7 -2.6 1.52E-02 
ENSG00000187800 PEAR1 2.6 2.26E-02 
ENSG00000154330 PGM5 2.2 3.62E-02 
ENSG00000144824 PHLDB2 2.2 2.83E-02 
ENSG00000109132 PHOX2B -2.0 4.90E-02 
ENSG00000175287 PHYHD1 2.2 4.30E-02 
ENSG00000103335 PIEZO1 2.4 2.02E-02 
ENSG00000167103 PIP5KL1 -2.1 3.69E-02 
ENSG00000181191 PJA1 -2.0 4.79E-02 
ENSG00000254681 PKD1P5 3.3 3.21E-03 
ENSG00000188257 PLA2G2A 2.4 3.84E-02 
ENSG00000122861 PLAU 2.6 1.27E-02 
ENSG00000121316 PLBD1 2.6 1.93E-02 
ENSG00000152952 PLOD2 2.1 3.48E-02 
ENSG00000102007 PLP2 2.1 3.51E-02 
ENSG00000004399 PLXND1 2.7 9.40E-03 
ENSG00000141682 PMAIP1 2.2 3.56E-02 
ENSG00000130822 PNCK -2.6 1.31E-02 
ENSG00000198883 PNMA5 -2.7 1.23E-02 
ENSG00000257088 PNMA6D -2.7 2.29E-02 
ENSG00000128567 PODXL 2.2 2.93E-02 
ENSG00000051341 POLQ 2.5 1.86E-02 
ENSG00000205578 POM121B 2.6 2.17E-02 
ENSG00000177380 PPFIA3 -2.1 3.41E-02 
ENSG00000088808 PPP1R13B -2.2 3.15E-02 
ENSG00000101445 PPP1R16B -2.4 2.25E-02 
ENSG00000225361 PPP1R26-AS1 -2.5 1.69E-02 
ENSG00000074211 PPP2R2C -2.7 9.97E-03 
ENSG00000214140 PRCD -2.1 4.41E-02 
ENSG00000046889 PREX2 2.1 4.02E-02 
ENSG00000126583 PRKCG -2.4 2.21E-02 
ENSG00000067606 PRKCZ -2.0 4.30E-02 
ENSG00000171864 PRND 2.7 1.65E-02 
ENSG00000143125 PROK1 -3.2 5.49E-03 
ENSG00000007062 PROM1 2.1 3.85E-02 
ENSG00000135406 PRPH 2.7 1.10E-02 
ENSG00000112619 PRPH2 -3.1 6.54E-03 
ENSG00000186654 PRR5 -2.0 4.84E-02 
ENSG00000224940 PRRT4 -2.7 1.09E-02 
ENSG00000059915 PSD -2.1 3.80E-02 
126   SUPPLEMENT 
ENSG00000146005 PSD2 -2.0 4.91E-02 
ENSG00000204264 PSMB8 2.3 2.45E-02 
ENSG00000240065 PSMB9 3.0 6.83E-03 
ENSG00000165983 PTER 2.4 2.73E-02 
ENSG00000107317 PTGDS 3.1 4.53E-03 
ENSG00000160951 PTGER1 2.9 9.19E-03 
ENSG00000152104 PTPN14 2.1 3.36E-02 
ENSG00000110786 PTPN5 -2.4 2.08E-02 
ENSG00000155093 PTPRN2 -2.5 1.74E-02 
ENSG00000139304 PTPRQ 2.4 3.89E-02 
ENSG00000196090 PTPRT 3.7 1.03E-03 
ENSG00000139832 RAB20 2.4 2.43E-02 
ENSG00000134594 RAB33A -2.0 4.14E-02 
ENSG00000105649 RAB3A -2.2 2.80E-02 
ENSG00000169213 RAB3B -2.0 4.48E-02 
ENSG00000122679 RAMP3 2.5 2.13E-02 
ENSG00000111344 RASAL1 -2.4 2.98E-02 
ENSG00000100302 RASD2 -2.3 2.40E-02 
ENSG00000146090 RASGEF1C -2.8 8.44E-03 
ENSG00000058335 RASGRF1 -2.7 1.02E-02 
ENSG00000068831 RASGRP2 -2.4 2.06E-02 
ENSG00000198774 RASSF9 3.1 4.26E-03 
ENSG00000167281 RBFOX3 -2.9 6.30E-03 
ENSG00000138207 RBP4 -2.9 9.34E-03 
ENSG00000115386 REG1A -3.2 6.79E-03 
ENSG00000225465 RFPL1S -2.0 4.75E-02 
ENSG00000128253 RFPL2 -2.2 3.70E-02 
ENSG00000090104 RGS1 2.4 3.95E-02 
ENSG00000132554 RGS22 2.3 3.07E-02 
ENSG00000104140 RHOV -2.4 2.31E-02 
ENSG00000101098 RIMS4 -2.3 2.39E-02 
ENSG00000183421 RIPK4 2.5 2.63E-02 
ENSG00000152214 RIT2 -2.8 1.07E-02 
ENSG00000159753 RLTPR -2.7 1.01E-02 
ENSG00000249803 RP11-114H21.2 3.1 8.90E-03 
ENSG00000259280 RP11-122D10.1 -3.2 6.23E-03 
ENSG00000273238 RP11-1263C18.1 -2.5 2.19E-02 
ENSG00000178715 RP11-169K16.8 -2.5 2.32E-02 
ENSG00000259234 RP11-17L5.4 -2.4 4.13E-02 
ENSG00000269916 RP11-193M21.1 2.3 4.11E-02 
ENSG00000187186 RP11-195F19.5 -2.6 1.86E-02 
ENSG00000261829 RP11-223I10.1 -2.3 2.94E-02 
ENSG00000203900 RP11-261N11.8 -2.9 1.21E-02 
ENSG00000234531 RP11-288G11.3 2.7 1.44E-02 
ENSG00000215146 RP11-313J2.1 3.6 2.25E-03 
SUPPLEMENT  127 
ENSG00000226530 RP11-348F1.2 2.6 2.81E-02 
ENSG00000226425 RP11-348J12.2 -2.6 2.76E-02 
ENSG00000271369 RP11-350D17.3 -2.1 4.67E-02 
ENSG00000203688 RP11-351J23.1 2.7 1.17E-02 
ENSG00000235531 RP11-383H13.1 3.0 7.77E-03 
ENSG00000264745 RP11-403A21.2 -2.4 4.20E-02 
ENSG00000261003 RP1-140C12.2 -2.6 2.64E-02 
ENSG00000273108 RP11-416N2.4 -2.4 2.09E-02 
ENSG00000242512 RP11-416O18.1 2.5 3.08E-02 
ENSG00000260987 RP11-423G4.7 -2.2 3.37E-02 
ENSG00000215866 RP11-426L16.8 -2.6 2.80E-02 
ENSG00000254973 RP11-429J17.7 -2.4 3.77E-02 
ENSG00000259577 RP11-430B1.2 -2.7 1.58E-02 
ENSG00000132832 RP11-445H22.3 -2.3 3.99E-02 
ENSG00000244558 RP11-445H22.4 -2.5 2.68E-02 
ENSG00000266045 RP11-466P24.7 -2.1 4.12E-02 
ENSG00000242828 RP11-47P18.1 -2.4 4.45E-02 
ENSG00000260769 RP11-491F9.5 -2.5 3.64E-02 
ENSG00000206113 RP11-503N18.1 2.7 1.52E-02 
ENSG00000249428 RP11-503N18.3 2.3 4.32E-02 
ENSG00000213642 RP11-561N12.5 -2.1 4.12E-02 
ENSG00000273087 RP11-566J3.4 -2.4 2.42E-02 
ENSG00000257499 RP11-571M6.8 -2.4 2.33E-02 
ENSG00000269975 RP11-58B17.2 -2.5 1.54E-02 
ENSG00000261374 RP11-64K12.10 -2.1 4.04E-02 
ENSG00000254682 RP11-660L16.2 -2.2 3.40E-02 
ENSG00000260081 RP11-66N11.8 -2.1 4.33E-02 
ENSG00000268555 RP11-678G14.3 2.4 4.29E-02 
ENSG00000273456 RP11-686O6.2 -2.4 2.67E-02 
ENSG00000234449 RP11-706O15.3 -3.1 4.16E-03 
ENSG00000271474 RP11-710C12.1 -2.5 2.26E-02 
ENSG00000251129 RP11-734I18.1 -3.7 1.24E-03 
ENSG00000254349 RP11-758M4.1 2.3 3.96E-02 
ENSG00000253706 RP11-758M4.4 2.1 4.96E-02 
ENSG00000266970 RP11-806H10.4 2.5 2.87E-02 
ENSG00000266456 RP11-806L2.2 -2.2 4.71E-02 
ENSG00000257935 RP11-82C23.2 -2.2 3.61E-02 
ENSG00000250138 RP11-848G14.5 2.6 2.46E-02 
ENSG00000254510 RP11-867G23.10 -2.0 4.87E-02 
ENSG00000262222 RP11-876N24.4 2.8 1.73E-02 
ENSG00000259439 RP11-89K21.1 2.5 2.91E-02 
ENSG00000250546 RP11-8L2.1 2.5 3.61E-02 
ENSG00000267651 RP11-95O2.1 -2.6 1.77E-02 
ENSG00000228659 RP1-23K20.2 -2.8 1.71E-02 
ENSG00000233508 RP1-269M15.3 2.4 4.44E-02 
128   SUPPLEMENT 
ENSG00000243902 RP1-63G5.5 -2.3 3.59E-02 
ENSG00000227012 RP1-97J1.2 -2.7 2.36E-02 
ENSG00000234546 RP3-510D11.2 -2.6 2.26E-02 
ENSG00000261675 RP5-1119A7.17 -2.6 1.41E-02 
ENSG00000225988 RP5-1119D9.4 -2.3 4.63E-02 
ENSG00000231302 RPL36P2 -2.7 2.35E-02 
ENSG00000177519 RPRM -2.2 3.18E-02 
ENSG00000198208 RPS6KL1 -2.1 3.94E-02 
ENSG00000132026 RTBDN -2.8 1.07E-02 
ENSG00000139970 RTN1 -2.0 4.51E-02 
ENSG00000159216 RUNX1 2.2 3.35E-02 
ENSG00000196218 RYR1 -2.2 3.32E-02 
ENSG00000164483 SAMD3 -2.4 2.87E-02 
ENSG00000205413 SAMD9 2.9 7.25E-03 
ENSG00000177409 SAMD9L 2.7 1.18E-02 
ENSG00000164764 SBSPON 2.5 1.57E-02 
ENSG00000198794 SCAMP5 -2.0 4.05E-02 
ENSG00000159307 SCUBE1 -2.6 1.46E-02 
ENSG00000167680 SEMA6B -2.4 1.88E-02 
ENSG00000250722 SEPP1 2.4 2.10E-02 
ENSG00000188488 SERPINA5 2.7 1.23E-02 
ENSG00000106366 SERPINE1 3.5 1.63E-03 
ENSG00000180440 SERTM1 -2.3 2.86E-02 
ENSG00000063015 SEZ6 -2.0 4.87E-02 
ENSG00000174938 SEZ6L2 -2.3 2.21E-02 
ENSG00000120057 SFRP5 -2.6 1.83E-02 
ENSG00000129810 SGOL1 2.1 3.81E-02 
ENSG00000163535 SGOL2 2.0 4.46E-02 
ENSG00000125731 SH2D3A -3.2 5.10E-03 
ENSG00000104611 SH2D4A 2.5 2.43E-02 
ENSG00000189410 SH2D5 -2.0 4.57E-02 
ENSG00000156463 SH3RF2 2.4 3.15E-02 
ENSG00000161681 SHANK1 -2.6 1.32E-02 
ENSG00000072858 SIDT1 -2.4 2.62E-02 
ENSG00000126778 SIX1 3.1 4.91E-03 
ENSG00000138083 SIX3 2.4 2.97E-02 
ENSG00000100625 SIX4 2.7 1.27E-02 
ENSG00000124140 SLC12A5 -2.3 2.41E-02 
ENSG00000141526 SLC16A3 2.8 1.04E-02 
ENSG00000168679 SLC16A4 2.4 1.99E-02 
ENSG00000187714 SLC18A3 -2.4 2.08E-02 
ENSG00000106688 SLC1A1 -2.0 4.92E-02 
ENSG00000105143 SLC1A6 -2.7 9.60E-03 
ENSG00000197847 SLC22A20 -2.2 4.52E-02 
ENSG00000185052 SLC24A3 -2.3 2.40E-02 
SUPPLEMENT  129 
ENSG00000181240 SLC25A41 -2.7 1.36E-02 
ENSG00000147606 SLC26A7 2.5 2.17E-02 
ENSG00000115194 SLC30A3 -2.7 1.40E-02 
ENSG00000164756 SLC30A8 -3.6 1.57E-03 
ENSG00000151812 SLC35F4 -2.9 7.76E-03 
ENSG00000138449 SLC40A1 2.0 4.55E-02 
ENSG00000162426 SLC45A1 -2.1 3.97E-02 
ENSG00000115665 SLC5A7 -2.2 3.80E-02 
ENSG00000197106 SLC6A17 -2.8 8.76E-03 
ENSG00000165970 SLC6A5 -3.7 1.44E-03 
ENSG00000011083 SLC6A7 -3.4 2.45E-03 
ENSG00000151012 SLC7A11 2.1 4.04E-02 
ENSG00000099960 SLC7A4 -2.4 2.44E-02 
ENSG00000118160 SLC8A2 -2.4 2.13E-02 
ENSG00000100678 SLC8A3 -2.2 3.00E-02 
ENSG00000101187 SLCO4A1 -2.4 2.44E-02 
ENSG00000172716 SLFN11 3.1 4.79E-03 
ENSG00000113810 SMC4 2.2 2.96E-02 
ENSG00000204323 SMIM5 2.7 1.44E-02 
ENSG00000188176 SMTNL2 -2.9 7.87E-03 
ENSG00000145335 SNCA -2.4 1.79E-02 
ENSG00000074317 SNCB -3.1 4.07E-03 
ENSG00000173267 SNCG -2.9 7.17E-03 
ENSG00000172803 SNX32 -2.3 2.39E-02 
ENSG00000184557 SOCS3 2.4 1.85E-02 
ENSG00000108018 SORCS1 3.3 2.59E-03 
ENSG00000198944 SOWAHA -2.5 1.90E-02 
ENSG00000100146 SOX10 3.1 7.00E-03 
ENSG00000203883 SOX18 2.4 2.78E-02 
ENSG00000067066 SP100 2.5 1.93E-02 
ENSG00000077327 SPAG6 2.9 7.05E-03 
ENSG00000185594 SPATA8 -2.4 4.13E-02 
ENSG00000167642 SPINT2 -2.4 2.08E-02 
ENSG00000183018 SPNS2 -2.4 2.12E-02 
ENSG00000134668 SPOCD1 3.2 4.56E-03 
ENSG00000244094 SPRR2F -2.7 2.02E-02 
ENSG00000070182 SPTB -2.4 2.08E-02 
ENSG00000160460 SPTBN4 -2.2 3.06E-02 
ENSG00000157005 SST -3.0 5.42E-03 
ENSG00000139874 SSTR1 -2.2 2.98E-02 
ENSG00000147488 ST18 2.0 4.95E-02 
ENSG00000070731 ST6GALNAC2 3.0 7.64E-03 
ENSG00000081320 STK17B 2.1 4.36E-02 
ENSG00000250535 STK19P -2.9 1.41E-02 
ENSG00000104435 STMN2 -2.0 4.64E-02 
130   SUPPLEMENT 
ENSG00000015592 STMN4 -2.3 2.58E-02 
ENSG00000133115 STOML3 3.2 3.69E-03 
ENSG00000099365 STX1B -2.3 2.44E-02 
ENSG00000136854 STXBP1 -2.0 4.84E-02 
ENSG00000060140 STYK1 -2.6 1.58E-02 
ENSG00000159164 SV2A -2.0 4.28E-02 
ENSG00000166111 SVOP -2.2 3.23E-02 
ENSG00000008056 SYN1 -2.1 3.41E-02 
ENSG00000157152 SYN2 -2.4 2.07E-02 
ENSG00000100321 SYNGR1 -2.1 3.96E-02 
ENSG00000127561 SYNGR3 -2.8 9.11E-03 
ENSG00000102003 SYP -2.7 1.09E-02 
ENSG00000173227 SYT12 -2.6 1.34E-02 
ENSG00000213023 SYT3 -3.2 3.41E-03 
ENSG00000132872 SYT4 -2.1 3.55E-02 
ENSG00000129990 SYT5 -2.6 1.28E-02 
ENSG00000134207 SYT6 -2.3 2.40E-02 
ENSG00000011347 SYT7 -2.7 9.91E-03 
ENSG00000006128 TAC1 -2.2 3.19E-02 
ENSG00000204261 TAPSAR1 2.3 3.74E-02 
ENSG00000133138 TBC1D8B 2.8 9.63E-03 
ENSG00000121068 TBX2 2.3 3.10E-02 
ENSG00000204065 TCEAL5 -2.0 4.78E-02 
ENSG00000176769 TCERG1L 2.8 1.53E-02 
ENSG00000152760 TCTEX1D1 3.2 3.74E-03 
ENSG00000151790 TDO2 2.6 2.58E-02 
ENSG00000167858 TEKT1 2.8 9.94E-03 
ENSG00000138336 TET1 2.2 2.87E-02 
ENSG00000087510 TFAP2C 2.2 3.22E-02 
ENSG00000120708 TGFBI 3.0 5.10E-03 
ENSG00000198959 TGM2 3.5 2.01E-03 
ENSG00000137801 THBS1 2.2 3.26E-02 
ENSG00000186340 THBS2 2.1 3.82E-02 
ENSG00000065717 TLE2 -2.2 2.87E-02 
ENSG00000174130 TLR6 2.5 3.05E-02 
ENSG00000107807 TLX1 -3.6 1.79E-03 
ENSG00000236311 TLX1NB -3.0 1.20E-02 
ENSG00000169908 TM4SF1 2.6 1.90E-02 
ENSG00000135926 TMBIM1 2.0 4.25E-02 
ENSG00000166448 TMEM130 -2.0 4.14E-02 
ENSG00000181234 TMEM132C 3.0 6.04E-03 
ENSG00000167619 TMEM145 -2.6 1.45E-02 
ENSG00000179292 TMEM151A -2.8 7.64E-03 
ENSG00000258986 TMEM179 -2.4 1.87E-02 
ENSG00000226287 TMEM191A -3.2 5.08E-03 
SUPPLEMENT  131 
ENSG00000206140 TMEM191C -2.4 3.33E-02 
ENSG00000135048 TMEM2 2.0 4.45E-02 
ENSG00000187824 TMEM220 2.5 2.23E-02 
ENSG00000198133 TMEM229B -2.2 3.30E-02 
ENSG00000214597 TMEM249 -2.4 3.38E-02 
ENSG00000105696 TMEM59L -2.3 2.63E-02 
ENSG00000125895 TMEM74B -3.1 4.49E-03 
ENSG00000176040 TMPRSS7 2.1 4.85E-02 
ENSG00000187653 TMSB4XP8 -2.0 4.39E-02 
ENSG00000173535 TNFRSF10C -2.2 4.25E-02 
ENSG00000028137 TNFRSF1B 3.2 5.67E-03 
ENSG00000000005 TNMD -2.3 2.84E-02 
ENSG00000159173 TNNI1 -2.4 3.22E-02 
ENSG00000118194 TNNT2 -2.8 1.40E-02 
ENSG00000130595 TNNT3 -2.6 2.46E-02 
ENSG00000131747 TOP2A 2.3 2.37E-02 
ENSG00000261594 TPBGL -2.3 3.63E-02 
ENSG00000159713 TPPP3 2.6 1.40E-02 
ENSG00000132481 TRIM47 2.2 2.77E-02 
ENSG00000162722 TRIM58 2.9 8.55E-03 
ENSG00000213186 TRIM59 2.2 2.99E-02 
ENSG00000146054 TRIM7 -2.6 1.92E-02 
ENSG00000187688 TRPV2 -3.1 6.52E-03 
ENSG00000175513 TSGA10IP -2.3 4.83E-02 
ENSG00000156298 TSPAN7 -2.6 1.14E-02 
ENSG00000235890 TSPEAR-AS1 -2.2 4.97E-02 
ENSG00000184205 TSPYL2 -2.1 3.85E-02 
ENSG00000180543 TSPYL5 3.8 1.25E-03 
ENSG00000174521 TTC9B -2.7 9.29E-03 
ENSG00000112742 TTK 2.4 2.22E-02 
ENSG00000104833 TUBB4A -2.4 2.07E-02 
ENSG00000117289 TXNIP 2.3 2.65E-02 
ENSG00000197355 UAP1L1 2.0 4.51E-02 
ENSG00000130477 UNC13A -2.0 4.66E-02 
ENSG00000113763 UNC5A -2.7 1.20E-02 
ENSG00000049247 UTS2 -2.4 3.02E-02 
ENSG00000171724 VAT1L -2.2 2.85E-02 
ENSG00000148704 VAX1 3.6 1.75E-03 
ENSG00000128564 VGF -2.4 2.01E-02 
ENSG00000106018 VIPR2 -3.0 8.51E-03 
ENSG00000163032 VSNL1 -2.7 1.11E-02 
ENSG00000187135 VSTM2B -2.6 1.56E-02 
ENSG00000168658 VWA3B 2.1 4.68E-02 
ENSG00000145198 VWA5B2 -3.0 5.84E-03 
ENSG00000225373 WASH5P 2.4 3.68E-02 
132   SUPPLEMENT 
ENSG00000166596 WDR16 2.4 2.32E-02 
ENSG00000136918 WDR38 2.8 9.14E-03 
ENSG00000174776 WDR49 2.0 4.82E-02 
ENSG00000197748 WDR96 2.3 2.28E-02 
ENSG00000156076 WIF1 -2.7 1.91E-02 
ENSG00000169884 WNT10B -2.2 3.65E-02 
ENSG00000162552 WNT4 -2.5 1.50E-02 
ENSG00000143184 XCL1 -3.3 3.83E-03 
ENSG00000229807 XIST 3.6 1.76E-03 
ENSG00000047597 XK -2.2 3.07E-02 
ENSG00000272501 XXbac-BPG299F13.17 -2.1 3.80E-02 
ENSG00000137693 YAP1 2.1 3.76E-02 
ENSG00000006047 YBX2 -2.4 2.45E-02 
ENSG00000257315 ZBED6 2.3 2.79E-02 
ENSG00000188707 ZBED6CL -2.0 4.90E-02 
ENSG00000181722 ZBTB20 2.3 3.23E-02 
ENSG00000174460 ZCCHC12 -2.8 7.47E-03 
ENSG00000166707 ZCCHC18 -2.2 3.18E-02 
ENSG00000180787 ZFP3 2.8 7.94E-03 
ENSG00000152518 ZFP36L2 2.0 4.26E-02 
ENSG00000105278 ZFR2 -2.5 1.82E-02 
ENSG00000004838 ZMYND10 2.1 3.73E-02 
ENSG00000196247 ZNF107 2.0 4.29E-02 
ENSG00000167383 ZNF229 3.9 8.07E-04 
ENSG00000256771 ZNF253 3.5 1.75E-03 
ENSG00000197935 ZNF311 3.1 6.57E-03 
ENSG00000177932 ZNF354C 2.6 1.45E-02 
ENSG00000187595 ZNF385C -2.1 4.05E-02 
ENSG00000197714 ZNF460 2.2 3.83E-02 
ENSG00000196263 ZNF471 3.5 2.80E-03 
ENSG00000164185 ZNF474 2.2 3.38E-02 
ENSG00000256229 ZNF486 3.7 1.28E-03 
ENSG00000196268 ZNF493 2.5 1.67E-02 
ENSG00000081665 ZNF506 3.8 9.14E-04 
ENSG00000198028 ZNF560 2.4 2.55E-02 
ENSG00000258405 ZNF578 3.7 1.52E-03 
ENSG00000245680 ZNF585B 2.6 1.42E-02 
ENSG00000188171 ZNF626 3.8 9.36E-04 
ENSG00000160229 ZNF66 2.4 3.25E-02 
ENSG00000198046 ZNF667 3.7 1.20E-03 
ENSG00000166770 ZNF667-AS1 3.5 2.98E-03 
ENSG00000197928 ZNF677 3.8 1.15E-03 
ENSG00000173041 ZNF680 2.5 1.77E-02 
ENSG00000197124 ZNF682 2.3 2.56E-02 
ENSG00000213967 ZNF726 3.1 6.49E-03 
SUPPLEMENT  133 
ENSG00000186777 ZNF732 2.8 1.51E-02 
ENSG00000237440 ZNF737 3.3 3.02E-03 
ENSG00000231205 ZNF826P 2.9 1.20E-02 
ENSG00000185869 ZNF829 3.4 2.44E-03 
ENSG00000257446 ZNF878 2.6 2.60E-02 
ENSG00000213988 ZNF90 3.0 1.11E-02 
ENSG00000184635 ZNF93 3.6 1.60E-03 
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